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Metagenome-wide associations and metabolic modeling to predict the
biomarkers for colorectal cancer
Nagavardhini Avuthu
University of Nebraska Medical Center, 2022
Supervisor: Chittibabu Guda, Ph.D.
Colorectal cancer (CRC) is the most common malignancy and the second most common
cause of cancer-related deaths in the world. It is a multifactorial disease mediated by genetic,
environmental, and lifestyle factors. Over time, the accumulation of genetic and epigenetic
changes results in the activation of oncogenes and deactivation of tumor suppressor genes in the
colon and rectal region which finally leads to tumor development. The gut microbiome is the
main factor linking the effects of diet and environmental factors to host metabolism. Several
studies showed the dysbiosis of gut microbiota in CRC patients with an increased proportion of
pathogenic microbes and a reduction in the gut commensals. And it is also evident from the
studies that pathogenic bacteria contribute to the CRC through DNA damage, pro-inflammatory
signals, and altered signaling pathways. This strong link between the gut microbiome and CRC
represents the gut microbiome as an ideal biomarker for CRC diagnosis and further harnesses it to
develop new therapeutic interventions for CRC. Currently, the gut microbiome has gained
immense importance in cancer research and human health.
In this dissertation, a meta-analysis of shotgun metagenomic CRC datasets belonging to
different geographical regions was performed using three distinct methods and identified 21
global microbial biomarkers for CRC. Co-occurrence network analysis of gut microbes showed
higher co-occurrence correlations among the pathogenic species in CRC networks; in contrast,
the control networks showed higher co-occurrences among gut commensals.
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Functional analysis of gut microbial communities showed variations in the enrichment of
metabolic pathways and microbial contributors to the metabolic pathways between CRC and
control gut communities. Analysis of butyrate synthesis pathways revealed the differences in the
source of butanoate in control and CRC metagenomes.
Pangenome gene family analysis of CRC-associated pathogenic species showed the high
variability of these microbial species across the geographic regions, mainly attributed to
differences in the accessory genes involved in bacterial virulence and antibiotic resistance. We
further leveraged the predicted metabolome of microbial communities and showed the differences
in metabolite composition of CRC and control groups. Our analysis also revealed altered
metabolite and microbial interactions in CRC, reflecting the role of gut microbiota in CRC.
Using metabolic modeling of CRC- and control-associated microbes on three different
diet media identified the metabolic flux differences in isoprenoid and butyrate biosynthesis
pathways in CRC and control communities. Overall, this study reported detailed taxonomic,
functional, and metabolic differences between dysbiotic CRC and healthy control gut
communities, which could serve as microbial and metabolite biomarkers for CRC. These findings
could serve in understanding the dysbiosis in CRC and the development of non-invasive
diagnostic and therapeutic strategies.
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Portions of the content and figures covered in this thesis are the subject of a submitted research
article that is currently under review (by Nagavardhini Avuthu and Chittibabu Guda)
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CHAPTER 1
Introduction
Introduction of Research Area
Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer and the second leading cause
of cancer mortality worldwide for men and women combined. According to GLOBOCAN 2020
estimates on cancers, 1,931,308 CRC cases and 935,173 deaths in 2020 (including anal cancers).
It accounted for 10.0 % of all new cancer incidences and 9.4 % of cancer deaths globally 1. In the
United States, CRC is the 4th most commonly occurring and death-causing among all cancers,
with an estimated 149,500 new incidences and 52,980 deaths in 2021. The epidemiology of CRC
varies globally, and CRC incidences are dramatically growing in economically transitioning
countries attributed to westernized lifestyles and dietary habits. The incidence and mortality rates
of CRC have declined progressively over the last few decades in the United States due to
increased early detection screenings in elderly people and treatment options. However, the
increased incidence of early-onset CRC (in beyond the 50 years of life) in the United States poses
a significant public health challenge in recent years. The increase in early-onset CRC is mainly
attributed to family history, a high-fat diet, increasing obesity, and the prevalence of type II
diabetes mellitus in younger generations 2. Despite the available advanced treatment options for
CRC, it is still a global health challenge due to the rise in the early onset CRC in addition to high
incidence and mortality rates around the world. The survival rate of CRC patients is mainly
dependent on the stage of diagnosis. Early diagnosis is an effective disease management strategy
for CRC, and it improves the prognosis and quality of life in CRC patients.
CRC is a heterogeneous disease with high inter-patient and intra-tumor variability
associated with the genomic and environmental risk factors. The environmental factors increase
1

the risk of CRC by altering the composition of gut microbiota. The dysbiotic gut bacteria in turn
influence CRC development by secreting toxic metabolites and modulating host immune
responses. Understanding the role of CRC risk factors could help intervene and develop new
diagnostic and treatment options for CRC.
Genetics factors
CRC develops as small polyps on the inner lining of the rectum or colon parts of the large
intestine and slowly develops into cancer over the years. A vast majority of the CRCs (over 95 %)
develop through adenocarcinoma sequence in the mucous glands of the colon and rectum, and
other less common tumors in colon and rectum are carcinoid tumors, gastrointestinal stromal
tumors, lymphomas, and sarcomas 3. The accumulation of genetic mutations in several key genes,
such as tumor suppressor genes and oncogenes, leads to CRC development. The most common
mutations in CRC are caused by loss of wild alleles of tumor suppressor genes (APC, TP53, and
SMAD4) and activation of oncogenes (KRAS and BRAF) due to chromosomal instability (CIN) 4,
and inactivation of DNA mismatch repair (MMR) genes due to microsatellite instability (MSI)
phenomenon 5. Ras oncogenes are involved in cell proliferation. APC gene inactivation leads to
activation of the Wnt/β-catenin signaling pathway, and leads to the development of familial
adenomatous polyposis 6.
In addition to these, the aberrant DNA methylation at CpG islands of gene promoters
blocks the gene expression, which results in CpG island methylator phenotype (CIMP) in CRC.
Even though inherited genetic susceptibility plays a major role in causing CRC, 70 – 80% of
CRC cases are sporadic and non-inherited, about 10 -30 % of CRCs have familial history, and
rest are hereditary CRCs include 2% to 3% HNPCCs (Hereditary Non-Polyposis Colorectal
cancer) < 1% are familial adenomatous polyposis (FAP) and < 0.1% include rare CRC syndromes
. APC gene mutations are mostly responsible for sporadic colorectal adenomas. In contrast,
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mutations in MLH1, MSH2, MSH6, and PMS2 genes (microsatellite instability) lead to the
2

development of Lynch syndrome, a predisposing factor to develop HNPCC 8. Majority of the
sporadic CRCs exhibit CIN and CIMP mutations primarily caused by environmental factors.
Also, the epigenetic inactivation of MLH1gene (CIMP) was observed in sporadic CRC 9.
Environmental factors
Several environmental factors have been identified as significant risk factors for sporadic
CRC. These factors include diet with high fat and low fiber, lifestyles such as alcohol
consumption, tobacco smoking and lack of physical activity, underlying disease conditions such
as hyperinsulinemia, ulcerative colitis, Crohn’s disease, and imbalance (dysbiosis) in the gut
microbiome. Most of these risk factors are implicated in developing CRC through gut microbiotamediated mechanisms on host metabolic and immune functions. The gut forms a complex and
dynamic microbial community in the human body with bacterial, archaeal, fungal, and viral
members, together termed as gut microbiota. The gut microbiota composition depends on the host
genetic and environmental factors such as diet, host health, age, antibiotic use, and other lifestyle
factors. Gut microbiota is dominated by bacterial members belonging to Firmicutes,
Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia 10. The human body is
estimated to contain 3.7x1013 bacterial cells with a 1.3:1 bacterial cell to human cell ratio 11. The
rough estimates indicate that human gut harbors nearly 1,000 bacterial species with about 2,000
genes in each organism. Together the gene content of the human microbiome is about 100-fold
higher than that of 20,000 12. A diverse and complex gut microbiome offers several health
benefits to the to the host that include various metabolic functions such as vitamin synthesis,
aiding in food digestion, and maintaining gut immune homeostasis. Most of the gut
microorganisms are commensal organisms, and they maintain the normal physiological activities
of the host. Environmental factors such as diet and lifestyle largely influence the structural
composition and dynamic operations of the gut microbial community. The imbalance of the gut
microbiota (also known as dysbiosis) has been shown to be associated with various diseases in
3

the host, including type 2 diabetes, inflammatory bowel disease (IBD), obesity, liver disease,
cardiovascular disease, and even cancers, especially the colorectal cancer. The altered gut
microbiota induces changes in the host metabolic and inflammatory mechanisms, thereby
affecting the development of colorectal cancer 13. The dysbiotic gut microbiota was shown to
mediate the pathological role in CRC by different processes, those include (i) induction of
chronic inflammation, (ii) biosynthesis of genotoxin and virulence factors, (iii) production of
toxic metabolites, and activation of diet mediated pro-carcinogenic compounds 14.
Induction of chronic inflammation
Impairment of gut mucosal barrier integrity mediated by pathogenic microorganisms is
one of the critical processes in CRC development 15,16. The growth of pathogenic microorganisms
weakens gut barrier function by disrupting the tight junctions and mucosal layer of the gut
epithelium. This leads to increased translocation of the bacterial cells into the lamina propria
through intercellular spaces of the gut epithelial cells. In the lamina propria, the toll-like receptors
present on macrophages and dendritic cells recognize the bacterial cells and trigger the release of
proinflammatory cytokines like IL-1, IL-6, IL-23 TNF-α, and INF-γ and subsequently activates
the host adaptive immune cells (T cells, B cells, and lymphocytes) and STAT3 and NF-kB
signaling pathways. The IL-23 mainly drives the development of TH17 cells, which further
activates the STAT3 in the epithelial cells through IL-17 secretion. The release of STAT3 and
NF-kB promotes abnormal cell proliferation that progresses to carcinogenesis. The other
pathological changes caused by epithelial injury include increased reactive oxygen species (ROS)
production from the rapid activation of innate immune cells and translocation of toxic metabolites
(secondary bile acids and H2S) and genotoxins from pathogenic bacteria into gut epithelial cells.
All these lead to oxidative stress, DNA damage, and aberrant cell proliferation and gradually
progress to cancer 15,17,18.
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Biosynthesis of genotoxin and virulence factors
Pathogenic gut microbe contributes to the carcinogenic process through biosynthesis of
genotoxins. Well-studied gut pathogens involved in the biosynthesis of genotoxin in CRC are
Bacteroides fragilis and E. coli. The enterotoxigenic B. fragilis (ETBF) has been shown to
produce a major virulence factor called fragilysin (bft2). It is a Zn binding metalloprotease,
cleaving the E-cadherin molecules in the gut epithelial cell junctions leading to increased
intestinal barrier permeability and promoting inflammation via the Wnt/β-catenin signaling
pathway 19. The other pathogen, E. coli, produces bacterial toxins called cyclomodulins that
interfere with the eukaryotic cell cycle. There are three different types of cyclomodulins those
include cytolethal distending toxin (CDT), cycle inhibiting factor (Cif), and cytotoxic necrotizing
factor (CNF). The CDTs are known to induce G (2)/M cell cycle arrest and enzymatic DNA
double-strand breaks that trigger a DNA damage response (DDR). However, cells exposed to
sub-lethal doses of CDTs exhibited increased frequency of mutations and accumulation of
chromosomal aberrations. 20. Previous studies identified the expression of CNF1 in many human
isolates of E. coli, and it is involved in the activation of Rho GTPases and disrupting the
functions in transformed epithelial cells 21. Another cyclomodulin called colibactin was also
identified in E. coli having a 54 kb polyketide synthase (pks) pathogenicity island in the genome.
Colibactins alkylate the DNA and induce double-strand breaks and chromosomal aberrations, and
finally, lead to cell cycle arrest in the G2/M phase 22. Different studies showed overrepresentation of pks+ E. coli in CRC 23,24, indicating the role of pks+ E. coli isolates in
tumorigenesis. E. faecalis is a commensal microorganism that has been shown to produce
reactive species (H2O2), superoxide (O2-) and hydroxyl radicals, and known to be responsible for
chromosomal instability (CIN) in sporadic CRC 25. A recent study has shown the role of
Campylobacter jejuni in CRC through the action of CDTs 26. In addition to acute infections,
Salmonella can cause chronic infections and colonic tumorigenesis through activation of beta-
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catenin signaling pathway by AvrA protein 27. F. nucleatum is an anaerobic oral commensal that
has been identified as a potential pathogen involved in the CRC predisposition. It binds to Ecadherin on CRC and non-CRC cells through virulence factor FadA, activates the Wnt/β-catenin
signaling, and produces an inflammatory and oncogenic response. Using another adhesin Fap2, F.
nucleatum binds to inhibitory immune receptor known as TIGIT that is expressed on the natural
killer cells and tumor-infiltrating lymphocytes and inhibits functions of those cells.The
fusobacterial adhesin Fap2, helps in colonization of F. nucleatum in colorectal tumours through
binding with a disaccharide tumor marker Gal-GalNAc (D-galactose-B(1-3)-N-acetyl-Dgalactosamine) expressed on the CRC tissues. It also induces chemoresistance to oxaliplatin in
CRC by autophagy via toll-like receptor 4 28.
Production of toxic metabolites, and activation of diet mediated pro-carcinogenic
compounds
The gut microbiota plays a vital role in host health and disease through metabolitemediated host-microbiota and microbe-microbe interactions. Gut microbiota can produce a
diverse set of metabolites, where environmental factors primarily shape the metabolite secretions
of the gut microbiota. Several metabolic products of the gut microbial community are implicated
in CRC, which is associated with dietary intake, drug metabolism, etc. These include metabolites
such as short-chain fatty acids (SCFAs) from complex carbohydrates metabolism, secondary bile
acids from a high-fat diet, and metabolites from protein fermentation 29. Understanding CRCrelated microbial metabolite patterns and associated environmental factors will provide accurate
diagnostic markers and therapeutic options for CRC.
Environmental factors and gut microbiota-mediated responses
Diet is one of the environmental factors affecting gut microbial composition and its
metabolism. Gut microbiota produces SCFAs such as propionate, acetate, and butyrate by
fermenting the non-digestible carbohydrates and dietary fiber. These SCFAs are critical factors
6

for maintaining gut health and preventing carcinogenesis. They mainly act by binding to Gprotein coupled receptors (GPCRs) as epigenetic regulators. Through GPCRs binding, SCFAs
participate in cellular pathways involved in releasing fat reserves, differentiation of T-reg cells,
and formation of IL-10 and IL-18 cytokines 30. Butyrate was shown to be associated with growth
inhibition of tumor cells by activation of cell cycle arrest and apoptosis. It acts by inhibiting
histone deacetylase (HDAC) and euchromatin formation 31. Bacteroides mainly produce
propionate and acetate, while butyrate is produced by Firmicute members. Specific gut
microorganisms such as Firmicutes (Roseburia spp. and Eubacterium rectale) and Actinobacteria
(Bifidobacterium spp. and Collinsella aerofaciens) are associated with butyrate formation in the
gut. Enrichment of these organisms was reduced on a low fiber and low carbohydrate diet 32.
Clinical studies showed that the reduced abundance of butyrate-producing organisms such as
Lachnospiraceae, Roseburia spp., and Bifidobacterium spp. was associated with reduced SCFAs
levels in CRC patients compared to controls 33.
Long-term adherence to diet with processed meats, low-calorie drinks, and fewer
vegetables and legumes increases the abundance of sulfur-metabolizing bacteria in the colon and
also the risk of the distal colon and rectal cancers. The genotoxic compound H2S was associated
with an increased risk of cancers 34. Mice fed with a Western diet (high-fat diet) developed a
higher percentage of colon tumors and promoted the growth of collagenolytic microbes compared
to controls fed on a standard diet 35. A high-fat diet induces increased bile acid discharge into the
intestine compared to a normal fat diet. The excess bile acids which are not reabsorbed in the
intestine are transformed by gut microbes such as Bacteroides, Clostridium, Lactobacillus,
Bifidobacterium, and Eubacterium into secondary bile acids, include deoxycholic acid (DCA) and
lithocholic acid (LCA) 36. These secondary bile acids are known to induce the development of
CRC by damaging gut mucosal layer integrity and increasing the production of pro-inflammatory
cytokines in the intestine. Animal models using APC Min/+ mice reported induction of colonic
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tumors and cancers on adding 0.2% DCA to diet for 8-10 months 37. DCA was shown to be a
transcriptional activator of COX-2 signaling in CRC associated fibroblasts, and this in turn,
enhances proliferation and invasiveness of colonic epithelial cancer cells 38. On the otherhand,
LCA has been implicated in CRC metastasis through inducing IL-8 expression and endothelial
cell proliferation 39.
Alcohol intake and tobacco smoking are well-known factors that were associated with
increased risk of CRC. Chronic consumption of alcohol leads to gut microbial dysbiosis, lowers
the abundance of butyrate-producing bacteria such as Faecalibacterium prausnitzii, Coprococcus
eutactus, and Roseburia spp., and enriches the potential acetaldehyde accumulators such as
Ruminococcus, Collinsella, Prevotella, and Coriobacterium 40,41. Anaerobic gut bacteria
metabolize alcohol to acetaldehyde via alcohol dehydrogenases, catalase, and cytochrome P450.
Acetaldehyde is known as a class 1 carcinogen according to IARC classification. It has been
shown that acetaldehyde degrades the folate required for DNA synthesis and repair. It also forms
ethano-DNA adducts by reacting with DNA bases, which results in genetic mutations that
contribute to carcinogenesis 42,43. Regarding tobacco usage, the toxic metabolites such as serum
nicotinine, O-cresol sulfate, and hydroxycotinine present in tobacco smoke were significantly
associated with increased incidence of CRC 44. Microbiome analysis of fecal samples from
smokers showed a higher abundance of Bacteroides-Prevotella than non-smokers. Chronic
cigarette smoke exposure showed microbial-induced changes in the gut epithelial layer and
increased inflammatory responses 45,46.
Diabetes mellitus (DM) and CRC are the most frequent causes of death globally;
however, the epidemiological association between the two varies widely. Even though CRC was
shown to be 27% higher in type 2 DM than non-diabetic controls, the potential confounders like
environmental factors need to be considered in understanding the correlations. For example, the
metformin and insulin use affect the correlation between DM and CRC; metformin is associated
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with lowering while insulin is associated with elevating the CRC incidence. The metformin use in
DM patients has been shown to increase the abundance of E. coli and Bifidobacterium and
decrease the abundance of Intestinibacter 47, resulting in the increased production of SCFAs in
the gut. Exercise and physical activity have been shown to increase the bacterial diversity
(increased Bacteroidetes/Firmicutes ratio) and production of SCFAs 48. Gut microbiome analysis
of athletes showed increased gut microbial diversity and metabolic capacity related to amino acid
and antibiotic biosynthesis, carbohydrate metabolism, and production of SCFAs 49. The most
prevalent gut disorder that was considered as the highest risk factor for CRC is IBD. Both
diseases share many commonalities- both are associated with multifactorial heterogeneity and
characterized by chronic inflammation in intestinal tissues. The long-standing CD- Crohn’s
disease and UC- ulcerative colitis (IBD types) were shown to be associated with an increased risk
of developing CRC, referred to as colitis-associated colorectal cancer (CAC). The CAC is more
aggressive than CRC, and in a group of patients with UC, the incidence of CRC increased by 60
% compared to of general population 50. Both CAC and CRC are characterized by altered
microbial composition, dysfunctional gut barrier, and a high amount of mucosa-associated
bacteria 50.

Relevance of gut microbiota as CRC biomarkers
Colorectal cancer persists as major public health burden with a high incidence and
mortality rate. It arises from the multifactorial perturbations involving genetic and environmental
risk factors; however, the inherited genetic predisposition contributes only to a small fraction of
CRC cases, while the majority of the CRC cases occur sporadically as a result of environmental
risk factors. As explained above, environmental factors such as the western diet, alcohol
consumption, smoking, disease conditions, and others could effectively modify the composition
of gut microbiota. The resulting altered gut microbiota initiates and facilitates tumor formation in
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the host through different processes such as eliciting abnormal immune reactions, pathogen
invasion through the gut membrane and secreting toxic metabolites and genotoxins in the host. In
a normal gut, the diverse commensal microbiota decomposes dietary residues in the intestinal
tract and produces varied metabolites such as SCFAs, polyphenols, vitamins, and polyamines.
These metabolites play an important role in gut barrier function and mucosal immune
homeostasis. Dysbiosis leads to altered gut microbial diversity and metabolites profiles in the
host, and it is shown to be associated with different human maladies such as obesity and
associated metabolic disorders (e.g., type 2 diabetes and non-alcoholic fatty liver), autoimmune
diseases (e.g., type 1 diabetes and inflammatory bowel disease), and several types of cancers 51.
Some microbial metabolites are also potent epigenetic modulators that regulate the host gene
expression and cellular functions. Altered metabolic profiles of dysbiotic gut microbiota may
trigger the susceptibility of the host to disease (e.g., cancers and other metabolic disorders)
through epigenetic alternations of histone modification and DNA CpG island methylation 52.
Several metagenomic studies revealed the differences in the composition of microbiota between
CRC and healthy gut 53–55, and animal model studies proved the pathogenic roles of certain
bacteria in CRC 28,56. These findings support the potential of utilizing gut microbiota as CRC
biomarkers.
At present, the screening methods for CRC include stool tests and colonoscopy. Stool
tests include guaiac fecal occult blood tests (gFOBT), fecal immunochemical tests (FIT), FITDNA tests, and colonoscopy screening 57. They significantly differ in specificity and sensitivity.
In FOBT, a chemical guaiac is used to detect blood in stool, whereas in FIT, antibodies are used
to detect blood in stool, and in the FIT-DNA test, the FIT is combined with DNA tests for altered
DNA. FOBT and FIT tests are inexpensive. However, they need repeated testing over a period of
time to avoid false-negative results. Colonoscopy is the gold-standard test for CRC diagnosis at
present; usually, the diagnosis is accompanied by adenoma resection. It resulted in a drastic
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decrease in CRC incidence in older age people. However, colonoscopy is an invasive procedure;
it needs patient bowel cleansing prior to the test and involves physicians’ time to perform the test.
Non-invasive microbial markers are required for CRC diagnosis to overcome limitations
associated with existing CRC diagnostic tests, which will provide cost-effective and non-invasive
procedures for diagnosis. Meta-analysis studies of CRC gut microbiomes provided multispecies
signatures as CRC biomarkers with an AUC > 0.8, which supports the development and use of
accurate stool-based diagnostic tests 58,59 for early detection for CRC.
Gut microbiota includes varied microbes with capabilities for beneficial and detrimental
responses to immunotherapy. Fusobacterium nucleatum has been shown to induce
chemoresistance to oxaliplatin and 5-FU in tumor cells through autophagy. Enrichment of
Bacteroidetes members has been shown to correlate with resistance to checkpoint-blockadeinduced colitis. Conversely, depletion of bacteria associated with genetic pathways involved in
polyamine transport and B vitamin biosynthesis are shown to increase the risk of colitis 60. These
studies suggest that microbiome-based interventions would help reduce the complications after
immunotherapy in cancer patients.
Microbiota manipulations as potential therapeutic strategies are gaining importance based
on their role in CRC pathogenesis and therapeutic outcomes. Microbial modulations include
enrichment of beneficial bacteria through dietary interventions (prebiotics and probiotics),
suppression of pathogenic bacteria through narrow-spectrum antibiotics, bacteriophages, or
monoclonal antibodies, and fecal microbiota transplantation (FMT) are gaining importance as
alternate prospects for CRC prevention and treatment. These microbial modulations are aimed to
reverse the established dysbiosis of gut microbiota to prevent and treat the disease. As individual
responses to microbial modulation treatments are highly dependent on individual genetics,
microbial composition, and gut barrier function, the development of personalized microbiome
treatments would be more beneficial and avoid side effects 61.
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With the increasing of gut microbiota contributions to carcinogenesis, gut microbiome
has become a newly emerging field in cancer research as early detection has proven to increase
survival rates in CRC. Screening procedures based on microbiota could provide a way to develop
accurate fecal-based non-invasive diagnostic and prognostic tools for CRC.

The rationale of the study
Dysbiosis of gut microbiota has been shown as the hallmark of CRC, which is
characterized by a reduction in commensal microorganisms and enrichment of pro-inflammatory
opportunistic pathogens. The microbial secretions of the altered gut play a significant role in CRC
development and progression. Identification of significant changes in the abundance of specific
gut microbes in CRC patients can serve as a biomarker for CRC diagnosis. Based on the
importance of gut microbes as biomarkers, several studies explored the differences in the
abundance of microbial composition in CRC and the healthy gut samples to identify CRC
biomarkers. However, the results are not conclusive due to cohort-specific associations that are
influenced by genomic, dietary, and environmental stimuli, and associated reproducibility issues
using different analysis approaches. In this study, we performed a meta-analysis of CRC gut
metagenomes from diverse geographical regions using multiple methods to avoid the effect of
heterogeneity factors and achieve reproducible results. Emerging evidence also demonstrates the
role of microbial metabolites in modulating host inflammation and DNA damage in CRC, while
playing a protective role in the healthy gut such as maintaining gut barrier integrity and immune
homeostasis. However, obtaining metabolomic data for microbiota-metabolite interaction studies
are hindered by cost and intensive technical aspects of commonly used NMR and mass
spectroscopy methods. Here, we used a machine-learning approach to predict metabolomic
profiles for existing CRC metagenomic datasets and analyzed for microbe-metabolite interactions
to identify metabolite biomarkers in CRC. In microbial community, altered microbe-microbe
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interactions cause variations in the functionality of the community. To understand the altered
microbial interactions in the CRC gut, we performed FBA on metabolic models of CRC and
control gut communities and analyzed resultant metabolite fluxes to identify altered metabolic
pathways. This study enhances our understanding of the role of CRC-associated microbes and the
microbial metabolites in CRC development and progression and paves the way for further
experimental investigations to facilitate the development of non-invasive diagnostic and
prognostic tools.

Structure of the thesis

The thesis will focus on the identification of global microbial biomarkers for CRC through a
meta-analysis approach based on the gut metagenomic data from diverse geographical regions
and then interrogate the CRC and healthy gut communities using co-occurrence networks,
functional characterization based on metabolic pathways, pangenome gene family analysis,
investigation of the predictive metabolome, and finally systems-based approach of metabolic
modeling. At the beginning of the thesis, a brief overview of the research area, the relevance of
gut microbiota in this research, and the rationale of the study would be presented. This will be
followed by the essential background required for the field of work. A thorough exposition of the
methodology will be reported covering the detailed strategy used in biomarker discovery, cooccurrence analysis, functional analysis, pangenome-based gene family analysis, metabolome
prediction, microbe-metabolite correlations, and metabolic modeling and flux balance analysis.
Results and discussion of each section will be presented, ending with a conclusion, as well as
future opportunities where this work can be extended and applied.
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CHAPTER 2
Essential Background
Metagenomics
The study of microorganisms has drastically changed ever since the initial discoveries of
microbes by Antonie van Leeuwenhoek in 1676 and the isolation of microbes by solid cultures by
Robert Koch (1888) to the present next-generation sequencing technologies. Discoveries such as
microscope and the staining techniques (Gram, Ziehl–Neelsen, and Schaeffer and Fulton) have
significantly improved the visualization of microbes 62. Seminal works by Louis Pasteur, Robert
Koch, and Sergei Winogradsky in the mid to late 1880s have laid foundations to the microbiology
field and enabled the isolation of microorganisma from their natural habitats and cultivation
under controlled conditions. These techniques were mainly applied in pathogenic and
environmental microbiology domains to study bacteria as disease-causing or crucial drivers of
geochemical cycles that eventually led to the development of microorganisms as the discipline of
immunology and cellular microbiology 62.
The field of microbiology has rapidly advanced after the development of culture media.
Louis Pasteur developed the first liquid culture in 1860 and was able to show the multiplication of
bacterium. Later, Robert Koch (1881) discovered solid media to enable the isolation of pure
cultures 62. Winogradsky’s contributions, mainly to the development of Winogradsky’s column
(in Microbial ecology), enabled culturing of microbes from the soils and sediments. Culture
media are well established to cater to the growth requirements of diverse microorganisms and
widely used in different areas of microbiology such as clinical, industrial, and food microbiology
for isolation and characterization of pathogens. As culture media was limited in resolution to
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identify evolutionary relationships, microbiologists resort to the new emerging molecular
techniques, such as rRNA gene cloning, PCR, and Sanger sequencing technologies.
From the mid-1970s, there has been an increased emphasis on using the genetic
similarities for classification than the phenotypic and behavioral traits. Based on rRNA gene
sequencing studies, Carl Woese and George Fox suggested that the 16S rRNA gene can serve as a
reliable molecular marker to measure the evolutionary distances in the phylogenic tree of life and
proposed three primary lines of evolutionary classification, which include- Eukarya, Bacteria, and
Archaea 63. Based on that proposal, the use of 16S rRNA gene as a microbial marker has
revolutionized the microbial research in conjunction with Sanger sequencing and PCR
approaches. These studies led to culture-independent studies of microbial communities. Further
advancements in molecular techniques such as gene cloning, RFLP, FISH, and gel
electrophoresis have led to the investigation of microbial community functions based on gene
expression techniques. These technological applications further led to the development of
biotechnology. As part of that, laborious cloning methods coupled with amplicon sequencing
methods helped the investigation of products such as terragines genes from Staphylococcus
lividians 64 and antibiotic genes from soil bacterium 65. However, these studies have revealed that
the strains with identical 16S rRNA genes are possessing different antibiotic phenotypes,
warranting the need for using new sequencing technologies to obtain more genetic information
from microbial communities, which was addressed by the metagenomic sequencing strategies.
Metagenomic sequencing (sequencing via Fosmid cloning approach) was first carried
out on planktonic marine archaeon to uncover its large metabolic diversity and physiological
capabilities 66. In 1998, Jo Handelsman used the culture-independent method such as cloning and
phenotype screening to study the biosynthetic gene clusters from collective genomes of soil
microflora and coined the term metagenomes of soils 67. Metagenomics studies microbial
communities accessed directly from their natural environments, without prior culturing 68. It
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differs from genomics, where genomic DNA of an individual organism or cell is studied after
isolation from its natural habitat. Metagenomics means “beyond the single genome study,” where
meta in Greek is “beyond” 69.
The initial metagenomic studies were mainly dependent on Sanger sequencing
technology and over time, the sequencing approaches have evolved to the current NextGeneration Sequencing technologies (NGS). The NGS technologies significantly impacted both
genomic and metagenomics studies through high-throughput sequencing of short-read fragments
at low cost and high speed without laborious cloning methods. Different NGS technologies
developed over the years include 454 sequencing platforms or pyrosequencing, Ion Torrent
platform, ABI SOLid sequencing, and Illumina technology. The sequencing methods used in
NGS technology are pyrosequencing, ion semiconductor sequencing, sequencing by ligation, and
sequencing by synthesis. Each technology has its pros and cons; however, all have been used in
metagenomic projects. At present, Illumina technology is the most popular due to its low cost and
high yield 70. Third-generation sequencing technologies such as PacBio RS and the Oxford
Nanopore are emerging for high-throughput long-length DNA sequencing. Long read sequencing
is more useful in genome assembly and detecting rare variants.

Metagenomic sequencing
In metagenomics, two fundamental approaches used for determining microbial diversity
and abundance include environmental gene surveys and random shotgun sequencing of genomes.
Environmental gene survey is performed using amplicon sequencing (metaprofiling), where
specific regions of the metagenomes are amplified using specific primers. These include 16S
rRNA gene sequencing in prokaryotes and intergenic transcribed spacers (ITS) or the large
ribosomal subunit (LSU) gene sequencing in eukaryotes. Shotgun metagenomics allows
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comprehensively sample all genes from all organisms of a community. It involves shearing of
DNA from whole genomes extracted from the environmental sample, sequencing the short reads
from mixed genomes, and identifying individual taxa in the sample using bioinformatics methods.

Amplicon sequencing
16S rRNA amplicon sequencing is the most widely used method for investigating the
microbiota of a given body site. In this method, DNA is first extracted directly from its natural
habitat, amplified with specific primers of 16S rRNA gene (amplicons), and sequenced using the
NGS methods such as Illumina MiSeq, Ion Torrent PGM, Roche 454, and PacBio RSII. The
sequenced reads are clustered into unique features and used for taxonomic identification based on
similarity search against the reference 16S rRNA gene sequence databases. Currently available
16S rRNA public databases include Greengenes 71, the Ribosomal Database Project 72, and
SILVA 73. The SILVA database has reference sequences for eukaryotic LSU sequences in
addition to bacterial 16S rRNA sequences. It can be used for the identification of fungi and other
metazoan microorganisms. The identified read counts of the microbial community can be
analyzed to determine the taxonomic composition of microorganisms using different software
packages such as QIIME 74, Mothur 75, MEGAN 76, and CARMA 77. Functional prediction for
taxonomic profiles of 16S rRNA sequencing data can be obtained using PICRRUSt 78 and
Tax4Fun2 79. While the 16S rRNA gene amplicon sequencing is powerful, it is not without
limitations. Results may be biased due to varying PCR amplification or incomplete reference
databases used for analysis resulting in inaccurate taxa representation. Species-level
identification may also be masked due to high similarity between 16S rRNA genes of closely
related species. Also, these methods only provide the relative abundance rather than absolute
values and do not resolve the biological functions such as antimicrobial susceptibility 70,80.
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Shotgun metagenomics
Unlike 16S rRNA sequencing, where only specific genes are targeted, the shotgun metagenomic
sequencing approach sequences all genes present in a microbial community. Shotgun sequencing
includes random fragmentation of the mixed community DNA and sequencing each fragment
independently. It provides insights into the taxonomic as well as functional diversity of a
community and allows the detection of low abundance members of the community as well as
functional characterization of the community. While the16S rRNA gene sequencing is mainly
limited up to genus-level identification, the shotgun metagenomics enables species-level or even
strain-level resolution of the community organisms.
Mostly used technologies for shotgun metagenomic sequencing include short-read
Illumina sequencing and long-read PacBio and Oxford nanopore technologies. The Illumina
sequencing technology can provide short reads of length up to 250 or 300 bp (single- or pairedend) with high sequencing depth. The Illumina family of sequencers include- MiSeq, NextSeq,
HiSeq and the most recent NovoSeq. PacBio and Oxford Nanopore (third-generation sequencing
platforms) are longer read sequencers but accompanied with higher error rates, lower sequencing
depth, and higher costs. They need repeated sequencing of a circular template, and a DNA insert
consensus generation to overcome the errors. PacBio sequencing is more useful for examining
abundant organisms, genome assembly, and efficient binning, whereas Illumina sequencing is
recommended for metagenomics studies and identification of rare microorganisms. Irrespective
of the method used, the high complexity and dimensionality of the metagenomic data present
challenges with analysis and computational problems.
While the whole genome (shotgun) metagenomic sequencing is relatively expensive than
the 16S rRNA amplicon sequencing, it is valuable in the identification of unknown/uncultivated
species and understanding the functional context of the communities. This approach has been
widely applied in the analysis of communities from different ecological environments such as
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soil, gut, ocean, and wastewater. It is an essential tool in understanding the role of human
microbiota in human health 81. It also identifies viruses 82 and characterizes genomic diversity and
metabolism of uncultured bacteria 83. It provides the understanding of antimicrobial resistance,
virulence factors, and enzyme biosynthesis required for scientific applications in human health
and other industries.

Metagenomic analytical strategies
Typical metagenomic analysis of a microbial community involves data generation using
NGS shotgun sequencing methods, quality control, read assembly to reference genomes, and
taxonomic and functional characterization 84. Taxonomic characterization provides the details
about the diversity of the community and identifies novel taxa in the community. The methods for
taxonomic characterization utilize three broader approaches that include marker gene analysis,
binning, and assembly. Gene prediction and functional annotation of metagenomic sequence data
would reveal biological functions associated with the community. Further, comparative analysis
of taxonomic and functional profiles between different communities (health vs. disease) helps in
the prediction of biomarkers.

Taxonomic characterization
Marker gene analysis
The shotgun metagenomic sequencing involves whole-genome sequencing of all
community members, so it provides information for markers like ribosomal and other gene or
phylogenetic markers. There are two different approaches for marker gene analysis of
metagenomes, which include 1) using sequences similarity between the read and marker gene.
For instance, MetaPhyler uses a pairwise sequence search of reads against the marker gene
database, while MetaPhlAn characterizes the metagenomic marker gene homologs-based
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sequence similarity against phylogenetic clade-specific markers 85, 2) using phylogenetic
information. Another method, AMPHORA 86, builds profiles of hidden Markov models (HMMs)
from marker protein sequences from representative genomes, uses the models to align the
sequencing reads and assemble into a phylogenetic tree, and annotated based on relative position
in the tree.
Binning
Binning is a process where each metagenomic read is assigned with a taxonomic
annotation. It provides insight into the community's diversity or the presence of novel genomes
and reduces the complexity of the data. It uses different strategies to cluster the metagenomic
sequences, including sequence alignment against reference genomes (similarity-based approach)
or sequence composition classification (based on shared characteristics such as K-mer
frequencies or GC content). Binning based on sequence similarity to reference genomes of
taxonomically annotated sequences requires more computational resources. However, they
provide higher annotation accuracy and resolution than sequence compositional binning. MEGAN
87

and MG-RAST

88

software are the most widely used sequence similarity approaches for

metagenomic binning. Another related method, MOSAIK 89, uses fragment recruitment, where the
metagenomes are partitioned based on identical alignments to genome sequences. On the other
hand, sequence composition classification does not need alignment to reference genomes as it
uses sequence characteristics to classify metagenomic sequences into different taxonomic groups.
Examples of such methods are PhyloPithia 90 , PhylopithiaS 91, and Phymm 92 that use super
vector machines and interpolated Markov models, respectively, to stratify the metagenomic
sequences into taxonomic groups. Another methods, Tetra 93, uses the frequency of
tetranucleotide patterns for binning.
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Assembly
Assembly is the process where the sequence reads are combined into contiguous DNA
fragments called contigs, based on sequence overlap between reads. Metagenome assembly needs
extensive read coverage. In metagenome de novo assembly, the genomes are reconstructed
directly from the read data. Different tools were developed for the de novo assembly, including
MetaVelvet 94, Ray Meta 95, MEGAHIT 96, and metaSPAdes 97. Most of these are built upon the
traditional de Bruijn graph approach, which is a graph/network model where k-mers (specified
length of sequence) of sequence reads with contiguous sequence overlap are linked through
overlapping sequence identity 98. MetaVelvet and Ray Meta are single k-mer de Bruijn graph
assemblers, whereas MEGAHIT and IDBA-UD 99 depend upon multiple k-mer strategies. The
choice of k-mer length affects the graph, small k values give more connections, but they cannot
resolve repeats. Large k values result in missing connections and are sensitive to sequencing
errors. Metagenome assembly using multiple k-mer lengths increases the quality of the assembly
. All aligners mentioned previously are based on Illumina short-read sequences. However, in
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recent tools, long reads (e.g., Pacific BioScience) are being implemented along with short reads to
improve the quality of the assembly 101.

Functional metagenomic analysis
Gene prediction and functional annotation
Gene prediction and annotation of predicted genes provide insights into the collective
functions of the metagenomic community. Assembled and unassembled reads could be used for
gene prediction. Gene prediction can be made using the reference genomes or de novo approach.
In the reference-based approach, metagenomic reads or contigs are aligned directly to a database,
or six-frame translated read sequences are used to search against the databases for gene
prediction. Reference-based approaches may provide gene annotations along with gene prediction
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for the searched metagenomic reads based on the availability of functional annotation for that
gene. However, identifying novel genes is not possible using the reference-based approach. A
high-throughput direct read mapping approach was used for cataloging the gut microbial genes in
the Human Microbiome Project 102. The de novo gene prediction methods are used for novel
gene identification. In this, gene prediction models are built based on characteristics of microbial
genes such as length, codon usage, and GC bias.
Different tools developed for de novo gene prediction include MetaGene, FragGeneScan,
MetaGun, Glimmer, and MetaGeneMark 103–107 . Then the predicted metagenomic genes are
annotated to protein families that represent the common function of the related proteins. The
annotations can be assigned based on nucleotide or translated sequence homology search against
a database of protein sequences or to a probabilistic model such as a HMM of a protein family
with known function. Sequence databases such as the SEED annotation system (employed in
MG-RAST), KEGG, MetaCyc, EggNOG, and Pfam are commonly used for gene function
annotation. Based on these databases, several web servers, including MG-RAST 88, CAMERA

,
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and IMG/M 109, and standalone applications such as SmashCommunity 110 and MetAMOS 111 were
implemented for metagenome functional analysis. These tools also provide options for
comparative analysis of metagenomes. Comparative analysis of predicted genes or proteins of
the human microbiome enables the detection of biomarkers for human diseases. LEfSe 112 is one
of the statistical methods developed for microbiome analysis to identify microbial, gene, or
pathways markers that could differentiate two or more metagenomic communities 84. Different
tools are available for comparative analysis on metagenomic data based on differential feature
abundances between two or more conditions, e.g., MEGAN, and Parallel-meta.
In this research, HUMAnN2 software was used 113 to identify gene families and pathways
from CRC and healthy gut metagenomic sequence data. In addition to gene prediction and
functional annotation of microbial communities, understanding the interaction of microbial
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communities would provide more insights into the role of microbes in host diseases, drug
resistance, and tolerance. Hence, we investigated the microbial interactions from co-occurrence
networks and microbe-metabolite interactions using metabolite data and community metabolic
modeling.

Microbial co-occurrence analysis
Host genetics and environmental factors influence the composition of the gut
microbiome, which in turn affect the host health. The dynamic associations of gut microbiota
need to be explored to understand the microbial community structure and key microbial
associations involved in the host health and disease. Microbial relationships are niche-specific in
the human body and occur mainly between closely related microorganisms 114. The interactions
between niche-specific microbiota are essential for community stability and host health.
Alterations in community interactions through the overgrowth of pathogens will lead to disease
conditions 115. Comparing the microbial co-occurrence patterns in healthy and disease
communities would provide the key microbial determinants of the host disease condition.
Different methods were developed to detect the co-occurrence patterns comprehensively in
complex microbial communities. Most of these methods are based on Pearson’s or Spearman’s
correlations, which measure the linear relationships and rank relationships. Methods based on
Pearson’s or Spearman’s correlations are insufficient to address the issues associated with
compositional data (relative abundances or proportion counts of microbiome data), including
zero-inflated datasets or missing data due to incomplete sampling and the complex direct and
indirect microbial associations 116. Different software tools have been developed by
implementing certain modifications to original correlation methods to handle the complexity of
compositional data. These include CoNet, Local similarity analysis, Maximal information
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coefficient, MENA, Random matrix theory, and SparCC. CoNet uses an ensemble of similarity
and dissimilarity measures with the permutation test to compute the P-value for the associations.
Another method, SparCC 117, uses Pearson correlations based on log-transformed proportions or
count data. It handles the compositional bias and sparsity issues using the Bayesian approach that
differentiates the true count pairwise associations from the observed counts. In recent years,
linear regression models such as CCLasso and REBACCA and graphical methods such as SPIECEASI, gCoda, and mLDM were developed to infer complex relationships in microbial
communities. As many tools were developed with different strategies to infer relationships in the
ecological communities, the implementation depends upon our requirements, data
compositionality, and computational time. In this study, we used the SparCC algorithm to obtain
correlations between microbial pairs among gut microbes. As suggested, it is best suited for the
data with higher compositionality 118, indicated by Inverse Simpson neff < 13. In our data, most of
the samples were with neff < 13. In addition, SparCC has been successfully applied in the Human
Microbiome Project to interrogate the fungal-fungal and fungal-bacterial relationships 119 and
identify microbial dysbiosis in gastric carcinogenesis 120.

Strain-level analysis of microbial community
Strains are microbial isolates refer to a collection of genomes within a narrow range of
phylogenetic variation or a subspecies clade. However, strains have a wide range of functional
architecture. Those processes are conserved across clades, such as a butyrate production
in Faecalibacterium prausnitzii. Others, conversely, vary between closely related clades (e.g.,
diffuse adherent, enterotoxigenic, and enteropathogenic E. coli pathotypes) 121. Slight genomic
variations between two strains could cause large phenotypic changes, such as point mutation in
drug resistance genes 122. The strain-specific characteristics are primarily associated with
increased virulence, antibiotic resistance, and defense. In addition, the probiotic properties of
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microorganisms are strain-specific (e.g., strains of Lactobacillus, Bifidobacterium, and other
genera) 123. The human gut hosts several bacterial strains with diverse metabolic capabilities,
involved in the host health maintenance, disease onset, and progression. The variations in strains
also affect the ecology and phylogenetics of the gut community. The evolution and diversification
of strain variants in the human gut are linked to host migration, geography, and lifestyle 124. It has
been observed that the strain variations in the human gut are closely related to diet, antibiotic use,
lifestyle, and other environmental factors. For example, fermented foods (kefir, kombucha,
sauerkraut) can increase the abundance of probiotic bacteria and fermentation-derived compounds
in the gut (biogenic amines and bioactive peptides) 125. Dietary fiber has the potential to increase
the strains involved in SCFA production in the gut, alter metabolic regulation and maintain the
gut barrier function 126. On the other, factors leading to dysbioses, such as diets with low-fiber
and high-fat, were associated with the increase of pathogenic strains. Different studies have
shown the links between pathogenic variants and human diseases, e.g., IBD microbiome is
enriched with pathogenic subspecies of E. coli and Ruminococcus gnavus. These strains are
adapted to oxidative stress response, adhesion, and nutritional acquisition from host mucus and
iron 127. In CRC, the role of pathogenic strains of pks+ E. coli, B. fragilis, and F. nucleatum was
evident from experimental studies 128–130. Identifying and analyzing strain-level microbial
variants contribute to understanding the host-pathogen interactions, characterization of unstudied
strains, epidemiological surveillance of bacterial diseases, and new treatment options.
Existing metagenomic tools are relatively well suited for species-level identification, and
these are unable to resolve closely related strains. Culture-based methods and direct imaging are
traditional practices used over the years to differentiate strains in microbiology. However, these
methods are insufficient to efficiently resolve the variants present in the community, and even
some microbes fail to cultivate in the lab. Over the last few years, many new algorithms are
starting to emerge for strain-level identification. These algorithms are based on sequencing
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technology, including the 16S marker gene approach and whole-genome sequencing. Compared
to 16S rRNA sequencing, shotgun metagenomic sequencing provide better accessibility of
genomic composition of microbial communities to identify closely related strains. There are
different algorithms developed for strain identification based on WGS data. Those are categorized
into reference-based and reference-free strain identification methods. Reference-based strainidentification algorithms include PathoScope, StarinPhlAn, MetaMLST, MetaSNV, ConStrains,
DESMAN, PanPhlan and others. Among these, most algorithms rely on SNV variants. They are
oriented to identify the dominant single novel strain of a species (e.g., StrainPhlAn, MetaMLST,
and MetaSNV) and multiple strains (e.g., PathoScope, ConStrains, and DESMAN). Another
reference-based algorithm, PanPhlAn, depends on structural variants to identify the strain-level
variants present in a community 121.
Reference-free strain identification methods use statistical analysis on SNPs or K-mers of
sequencing reads to identify the number and proportion of unique strains present in a sample.
Such algorithms include MetaID 131, DEploid 132 , estMOI 133 and pfmix 134. In our research, we
used PanPhlAn to characterize the strains of CRC-associated microbes. It identifies the
combination of genes present in a sample based on the pangenome of each species. Using
PanPhlAn, it is possible to analyze the DNA and RNA sequencing data and get the full view of a
microbial community 135. Recent advances in sequencing technologies such as long-read
sequencing and single-cell sequencing would offer extreme fidelity in strain-level identification
than existing short-read sequencing methods. They provide full-length gene reads and avoid the
need for metagenomic assembly or binning. The long reads are more convenient for SNV
analysis and provide better resolution of strain-level differences 121.
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Metabolic modeling of microbial interactions
Microbes live in communities, and they interact with each other and the host through
chemical signals and metabolites 136. These biochemical interactions of a microbial community
are vital for human and environmental health. Microbial interactions are dynamic and influenced
mainly by environmental stimuli and internal microbial changes. Genome-scale metabolic
modeling is a powerful approach to interrogate complex community interactions that drive the
microbial community 137. In silico computational modeling uses an organism's genome-scale
metabolic models (GEM) built from genomic annotations138. It has wider application in strain
development, drug design, and understanding cellular behavior. GEM is a collection of the whole
set of cellular metabolic reactions of an organism associated with gene-protein-reactions (GPRs)
based on genome annotations. Its key component is the matrix (S) of stoichiometric coefficients
for mass-balanced metabolic reactions present in the metabolic network of an organism 139.
Simulation of GEMs using Flux Balance Analysis (FBA) enables the identification of the
microbial community's microbial interactions and metabolite flux rates in a particular
environment/context. Metabolic modeling of the microbial community of a diseased condition
would reveal the altered metabolites, reactions, pathways, and related microbes associated with
the disease condition, which could be considered as potential targets for drug therapy 140. Multiple
species are known to involve in the pathogenesis of CRC. So, community metabolic modeling is
more conducive to exploring microbial metabolism and microbe-metabolite interactions in the
CRC gut community.

Metabolic network reconstructions
Metabolic modeling requires GEnome-scale Metabolic models (GEMs) that are gapfilled and curated forms of GENome-scale metabolic REconstructions (GENREs). GENRE is a
repository of all biochemical reactions of an organism built from genome annotations and its
candidate metabolic functions. Several tools have been developed to build GENREs over the last
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decade, which made the process faster by automating tasks such as draft metabolic network
generation, curation, and gap filling. Few currently available reconstruction tools include
AutoKEGGRec, AuReMe, RAVEN, MetaDraft, CarveMe, ModelSEED, Pathway Tools, KBase,
and rBioNet 141.
In this study, we used the KBase tool to build single species metabolic models and
community metabolic models. Kbase (the Department of Energy Systems Biology
Knowledgebase) is a web-based software platform for system biology applications. We used
Annotate Genome/Assembly with RASTtk, Build Metabolic Model, Merge Metabolic Model
Annotation, and Run Flux Balance Analysis apps from Kbase to build metabolic models of the gut
community. The Build Metabolic Model app uses the ModelSEED pipeline for genomes. Also, it
needs RAST annotated genomes because RAST annotations are linked directly to biochemical
reactions in the ModelSEED biochemistry database, which KBase uses for model building 142.
RAST server is devoted to annotating bacterial and archaeal genomes. After annotating the
genome, draft models are generated using the build metabolic model app.
The draft model contains the complete network of gene-protein-reactions (GPRs),
predicted Gibbs free energy for reactions, and biomass reaction. Biomass production of an
organism is represented by biomass reaction and is specific to an organism. It contains all
individual growth components and energetic requirements (i.e., DNA, RNA, cell wall
components, cofactors, protein, lipid, carbohydrate, DNA, and RNA) for biomass generation 143.
The completeness of the draft metabolic model depends upon the available annotations for the
genome reconstructions. Genome with incomplete annotations will lead to gaps in the metabolic
model that prevent biomass production on media where it typically grows. KBase Build metabolic
model app has an option for the gap-filling process. It identifies the minimum set of reactions
missing in the draft model for producing biomass in a specified media and fills those gaps. It
takes the gap-fill reactions from the curated ModelSEED biochemistry database, where it has
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integrated the reactions from multiple databases, including KEGG, MetaCyc, EcoCyc, Plant
BioCyc, Plant Metabolic Networks, and Gramene. After gap filling, the model is able to produce
the biomass on specified media. These models can be used for predicting reaction fluxes,
reaction essentiality, and metabolic contributions of individual organisms 142. Flux balance
analysis (FBA) is a widely used method for predicting metabolite flux/flow through genome-scale
metabolic network reconstructions.

Flux balance analysis
FBA is a constraint-based modeling approach. It calculates the flow of metabolites based
on stoichiometric metabolic models by imposing constraints and enables the prediction of the
growth rate of an organism or the rate of production of metabolites. In genome-scale metabolic
networks (stoichiometric metabolic models), the number of reactions is more than the number of
metabolites. So, it would have multiple feasible flux solutions without constraints on the model
(unconstrained solution space). The solution space can be narrowed down by imposing
constraints on the network through the stoichiometric matrix (mass balance constraint) and
reaction bounds. The most common objective of FBA is maximum biomass production, which
can be achieved by optimizing biomass objective function (BOF) through FBA, where it
identifies single optimal flux distribution for biomass production 144.
Mathematical representation of FBA 144
Metabolic network reconstruction is a stoichiometric matrix with a list of balanced biochemical
reactions of an organism. It shows the relationship between rates of different reactions to the rate
of change of metabolite concentrations
Stoichiometric matrix (S) of size m x n:
Sm x n
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Where m is metabolites in rows, n is reactions in columns, and each cell value represents
the stoichiometric coefficients of metabolites participating in a reaction.
System of mass balance equation at steady state:
𝒅𝒅𝒅𝒅
= 𝟎𝟎
𝒅𝒅𝒅𝒅

𝒅𝒅𝒅𝒅
= 𝑺𝑺. 𝒗𝒗
𝒅𝒅𝒅𝒅

𝑺𝑺. 𝒗𝒗 = 𝟎𝟎

where x is metabolite concentrations (vector of length m), v is reactions fluxes (vector
of length n)
Mass balance of metabolites equation defines the system of linear equations at a
steady state.
FBA aims to maximize or minimize an objective function: e.g., maximize growth or biomass

Z = CTV

( 𝒁𝒁 = 𝑪𝑪𝑪𝑪 ∗ 𝑽𝑽𝟏𝟏 + 𝑪𝑪𝑪𝑪 ∗ 𝑽𝑽𝑽𝑽 + ⋯ . . )

Where Z is an objective function, it represents a linear combination of fluxes, C is a
vector of weights of each reaction that contributes to the objective.
FBA calculates fluxes that minimize or maximize objective function Z. It uses linear
programming to solve the equation Sv = 0 under a given set of upper and lower bounds for the
flux of the reaction i.e., vmin ≤ v ≥ vmax.
Different tools available to perform FBA include MatLab COBRA Toolbox,
MetaFluxNet, CellNetAnalyzer, PSAMM, Escher-FBA, and OptFlux 145. We have used the KBase
Run Flux Balance Analysis app to predict the metabolite fluxes in gut microbial communities. It
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provides more than 500 media conditions for FBA, and it uses to maximize the biomass function
(default). It also provides an option for using user-defined media for FBA.

Metabolomics
Metabolomics is the study of identifying and quantifying small molecules/metabolites of
a biological system such as cell, tissue, organ, biological fluid, microorganism, and microbial
community. Metabolomic measurements of the small molecules include substrates,
intermediates, and products (typically measures < 1500 Da, e.g., carbohydrates, fatty acids,
organic acids, amino acids, nucleotides, steroids, and lipids) from biological samples. These
metabolic profiles of a biological system reflect the metabolic responses of the system to
pathophysiological stimuli or genetic modifications 146. It depicts the direct consequences of
changes that happen in the biological system. Thus, metabolomics data has the potential as an
efficient marker for disease diagnosis. Mass spectrometry and NMR spectroscopy are the widely
used technologies for metabolome profiling. These methods can handle a wide range of
metabolites and allow the identification of structure and quantification of molecules (Nicholson
and Lindon 2008). Continued improvements in these two analytical technologies have
significantly increased the sensitivity and reduced the sample preparation. Unfortunately, as the
sample size increases, the experiments become costly and limit the usage of these powerful
technologies. Different tools were developed to overcome these limitations and efficiently extract
the quantitative metabolite information from the existing publicly available microbiome
sequencing data. These include PRMT 147, MIMOSA 148, and MelonnPan 149.
PRMT approach uses the relative abundance of the genes encoding for unique enzyme
functions and predicts the change in metabolite turnover between the metagenomes. PRMT was
applied in coastal marine metagenomic dataset analysis. MIMOSA also uses a similar
methodology as used by PRMT to approximate the metabolites after inferring the gene content
based on available genomic information. MIMOSA has been used for metabolite prediction from
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autism datasets. Both PRMT and MIMOSA are reference-based methods that use KEGG data for
metabolite prediction, whereas MelonnPan uses a machine learning approach to predict
metabolomic potential from metagenomes. It has been applied to IBD datasets and showed
promising results 150. First, it builds a model based on paired metagenomic and metabolome data
obtained from the same samples and uses this model to predict metabolite profiles of a different
metagenomic dataset. We applied MelonnPan software to predict metabolite profiles of CRC
metagenomics data from fecal samples. For this, we used metagenomics and metabolome data
from the same CRC fecal samples to train the model.
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CHAPTER 3
MATERIALS AND METHODS
Metagenomic datasets
We used the shotgun metagenomics sequencing datasets obtained from the fecal samples of CRC
and healthy controls belonging to the USA, China, France, Austria, Japan, Italy, and the USACanada (samples from the US and Canada) in this dissertation work. These datasets were
downloaded from public databases, the European Nucleotide Archive (ENA) and the DNA Data
Bank of Japan (DDBJ). Two other datasets used for validation include the Austrian (ERP008729)
and Japanese (DRA006684 &DRA008156) datasets were downloaded from the ENA and DDBJ
Sequence Read Archive (DRA), respectively. National Center for Biotechnology Information
(NCBI), EBI, and DDBJ are the primary resources that together serve as an international public
archival resource for next-generation sequencing data known as Sequence Read Archive (SRA).
It was established as a part of the International Nucleotide Sequence Database Collaboration
(INSDC). SRA is the best resource to access the next-generation sequencing data for the
scientific community. Details of the samples with accession numbers of the datasets used in this
study are in Table 1 and characteristics of the samples were given in Appendix A. All seven
metagenomic sequencing datasets used in this study were sequenced using the Illumina platform
as paired-end sequence reads. We obtained the metadata information of metagenomic datasets
(except for the Japan dataset) from the EBI BioSamples database. And the downloaded metadata
(JSON-formatted) files were parsed using Perl/Python scripts and converted into table form with
each metadata field in the columns, including sample ID, study ID, secondary ID, sequencing
type, country, age, BMI, and diagnosis. The metadata for the Japan dataset was obtained from the
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original publication 151. And the metadata for Italy and USA-Canada datasets were obtained using
curatedMetagenomicData package in R 152.
Datasets belong to
the geographic
region

Accession number

Samples from the
corresponding dataset used in
this study

Database

USA55

PRJEB12449

52 CRC and 52 Control

ENA

France54

ERP005534

53 CRC, 61 Control, and 42
Adenoma (large & small)

ENA

China153

PRJEB10878

74 CRC and 54 Control

ENA

Austria53

ERP008729

46 CRC, 63 Control**, and 47
Adenoma

ENA

Japan151

DRA006684,
DRA008156

258 CRC and 246 Control, 67 MP

DDBJ

Italy58

SRP136711

22 Control, and 26 Adenoma

ENA

USA-Canada154

PRJNA389927

27 Control, and 26 Adenoma

ENA

(source)

Note: MP- multiple polyploid adenomas, ENA - European Nucleotide Archive, DDBJ the
DNA Data Bank of Japan, ** indicates control samples with missing age and BMI values.
*Based on metadata, CRC and control samples differ from original reported in article.
Table 1: Details of the datasets and samples used in this study. CRC biomarkers were identified using the
control and CRC samples belonging to the US, Chinese, and French geographic regions and validated using
Japanese and Austrian's control and CRC samples. On the other hand, for identifying adenoma biomarkers,
the control and adenoma samples of French, Italian, and the US-Canadian (combined) datasets were used.
The metagenomic and metabolic profiles of the Japan dataset were used to predict the metabolite profiles of
the US, China, and France datasets. From Italy and USA-Canada datasets, only adenoma, and control
samples were used (not CRC samples) in this study. From the Japan dataset, we have used CRC and
controls but not the samples belonging to the history of colorectal surgery (HS) and a few polyps (FP). In
the Japan & France datasets, samples for the stage of cancer are available, but we considered the stages of
cancer data together as CRC. The sample size of adenomas and controls in the Italy and USA-Canada
datasets differ from the original reported article due to metadata issues (In the original article, the Italy
dataset has 27 adenoma and 24 control samples; the USA-Canada dataset has 28 control and 27 adenoma
samples).

Identification of taxonomic profiles of metagenomic datasets
The quality of all seven metagenomic sequence datasets (Table 1) was assessed using
FastQC software 155. Then reads were aligned against Coliphage phi X 174 genome to remove
sequencing vector Phi X contamination and a human reference genome (GRCh38) to remove
human sequence read contamination using BBduk and BBmap tools 156. Data was further
analyzed using the MetaPhlAn2 software 157 and quantified the taxonomic composition of
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microbial communities of each sample. MetaPhlAn2 is marker-based software, and it depends
upon clade-specific markers from ~17,000 reference genomes, including bacterial, viral, and
eukaryotic genomes. It provides the taxonomic profiles up to species-level. For our analysis, we
used species-level abundance profiles and filtered out the species whose relative abundance was <
0.1% across the samples of the corresponding dataset to reduce the noise in the dataset. The
relative abundance profiles, taxonomic data, and metadata of each community were integrated
using Phyloseq package in R and were analyzed for alpha and beta diversities using the Vegan
package in R. The diversities are graphed using ggplot2 package in R.

Identification of CRC Biomarkers
In this study, we have performed the biomarker identification for CRC vs. healthy
controls and adenoma vs. healthy control cohorts. We have used LEfSe, co-occurrence networks,
and random forest methods for both CRC and adenoma biomarker identification. However, the
samples were different, as explained in Table 1. Brief description of methods used for
identification CRC- and healthy gut-associated microbes,
Linear Discriminant Analysis (LDA) effect size (LEfSe)
It is a statistical method that identifies biomarkers between 2 or multiple groups based on
the relative abundances 112. First, it identifies the differential features among the groups using a
non-parametric Kruskal-Wallis (KW) sum-rank test, followed by Wilcoxon rank-sum test to
identify consistent biological differences between the sub-groups. Finally, it estimates the effect
size of differential features using LDA. After LEfSe analysis, we selected the differential features
with LDA score > 2.0 and FDR-adjusted p-value ≤ 0.05.
Random Forest (RF) algorithm
RF is an ensemble machine learning method. It builds a multitude of decision trees
trained on different parts of the same training data and merges the decision from all decision trees
for more accurate prediction. It is one of the best prediction algorithms even in highly nonlinear
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systems 158 and is the most used method for microbiome data 58. The RF algorithm has advantages
over other machine learning models in anti-interference, simple optimization, and high
interpretability. It provides the feature importance through the Gini index (a measure of impurity)
that increases the interpretability of random forest models. The over-fitting in the random-forest
model can be avoided easily by optimizing the hyperparameters like the number of decision trees
and random sampled variables used in each split. Tuning of hyperparameters can be done via kfold cross-validation, where the tuning parameters are selected in such a way as to minimize the
test sample prediction error. RF models with more number of trees will improve prediction
accuracy. In this study, randomForest and Caret packages in R were used for building the RF
models. Species-level relative abundance data were converted into Z-score and used as input for
RF analysis along with group information. Then, we built separate RF classifiers by training each
dataset based on 10-fold cross-validation and selected the top-ranked microbes (with a higher
mean decrease in the Gini index) from each classifier as differential markers for each dataset.
Biomarker prediction using co-occurrence networks
We used SparCC 117 and DyNet 159 software for this method. Co-occurrence networks
were built based on correlation values among the community members. Briefly, SparCC v 0.1
software was developed for inferring the correlations for compositional data, with a large number
of different components where only sparse correlations exist among them. It takes the true
abundance values as input, performs the log-transformation, and estimates the linear Pearson
correlations. It uses the log-transformation to overcome the compositionality of metagenomics
data in correlation calculation 160. We used SparCC to estimate the correlation coefficients from
the species-level relative abundance data (normalized to 1 million counts) for CRC cases and
control samples separately for each dataset. The permutation-based approach was used to
estimate the correlation coefficients, and p-values for correlations were determined from 1000
bootstrap samplings. The duplicate correlations were removed and selected the correlation
coefficients > 0.5 (at p-value < 0.05), and plotted networks using Cytoscape 3.7.1 161. Later, CRC
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and control networks were synchronized using DyNet plugin to identify rewired nodes across the
two networks. DyNet allows the visualization and analysis of dynamic networks with changing
interactions and provides information about changed or rewired nodes. After analyzing
synchronized networks of each dataset, we selected the nodes with rewiring metric or Dn-score ≥
2.0 and an edge count ≥ 4 for each dataset as differential markers between CRC vs. healthy
controls.
Assessing the performance of predicted CRC markers

Differential microbial markers identified from each dataset and the combined
common-method specific markers were tested using RF models with 10-fold crossvalidations. The performance of RF classifiers was measured in terms of the area under the
curve (AUC) and the set of biomarkers with large AUC scores were selected. Then we calculated
the random effect size of each biomarker using the MetafoR package 162 in R and selected the
biomarkers with the highest random effect size associated with either CRC or control groups as
CRC global biomarkers.

Identification of adenoma biomarkers
For the identification of adenoma biomarkers, we have used the RF method (sample
details in Table 1). We have done the analysis with and without imputed data. Imputation of zeros
in the relative abundance data was done using the kNN() method from the VIM package in R.

Identification of gene families of strains of CRC pathogens
Pangenome-based phylogenomic analysis of CRC-related microbial species was
performed to understand the strain heterogeneity and CRC. We used PanPhlAn v 3.0 software 163
to perform analysis. It constructs the presence and absence matrix of the strain-specific sets of genes
based on a species-specific pangenome database. It can also build a custom pangenome database
from species-specific reference genomes. But we used the pre-processed pangenome database
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provided

with

the

software

for

this

analysis,

which

is

available

at

http://segatalab.cibio.unitn.it/tools/panphlan/species-db. It has pangenomes for most of the gut
microbial genomes. It takes metagenomic sequence reads (“FASTQ” formats) as input. It estimates
the gene and gene family coverage of metagenomes by mapping reads against the species-specific
pangenome using Bowtie2 and Samtools. Then predicts the presence of a strain in a metagenome
based on a minimum coverage of selected gene families (threshold of >0.5x) and uniform coverage
depth of median abundance of gene families (upper and lower threshold are < 1.20 and > 0.80,
respectively). The presence of multiple strains is detected by applying an upper threshold (< 0.20)
of median abundance. Finally, gene family coverage values are converted to presence and absence
profiles of individual strains of a species 163.
This analysis provides the functional characterization of strains across metagenomes and
is useful for pathogen discovery and disease epidemiology. In this study, we identified
pangenome gene family profiles of CRC-associated pathogens, including Fusobacterium
nucleatum, Bacteroides fragilis, Ruminococcus torques, Parvimonas micra and Escherichia coli
and compared the gene families of strains across the geographical regions, the USA, China, and
France. Fisher’s exact test was used to identify differentiating gene families (UniRef90), and the
functional roles of those genes were identified from UniProt Knowledgebase 164.

Prediction of metabolome profiles from metagenomic features
The metabolome of CRC and healthy gut microbiome samples were predicted to
understand the metabolic functions of the gut microbial community. This analysis was done using
the machine learning-based MelonnPan v1.0.0 software 149. Briefly, it uses the machine learning
approach to build a predictive model based on the metagenomic and metabolomic profiles of a
community. And it identifies the minimum set of microbial features (taxa or genes abundance)
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required for predicting a metabolite from the paired omic data using elastic net regularized
regression. Then select the best-fit metabolites based on cross-validate, and correlation weights
and use those metabolites to predict the metabolite profiles of a new community. MelonnPan can
be used for the 16S rRNA or shotgun metagenomic sequencing data to predict metabolite
information.
We used the metagenomic and metabolomic data of the Japan dataset to construct the
predictive model using MelonnPan. Then this model was used to predict the metabolomic profiles
of the US, Chinese and French populations based on the taxonomic feature. The predicted
metabolomic profiles of the three datasets were merged and analyzed using the edgeR and limma
package in R 165,166. Pathway analysis was performed on significant differential metabolites using
MetaboAnalyst v5.0 167. And then estimated the interactions between gut microorganisms and
metabolites in CRC samples from three geographic regions, the US, France, and China, using
Spearman correlations, and analyzed the correlations between global CRC microbial biomarkers
and differential metabolites identified in our study. Results plotted using ggplot2 and gplot
packages in R.

Microbial co-occurrence networks comparison between CRC and
controls
Cooccurring relationships in microbial communities were analyzed using co-occurrence networks
built from the correlations calculated using the SparCC algorithm. The topological parameters of
the networks were calculated using the Network Analyzer option in Cytoscape, and the MCODE
plugin was used to identify the highly connected clusters in the networks. These clusters were
compared between case and control networks. In addition to this, associations between identified
CRC microbial markers were compared using co-occurrence networks.
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Statistical analyses
Nonparametric Fisher’s exact test was used for the differential analysis of gene families.
Microbe-microbe or microbes-metabolites interactions were estimated using Spearman’s
correlation coefficients. For statistical significance, P < 0.05 and Benjamini-Hochberg corrected
FDR values were considered as appropriate. Standardized (Z-score) data were used for metabolite
analyses. The covariate effect on species diversity was tested using a multivariate linear
regression method. Batch effect on metabolite profiles was tested using edgeR and limma in R.
All data analyses and visualizations were conducted in R v 4.0.0. and above 168.

Functional analysis of metagenomes
Functional profiles of CRC metagenomic sequence data from the USA, China, and
France were identified using HUMAnN2 (the HMP Unified Metabolic Analysis Network)
software 113. It identifies the species-level functional profiles of microbial communities directly
from metagenomic reads without assembly. It quantifies the relative abundances of gene families
and pathways of microbes present in each metagenome. It also provides the stratified gene family
and pathway data at the species level that indicates the functional contributions of each species
present in the community. It uses a tiered search approach to identify gene families and pathways
from metagenomic reads. Initially, it identifies the microbial species using MetaPhlAn2 software.
Then it maps the sequence reads against sample-specific species pangenome database
(ChocoPhlAn database) to identify the gene families and known taxonomy. The unmapped reads
are translated and searched against UniRef90 or UniRef50 protein databases. Finally, gene
families are annotated to metabolic pathways based on the MetaCyc database using the MinPath
approach 169.
Downstream analyses of HUMAnN2 quantified metabolic pathways were performed to
identify the differential pathways between CRC and healthy metagenomes of the US, Chinese and
40

French populations and the specific contribution of microbes in CRC- and healthy gut-associated
pathways. Based on the unstratified pathway data, PCA (principal component analysis) and LEfSe
analyses were conducted to compare the distribution and differential pathways between CRC
cases and controls, respectively. PCA is a dimensionality reduction technique. Here we used the
base R function prcomp() to analyze the distribution of metabolic pathways between CRC and
control samples. Combined relative abundance profiles of the metabolic pathways of the US,
Chinese, and French populations were provided as input to PCA. The prcomp() function has
optional parameters to do normalization on input data, including center and scale. The parameter
scale=TRUE would normalize the variables, such that standard deviation equal to 1 and default
center option would center the variable mean equal to zero. The principal components, 1, 2, and 3
were extracted and plotted the results to show the differences between CRC cases and controls
across the datasets. The stratified pathway output from HUMAnN2 was analyzed to understand
the species’ contribution in metabolic pathways in CRC and healthy conditions and plotted the
graphs using the ggplot2 package in R.
The gut microbial communities (in the large intestine) are major producers of SCFAs.
They produce acetate, propionate, and butyrate through carbohydrates and amino acids
fermentation. Among the SCFAs, butyrate is a preferred energy source for gut epithelial cells,
maintains gut epithelial development, and protects it from colonic diseases such as colitis and
CRC 170,171. The butyrate production in gut microbes occurs through four major pathways. These
include Pyruvate, 4-aminobutyrate, Glutarate, and Lysine fermentation pathways. The name of
the pathway indicates the starting substrate that is utilized in the pathway. The final intermediate
compound for all butyrate synthesis pathways is crotonyl-CoA. It is converted to butyryl-CoA
and then to butyrate, these reactions are catalyzed by butyryl-CoA dehydrogenase complex
(NAD+, ferredoxin) and butyrate kinase (Ca), respectively 172–174.
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Dysbiosis in the gut microbiota to linked to CRC, the consequent overabundance of
pathogenic microbes in the CRC gut may alter the butyrate production. To understand the effect
of dysbiosis on microbial butyrate synthesis, we performed a pathway-based analysis of gene
families in the CRC and healthy gut metagenomes. For this analysis, we considered the butyrate
synthesis pathways based on the work by Anand et al., 2016 174. We extracted the gene families
involved in butyrate production pathways from the unstratified pathway output and compared
between CRC and control samples based on Welch’s t-test using STAMP software. The extraction
of gene families was solely based on text search, i.e., full gene names were used for the search,
not considered putative forms and derivatives of the gene products. Then, also analyzed for the
contributing microbes of each butyrate pathway in CRC and healthy gut communities based on
stratified pathway output.

Metabolic modeling of CRC and healthy gut communities
In this study, we used the KBase tool to build single species metabolic models and
community metabolic models. KBase (the Department of Energy Systems biology
Knowledgebase) is a web-based software platform for system biology applications. We used
Annotate Genome/Assembly with RASTtk, Build Metabolic Model, Merge Metabolic Model
Annotation, and Run Flux Balance Analysis apps from KBase to build metabolic models of the
gut community. The Build Metabolic Model app uses the ModelSEED pipeline for genomes.
Also, it needs RAST annotated genomes because RAST annotations are linked directly to
biochemical reactions in the ModelSEED biochemistry database, which KBase uses for model
building 142. RAST server is devoted to annotating bacterial and archaeal genomes. After
annotating the genome, draft models are generated using the build metabolic model app. We
chose the gap-fill option in KBase metabolic modeling to obtain gap-filled model, that enables
biomass production. Gap-fill algorithm identifies missing reactions and fills those gaps based on
media stoichiometry.
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We used different media for metabolic modeling based on human diets that include
vegetarian diet (Appendix B), unhealthy diet (Appendix C), and US recommended diet (Table 2).
The vegetarian and unhealthy diets were taken from the Virtual Metabolic Human (VMH)
database contain 91 metabolites 175,176. The unhealthy diet was designed to contain very low
dietary fiber, high calories, simple sugars, saturated fatty acids, and cholesterol. The vegetarian
diet was based on the dietary intake information from vegetarian population in France. We built
the custom US diet medium (Table 2, Appendix D) based on the dietary guidelines for Americans
. In the designed diet, the food quantities details were in the form of volume of consumption
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per week (cup eq/week). The volume to weight (gm/day) conversion of diet components were
done using ‘calories and nutrient calculator’ at web link https://www.aquacalc.com/calculate/food-volume-to-weight. Then the weight quantities of each component of US
diet (gm/day) were fed into ‘diet designer’ app on VMH database to obtain in the corresponding
molecular composition and flux values (mmol/(human*day) for the uptake rate of metabolic map
nutrients. It also provides the information on total calories and percentage of energy contributed
from lipid, carbohydrates, proteins, and alcohol (Table 3). To get the feasible metabolic model
using these diet media, we added few trace elements like cobalt and molybdate, which are
required for the bacterial growth to diet media. The BiGG database metabolite IDs used in the
VMH database diet designer are not compatible for KBase metabolic modeling. KBase uses
ModelSEED database metabolite IDs, so we converted BiGG metabolite IDs to corresponding
ModelSEED metabolite IDs in all three-diet media to use these media in KBase modeling.
Then, we built the individual metabolic models of CRC- and control-associated microbes
(Table 4) and performed flux balance analysis (FBA) of these metabolic models using vegetarian,
unhealthy, and US diet media, separately, to check the growth of each microbe on corresponding
medium. After that, the gap-filled metabolic models of CRC- and control-associated microbes
(Table 4) constructed on different media were merged, separately, into community models and
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performed FBA on each community model. We used the compartmentalized multi-species
merging for community building, where each community member has a separate compartment
and a single extracellular cytosol compartment (gut). The default biomass reaction (KBase
metabolic model) was used for the objective value for each model. Then, we analyzed the flux
values (uptake/secretion rate of metabolites) of metabolic reactions between the CRC and control
communities in different diet media to understand the metabolic capabilities of CRC- and controlcommunities. Individual contributions of community members were also analyzed based on the
reaction flux values of the pathways. This study mainly focused on metabolic flux values of the
2C-methyl-D-erythritol 4-phosphate (MEP) pathway, the mevalonate pathway, and the butanoate
synthesis (pyruvate to butanoate metabolism) pathway of CRC and control communities on three
diet media.
Compounds

cpd00001
cpd01420
cpd00365
cpd00305
cpd00166
cpd00220
cpd00218
cpd00133
cpd00644
cpd00419
cpd00263
cpd00215
cpd00104
cpd00345
cpd00087
cpd00059
cpd03226
cpd01628
cpd01401
cpd00063
cpd00099
cpd00205
cpd00254
cpd00971

Name

H20
Beta-Carotene
Retinol
Thiamin
Calomide
Riboflavin
Niacin
Nicotinamide
PAN (Pantothenate,
vitamin B5)
PM (Pyridoxamine)
Pyridoxol
Pyridoxal
BIOT
5Methyltetrahydrofolate
Tetrahydrofolate
L-Ascorbate
Vitamin D3
Vitamin E
Vitamin K1
Ca2+
ClK+
Mg
Na+

Formula

MinFlux

MaxFlux

Concentration

C9H16NO5
C8H13N2O2
C8H11NO3
C8H9NO3
C10H15N2O3S

-100
-100
-100
-100
-100

0.030939
0.003857
0.003857
0.003904
0.003015

0.030939
0.003857
0.003857
0.003904
0.003015

C20H23N7O6
C19H21N7O6
C6H7O6
C27H44O
C29H50O2
C31H46O2
Ca
Cl
K
Mg
Na

-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100

0.000257
0.000266
0.909594
1.79E-05
0.022081
0.000257
36.41772
203.5486
92.85283
19.9151
67.52426

0.000257
0.000266
0.909594
1.79E-05
0.022081
0.000257
36.41772
203.5486
92.85283
19.9151
67.52426

H2O
C40H56
C20H30O
C12H17N4OS
Calomid
C17H19N4O6
C6H4NO2
C6H6N2O

-100
-100
-100
-100
-100
-100
-100
-100

81998.05
0.010513
0.003015
0.006524
4.76E-06
0.006968
0.073867
0.073853

81998.05
0.010513
0.003015
0.006524
4.76E-06
0.006968
0.073867
0.073853
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cpd00009
cpd00058
cpd10515
cpd10516
cpd00030
cpd00034
cpd00208
cpd01355
cpd00076
cpd00082
cpd00709
cpd00035
cpd00051
cpd00041
cpd00023
cpd00033
cpd00119
cpd00322
cpd00107
cpd00039
cpd00060
cpd00066
cpd00129
cpd00054
cpd00161
cpd00065
cpd00069
cpd00156
cpd01107
cpd01741
cpd03847
cpd15298
cpd17034
cpd00214
cpd15609
cpd01080
cpd15269
cpd01122
cpd30350
cpd15016
cpd03848
cpd16341
cpd14900
cpd00188

Phosphate
Cu2+
Fe+2
Fe+3
Mn2+
Zn2+
LACT
Beta-Maltose
Sucrose
D-Fructose
Beta D-Galactose
L-Alanine
L-Arginine
L-Aspartate
L-Glutamate
Glycine
L-Histidine
L-Isoleucine
L-Leucine
L-Lysine
L-Methionine
L-Phenylalanine
L-Proline
L-Serine
L-Threonine
L-Tryptophan
L-Tyrosine
L-Valine
Decanoate
ddca (Dodecanoate)
Myristic acid
Tetradecenoate
Pentadecanoate (nC15:0)
Palmitate
Heptadecanoate
(C17:0)
Ocdca (Octadecanoic
acid)
Octadecenoate
Linoleate
Alpha-Linolenic acid,
C18:3, n-3
Stearidonic acid, 4
Arachidic acid, 4
Icosenoic acid
(11Z,14Z)Icosadienoyl-CoA
Arachidonate

HO4P
Cu
Fe
Fe
Mn
Zn
C12H22O11
C12H22O11
C12H22O11
C6H12O6
C6H12O6
C3H7NO2
C6H15N4O2
C4H6NO4
C5H8NO4
C2H5NO2
C6H9N3O2
C6H13NO2
C6H13NO2
C6H15N2O2
C5H11NO2S
C9H11NO2
C5H9NO2
C3H7NO3
C4H9NO3
C11H12N2O2
C9H11NO3
C5H11NO2
C10H19O2
C12H23O2
C14H27O2
C14H25O2

-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100

22.54247
0.029273
0.176083
0.176083
0.121168
0.192507
96.11881
4.097743
20.34214
75.72849
20.87944
16.04321
20.42874
21.61436
78.04939
34.37761
10.35644
19.58973
35.045
27.31752
9.103951
16.48431
15.232
27.17632
19.35086
3.662143
11.1881
26.2975
2.173545
1.94166
7.208576
0.11796

22.54247
0.029273
0.176083
0.176083
0.121168
0.192507
96.11881
4.097743
20.34214
75.72849
20.87944
16.04321
20.42874
21.61436
78.04939
34.37761
10.35644
19.58973
35.045
27.31752
9.103951
16.48431
15.232
27.17632
19.35086
3.662143
11.1881
26.2975
2.173545
1.94166
7.208576
0.11796

C15H29O2
C16H31O2

-100
-100

0.160693
46.25685

0.160693
46.25685

C17H33O2

-100

0.145036

0.145036

C18H35O2
C18H33O2
C18H31O2

-100
-100
-100

16.65582
119.3704
48.92258

16.65582
119.3704
48.92258

Undefined
C18H27O2
C20H39O2
C20H37O2

-100
-100
-100
-100

2.253888
0.072001
0.479069
0.858232

2.253888
0.072001
0.479069
0.858232

C41H66N7O17P3S
C20H31O2

-100
-100

0.009732
0.266228

0.009732
0.266228
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cpd05196
cpd05231
cpd16301
cpd03852
cpd00211
cpd03846
cpd00160
cpd00027
cpd05274
cpd05235
cpd00393
cpd16142
cpd30041
cpd00098
cpd28193
cpd03851
cpd00117
cpd00320
cpd00567
cpd00851
cpd00149
cpd11574

Docosanoate
Erucic acid, 4
Docosapentaenoic acid
Docosahexaenoic acid
Butyrate
Octanoate
Cholesterol
Glucose
Palmitoleic acid
Tetracosanoate
Folate,4
Amylose(n)
Starch n=300 repeat
units (80 amylose, 220
amylopectin)
Choline
Starch
Eicosapentaenoic acid
D-Alanine
D-Aspartate
D-Proline
Trans-4-Hydroxy-Lproline
Cobalt(Co2+)
Molybdate

C22H43O2
C22H41O2
C22H33O2
C22H31O2
C4H7O2
C8H15O2
C27H46O
C6H12O6
C16H29O2
C24H47O2
C19H17N7O6
Undefined

-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100

0.203476
0.454425
0.137831
0.548221
3.799548
2.12061
0.32442
66.04202
3.953317
0.043029
0.000364
15.39518

0.203476
0.454425
0.137831
0.548221
3.799548
2.12061
0.32442
66.04202
3.953317
0.043029
0.000364
15.39518

undefined
Choline
Starch
Eicosapentaenoic
acid
D-Alanine
D-Aspartate
D-Proline
trans-4-Hydroxy-Lproline
Co2+
Molybdate

-100
-100
-100

0.142535
2.816046
54.98281

0.142535
2.816046
54.98281

-100
-100
-100
-100

0.470711
16.04321
21.61436
15.232

0.470711
16.04321
21.61436
15.232

-100
-100
-100

0.038569
0.001
0.001

0.038569
0.001
0.001

Table 2: Metabolite flux values of the US diet media.

Vegetarian

Total
Lipids
Energy
%Energy
(Kcal)
1888.29 33.9803

Unhealthy

3847.05

48.7122

30.1623

16.2132

US recommended
diet

2001.52

33.95

48.033

20.38

Diet name

Carbohydrates %
Energy

Protein
%Energy

Alcohol
%Energy

51.3355

10.7402

0.464363
2.50259
not
recommended

Table 3: Intake of total calories of diets used in this study. Vegetarian and unhealthy diet are from VMH database, US
diet was custom made diet using VMH diet designer.
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Refseq ID

Microbe

Associated condition

GCF_001286525.1

Bacteroides fragilis

CRC

GCF_009730315.1

Gemella morbillorum

CRC

GCF_008632235.1

[Clostridium] symbiosum

CRC

GCF_003019785.1

Fusobacterium nucleatum subsp.
nucleatum ATCC 23726

CRC

GCF_003475105.1

Eubacterium ventriosum

Healthy

GCF_003312465.1

Faecalibacterium prausnitzii

Healthy

GCF_902387955.1

Roseburia hominis

Healthy

GCF_000146185.1

Eubacterium eligens

Healthy

Table 4: Gut microbe for metabolic community models.
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CHAPTER 4
RESULTS & DISCUSSION
Identification of global biomarkers for colorectal cancer
Results
Gut microbial communities associated with CRC
In this study, we have taken shotgun metagenomic sequencing data from three different
geographical regions (Table 1), the USA, China, and France, and identified the taxonomic
composition using MetaPhlAn2 software, which revealed the existence of bacteria, archaea,
viruses, and eukaryotes in most samples. Among those, bacterial members were dominant with
>97% of the total taxa identified in each sample. The MetaPhlAn2 profiles from each geographic
region were merged separately, and species profiles were extracted and filtered to remove species
with < 0.1% relative abundance from each sample. Finally, 418, 410, and 469 microbial species
were obtained in the US, Chinese, and French CRC datasets, respectively. All downstream
analyses were conducted using species-level taxonomic profiles. We explored the differences in
the gut communities and identified the top 20 species based on mean relative abundance from
each geographic region. In each sample, the top 20 microbial species covered greater than 50% of
the total abundance. The top species include Faecalibacterium prausnitzii, Eubacterium rectale,
and Eubacterium eligens in controls, and Prevotella copri, Ruminococcus torques, and
Bacteroides vulgatus in CRC samples (Figure 1).

48

Figure 1: Stacked bar plot of top 20 species-level taxa of CRC and healthy controls gut communities.

Diversity Analysis
Diversity of gut communities was measured using Shannon alpha diversity index and
Bray-Curtis dissimilarity measures, and we performed NMDS along with PERMANOVA
evaluation on Bray-Curtis dissimilarity measures. It showed that alpha diversity was not
significantly different between CRC and control communities across datasets. Beta diversity
based on Bray-Curtis dissimilarity measures showed significant differences between CRC and
control communities in French and Chinese datasets with no significant differences in the US
dataset (Fig. 2A-D, 3B). We also compared CRC and healthy gut communities separately across
the geographical regions (Fig. 3C and D). It showed the differences in control samples and CRC
samples across the three geographical regions. The effect of confounding factors analyzed using
multivariate linear regression analysis showed that the species diversity of CRC and control
communities were not affected by potential confounding factors like age, BMI, and sex (Fig. 3A).
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Figure 2: Alpha and beta diversity comparisons among CRC and control groups.
Analyses were performed at species-level taxa. (A) Boxplots showing the Shannon species diversity in each dataset.
Significance between the groups was calculated by two-tailed Wilcoxon rank-sum tests; Non-metric Multidimensional
Scaling (NMDS) ordination plots depict the beta-diversity among CRC and control samples, which were measured in
Bray-Curtis dissimilarity metrics. Ellipses in the figure show the 95% confidence intervals of each group of samples.
Each dot denotes the microbial composition of a single sample in a low-dimensional space. (B) NDMS ordination in
France dataset; (C) NDMS ordination in China dataset; (D) NDMS ordination in USA dataset. Significance between
the groups was measured based on the Adonis test.
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Figure 3: Beta diversity and covariate analysis across CRC datasets. Analyses were performed at species-level taxa.
(A) Multivariate analysis of Shannon diversity coefficients using raw and BMI-, age- and sex-adjusted coefficients
from linear regression models; (B) Boxplots showing the Bray-Curtis distances between the comparison pairs of gut
microbial communities. Dots represent the distance between the samples in each comparison group and the lines in the
boxes correspond to the median. Significance between the groups was calculated by two-tailed Wilcoxon rank-sum
tests. Non-metric Multidimensional Scaling (NMDS) ordination plots depict the beta-diversity across the datasets.
Ellipses in the figure show the 95% confidence intervals of each group of samples. Each dot denotes the microbial
composition of a single sample in a low-dimensional space. (C) NDMS ordination in CRC samples across three
datasets; (D) NDMS ordination in control samples across three datasets; The significance between the groups was
measured based on the Adonis test.
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Altered microbial associations in CRC communities
For this analysis, we have used three different methods that include co-occurrence
networks, LEfSe algorithm, and RF methods, on each dataset separately. Then evaluated the
identified markers separately as dataset-specific markers, and as a combined set of markers from
three datasets from each method using only the RF model.
Co-occurrence network analysis
The correlations between pairs of microbes were estimated using the SparCC algorithm in CRC
cases and controls, separately. Then constructed both CRC and control co-occurrence networks
based on the significant positive correlations r > 0.4 at P-value < 0.05 for each geographic region.
Co-occurrence patterns in the gut microbial communities were analyzed based on the cooccurrence networks. Those details were provided under the section- co-occurrence networks of
CRC-associated microbial species. For biomarker discovery, we used DyNet software to
synchronize the CRC and control networks of each geographic region and identify the rewired
nodes between CRC and control networks. Rewired node score was indicated by Dn-score. It
indicates the changed interactions of a microbe across the synchronized networks. The
synchronized CRC and control networks showed 156, 65, and 81 rewired nodes in the US,
French, and Chinese datasets, respectively. Example for DyNet visualization of synchronized
networks shown in Fig. 4A. The rewired nodes were compared among the datasets (Fig. 4B). The
UpSet plot shows a set of 40 microbes as rewired nodes that were found in all datasets. Most of
these 40 microbes include gut commensal microorganisms such as Roseburia hominis,
Eubacteriun halli, Blautia producta and Faecalibacterium pratsnitzii, and pathogens such as
Ruminococcus gnavus, Clostridum spp., and Solobacterium moorei. There were 156 rewired
nodes in the US dataset, among them it showed a high number of 87 unique rewired nodes
(differential species) (Fig. 4B). A different set of rewired nodes was selected and assessed the
performance of DyNet markers, and those include differential taxa identified in each geographic
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region by DyNet (DyNet dataset-specific markers) and a set of 78 rewired nodes that were
common in 3 or 2 geographic regions (common DyNet-specific markers).

Figure 4: Co-occurrence networks and DyNet dataset-specific markers.
(A) DyNet visualization of synchronized CRC and healthy control co-occurrence networks of microbial species from
Chinese dataset. The red-colored nodes and edges are present only in the CRC network, green-colored nodes and edges
are present only in the control network, and white nodes are present in both. (B) An Upset plot visualization of DyNet
dataset-specific markers intersections across France, USA, and China datasets. Each bar represents the number of
dataset-markers in that category, and orange dots below the bar indicate their conservation across the datasets. For
instance, the 1st bar shows 40 DyNet dataset-specific markers common in all three datasets.

LEfSe analysis
Differential microbial species between CRC and control groups were selected at LDA
<2.0 and P-value <0.05 (Fig. 5A, Fig. 6A, and B). From the three datasets, a total of 110
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microbial species were identified as differential species. The UpSet plot of these differential
markers showed eight common pathogenic microbes in all three geographic regions, those
include, F. nucleatum, B. fragilis, Prevotella intermedia, G. morbillorum, C. symbiosum, P.
stomatis, Parvimonas spp., and P. asaccharolytica. These species were identified by LEfSe
analysis as CRC enriched microbes. Other species include some that were unique to a geographic
region or as common in at least two geographic regions (Fig. 5B). Then selected different sets of
markers to evaluate the performance, those include- LEfSe dataset-specific markers from each
dataset and a set of common LEfSe dataset-specific markers present in two or more geographic
regions (common LEfSe-specific markers).
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Figure 5: LEfSe analysis.
(A) Histograms of differential species in Chinese dataset. CRC enriched species were indicated with a negative LDA
score (red), and species enriched in healthy controls were indicated with a positive LDA score (green). Only species
with LDA score > 2.0 at P < 0.05 were shown in the plot; (B) An Upset plot visualization of LEfSe dataset-specific
marker intersections across the three datasets (France, USA, and China). Each bar represents the number of differential
species in that category. The orange dots below the bar indicate their conservation across the datasets. For instance, the
1st bar shows eight LEfSe identified differential species common in all three datasets.
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Figure 6: Visualization of LEfSe identified the differentially abundant species between CRC and healthy controls.
CRC enriched species are indicated with a negative LDA score (red), and species enriched in healthy controls are
indicated with a positive LDA score (green). Only species with the LDA score > 2.0 at p < 0.05 are shown in the plot.
(A) Histograms of differential species in USA dataset. (B) Histograms of differential species in France dataset.
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Random forest models
In this method, the RF models were built by training on each dataset separately using 10-fold
cross-validations. The differential markers were selected based on the RF internal ranking using
Gini importance. Forty top-ranked species were selected from each geographic region as
differential marker sets. The UpSet plot analysis of these markers showed 15 common differential
species in all three geographic regions, whereas the rest of them were randomly distributed
among the geographic regions (Fig. 7B). An example set of RF-identified microbial markers are
shown in Fig. 7A. Then we selected RF identified differential taxa for each geographic region
(RF dataset-specific markers) and RF dataset-specific differential markers common in two or
more geographic regions (common RF-specific markers) for further assessment among the
geographic regions.
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Figure 7: Random Forest (RF) identified microbial markers of CRC in USA, French, and Chinese datasets.
(A) In the random forest cross-validations, the prediction performance of each species was scored based on internal RF
rankings. The figure shows the rankings of the RF identified species markers with a rank below 20 in at least one
dataset. (B) An Upset plot visualization of RF dataset-specific markers intersections across the three datasets. Each bar
represents the number of dataset-specific markers in that category, and the orange dots below the bar indicate their
conservation across the datasets. For instance, the 1st bar shows the 15 RF dataset-specific markers common in all three
datasets.
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Identification and validation of global microbial markers for CRC
For the identification of global CRC biomarkers, we built the RF classifiers based on the
dataset-specific and common method-specific markers. We tested the performances of each
classifier based on inter-cohort and cross-cohort 10-fold cross-validations. The performance was
measured as AUC values. After that, the markers were validated against Austria and Japan
datasets, which were not used in model building.
To identify global CRC biomarkers, we first compared the AUC values of the classifiers
based on the dataset-specific markers (Fig. 8A) and common method-specific markers (Fig. 8B).
These comparisons showed higher performance of the common method-specific markers (RFand DyNet-specific markers) than the corresponding individual dataset-specific markers.
Individual dataset classifiers. The individual dataset DyNet- and RF classifiers’ average
performance range from 0.57 to 0.60 and 0.58 to 0.66, respectively, whereas the common DyNetand RF-specific marker classifier’s average performance ranged from 0.54 to 0.70 and 0.59 to
0.72, respectively, across the datasets. The individual and common LEfSe-specific marker
classifiers showed similar average performance ranging from 0.58 to 0.70. Among the common
method-specific biomarker classifiers, RF-specific classifiers showed better performance scores
ranging from 0.56 to 0.78 compared to LEfSe-specific (AUC score 0.53 to 0.74) and DyNetspecific (AUC score 0.5 to 0.73) models on cross-validation of datasets. Based on this analysis,
we selected a set of 58 common RF-specific markers for further validation on other datasets.
The bigger the list of microbial markers the more challenging it gets to handle in routine
diagnostic procedures. So, to select a more precise list of markers, we filtered the RF markers
based on RF ranking and the random effect size of each marker. First, we selected the markers
with ranking < 30 in at least one dataset, then estimated the random effect size of the markers and
selected a list of 21 microbial biomarkers with the highest random effect size associated with
either CRC or controls across the US, Chinese, and French datasets (Fig. 9A).
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Figure 8: Prediction performance of the random forest (RF) classifiers.
Row indicates the RF classifier trained on the dataset-specific or common method-specific CRC markers; column
indicates the classifier applying to the dataset of the corresponding column. In each three-by-three matrix of AUC
values, diagonal values represent the AUC values of cross-validation obtained by applying the trained row RF classifier
on the column dataset. Off-diagonal values represent the AUC values of cross-cohort validation obtained by applying a
trained row RF-classifier on corresponding column dataset. (A) RF-classifiers were built from dataset-specific markers
(row); (B) RF-classifier were built from the common markers present in at least two datasets from USA, France, and
China (common method-specific markers). The ‘Average AUC score’ row represents the column average of the
corresponding three by three AUC score matrices. Notation: e.g., DY_USA_sp_USA, means classifier trained on the
USA data based on the USA-specific markers identified by DyNet method, common_DY_USA means classifier trained
on the USA data based on the common markers identified by DyNet method those are present in at least in two datasets
DY - DyNet, LF – LEfSe, RF – random forest, and sp – specific.

Then, the biomarkers were validated on the Japanese and Austrian datasets and identified
a set of 21 RF-specific markers. These 21 markers showed similar performance to the larger set
of 58 RF-specific markers on three datasets. The cross-validation AUC scores of these markers
range from 0.62 to 0.78 AUC (Fig. 9B), and cross-validation AUC scores on Austrian and
Japanese datasets were 0.66 and 0.61. The meta-analysis showed associations of these
biomarkers- 14 biomarkers were associated with CRC samples. In contrast, seven biomarkers
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were associated with control samples across the USA, China, and France regions (Random-effect
model fit, p < 0.0001). Most of the pathogenic species were found associated with CRC, those
include Bacteroides fragilis, Fusobacterium nucleatum, Ruminococcus torque, Clostridium
symbiosum, Gemella morbillorum, Clostridium citroniae, Solobacterium moorei, Parvimonas
micra, and others. In contrast, non-pathogenic species like Faecalibacterium prausnitzii,
Eubacterium eligens, Eubacterium ventriosum, Eubacterium hallii, and others were associated
with control samples. (Fig. 9A).

Discussion
In this study, we comprehensively assessed the composition of CRC and control gut microbiomes
belonging to diverse geographic regions. Diversity analysis showed qualitative differences
between CRC and control samples; CRC samples were enriched with pathogenic microbes such
as B. fragilis and B. vulgatus, whereas controls were enriched with Eubacterium spp.,
demonstrating the dysbiosis of the gut microbiome in CRC 178. Gut microbial dysbiosis and
changes in its structural components, such as the increase in pathogenic microbes, are associated
with CRC development 179. Different studies considered the dysbiosis as the altered abundance of
gut microbiota in CRC and identified the specific microbial associations as biomarkers of CRC
53–55,151

. However, results were inconsistent across the studies due to heterogeneity of gut

microbial composition, which varies with genetic traits and environmental stimuli, lifestyle, and
dietary habits. This results in biased associations based on dominant influencing factors
associated with cohort/population. We performed a meta-analysis based on the datasets from
diverse geographic regions and identified a set of global CRC biomarkers that were consistent
across the datasets. In this analysis, we selected common CRC-microbial associations across
geographic regions based on each method to avoid nonspecific associations introduced by the
heterogeneity factors. Validations on other datasets with the selected common microbial
associations showed that the RF method performed better than the LEfSe and co-occurrence
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network methods. The performance of RF-specific markers was consistently increased on all
datasets for common RF-specific markers compared to RF dataset-specific markers. LEfSe
method performed better with independent dataset-specific biomarkers compared to common
LEfSe-specific biomarkers. DyNet co-occurrence networks markers performed better with
common DyNet-specific markers than dataset-specific DyNet markers. However, its performance
was lower compared to common RF-specific markers. In our study, RF showed higher
performance, and it consistently increased from RF dataset-specific markers to common RFspecific markers. Hence, we selected the RF-identified markers as global CRC markers.
The identified biomarkers in our study were consistent with the other studies 58,59. We
also identified new biomarkers in this study that were not reported as biomarkers in the previous
studies, which include Alistipes onderdonkii and Clostridium citroniae. The genus Alistipes is
known to contribute to the inflammatory effects in the host due to the presence of putrefaction
pathways such as histidine degradation and productions of indole, tetrahydrofolate, and phenol
. And the C. citroniae has shown to present in early-stage to later-stage CRC samples with
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incremental abundances 181. The other CRC-associated biomarkers identified in this study were
pathogenic microbes- F. nucleatum and B. fragilis were shown to be responsible for pathogenic
reaction in the host 179,182–184, and P. stomatis and S. moorei were enriched in saliva and stool

of CRC patients 185. The control-associated biomarkers are gut commensal organisms, which
include F. prausnitzii, E. ventriosum, and E. hallii. They are known to produce SCFA, butyrate,
which plays a favorable role in gut mucosal health 186.
Adenoma Biomarkers
We used RF method to identify the differential markers between control and adenoma samples in
Italy, USA-Canada, and France datasets. It showed very lower AUC score, average AUC scores
were 0.58, 0.65, 0.67 in individual RF models with 10-fold cross-validations for France, Italy and
USA-Canada datasets, respectively. None of these models performed well on inter-cohort datasets,
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the performance score decreases further. The prediction accuracy was not improved even using
imputed data; hence, no biomarkers were identified for adenoma prediction. These results were
consistent with previous studies, the adenoma microbiome is similar to healthy gut microbiome 58.

Figure 9: Meta-analysis and prediction performance of CRC biomarkers.
A. Meta-analysis of selected Random Forest CRC biomarkers markers using MetaPhlAn2 profiles from USA, China,
and France geographic regions. The colored lines represent the 95% confidence interval for each dataset and random
effect model estimate, B. Cross-validations of a minimum set of random forest CRC biomarkers on USA, France, and
China datasets. The AUC values on each cell of heatmap were obtained by the random forest classifier (built from
selected random forest features) trained on the row dataset by applying the classifier on the column dataset.
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Co-occurrence networks of CRC-associated microbial species
Results
To understand the microbial co-occurrence patterns in CRC- and healthy-gut
communities, we analyzed the community networks built based on the estimated correlations
using the SparCC algorithm. We observed more pairwise correlations in control communities
than in CRC communities in the US, Chinese and French population (r values ranged from -0.52
to 0.92 at p-value < 0.05). In each community, positive correlations were greater than negative
correlations (Figure 10A). However, comparing the stronger positive correlations (r > 0.4)
showed higher correlations in CRC communities of the USA and France than corresponding
control communities. In this study, we focused on the positive correlations (r > 0.4) of the gut
microbes (Figure 10B). To visualize those microbial associations, we extracted all pairwise
correlations with r > 0.4 and built the co-occurrence networks, separately, for CRC cases and
controls of each geographic region. The node and edge details and other topological properties of
those networks are shown in Table 5, each node represents a microbe, and edges are significant
correlations between the microbes. The high heterogeneity and R2 values and node degree
distribution (Figure 10C) of the networks indicate the non-random co-occurrence pattern in the
microbial networks, which is the property of scale-free networks. The heterogeneity of CRC
networks in the US and French networks was higher than the corresponding control networks.
Average mean degree and number of edges (stronger correlations) were higher in CRC and
control networks of the US population compared to corresponding networks of Chinese and
French populations, which is probably be due to more nodes with > 0.4 correlations in the USA
networks.
We observed a few nodes with high node degree (> 10) in CRC and healthy gut microbial
networks; some of those include, Clostridium bolteae, Clostridium clostridioforme, Eggerthella
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unclassified, Roseburia hominis, Faecalibacterium prausnitzii, Alistipes shahii, Clostridium
hathewayi, Ruminococcus gnavus, Flavonifractor plautii, Dorea formicigenerans, Bacteroides
cellulosilyticus, Granulicatella adiacens and Clostridium symbiosum. Some of these microbes are
commensal organisms of normal gut microbiota, while some are implicated in colorectal cancer.
Roseburia hominis and Faecalibacterium prausnitzii are commensal bacteria involved in butyrate
production that is essential for gut physiology and human health 187,188. Another gut commensal
microbe in this list is Bacteroides cellulosilyticus, which is a strict anaerobic bacterium belong to
the genus Bacteroides. The members of the Bacteroides play an essential role in the degradation
and fermentation of organic materials. Bacteroides cellulosilyticus is involved in the conversion
of cellulose and other sugars into small molecules such as acetate, propionate, succinate, formate,
and lactate 189. Clostridium bolteae and Clostridium clostridioforme are members of normal gut
microbiota. However, these can cause opportunistic infections when the gut barrier is damaged
due to antimicrobial resistance genes in their genomes 190. The bacterial species, Alistipes shahii,
Clostridium hathewayi, Ruminococcus gnavus, Flavonifractor plautii, Dorea formicigenerans,
Granulicatella adiacens, and Clostridium symbiosum were known to be associated with
inflammatory reactions, colorectal cancer, and other disease conditions in the host 150,153,191–193.

65

Figure 10: Microbial interaction pairs in CRC and healthy gut communities at P value < 0.05.
(A) Total microbial interactions ranged from correlation values -0.52 to 0.92. (B) Microbial interactions at correlation >
0.4.
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R-squared (Node degree)

Clustering coefficient

Avg. degree

Heterogeneity

R-squared (node degree)

5.08

0.86

0.79

205

375

0.27

3.65

0.91

0.89

186

259

0.28

2.78

0.83

0.92

185

306

0.29

3.30

0.77

0.86

180

257

0.29

2.85

0.80

0.90

135

178

0.30

2.63

0.84

0.85

No. of Edge

Heterogeneity

0.37

No. of Nodes

Avg. degree

691

No. of Edges

272

No. of Nodes
USA
China
France

Control network

Clustering coefficient

CRC network

Table 5: Properties of microbial co-occurrence networks built based on the SparCC correlations.

Cluster analysis (using MCODE) on the co-occurrence networks of species with positive
correlations > 0.4 identified highly connected clusters in both CRC and control networks. The
clusters from CRC and control networks of the USA are shown in Figure 11. Most of the cluster
members (species) belonged to phylum Firmicutes, and very few members were from
Bacteroides, Actinobacteria, Proteobacteria, and Fusobacteria. Similar clusters were observed in
CRC and control networks, i.e., clusters A, B, C, and D in CRC networks were identical to
clusters a, b, c, and d in control networks, respectively. However, the pairwise associations were
less in control networks than CRC networks. Species in clusters A, B, C, D, a, b, c, and d were
mainly from Firmicutes. Cluster E and F were found in CRC networks, whereas cluster e mainly
consisted of Lachnospiraceae found in control networks. Cluster E and F include the species
belonging to Firmicutes, Bacteroides, Actinobacteria, Proteobacteria, and Fusobacteria. A virus
species, Porcine type-C oncovirus was also associated with cluster E. Species from clusters F and
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C identified as differential markers in all three geographic regions. Species from cluster F
(Gemella morbillorum, Parvimonas unclassified, Parvimonas micra, and Porphyromonas
asaccharolytica) were associated with CRC samples, and species from cluster C
(Faecalibacterium prausnitzii, Eubacterium hallii, and Eubacterium eligens) were associated
with control samples.
We constructed the co-occurrence networks with pairwise correlations < -0.4 and > 0.4 to
observe the associations of CRC biomarkers in CRC samples. These networks showed a
prominent cluster with positive associations formed from CRC-associated oral microbes, those
include Gemella morbillorum, Porphyromonas asaccharolytica, Parivimonas spp.,
Peptostreptococcus stomatis, Prevotella intermedia, Parvimonas micra, and Fusobacterium
nucleatum (Figure 12 & 13). There were negative associations between CRC-associated
microbes (Peptostreptococcus stomatis, Parvimonas spp., Clostridium citroniae, and Clostridium
symbiosum) and control-associated microbes (Faecalibacterium prausnitzii, and Coprococcus sp
ART 55_1). And some of the microbes like Clostridium clostridioforme, Coprobacillus spp., and
Clostridium hathwayi, which were positively associated with Clostridium symbiosum were
negatively interacted with Faecalibacterium prausnitzii. The negative interactions between oral
pathogens and control-associated microbes were absent in control networks (not shown as figure).
We also constructed a co-occurrence heatmap using all pairwise correlations among CRC
biomarkers (Figures 14 &15) from CRC and controls samples, separately. These maps demarked
the CRC biomarkers’ associations in CRC and control samples. There were higher positive
correlations of CRC-associated biomarkers in CRC samples than in control samples whereas,
higher positive correlations of control-associated biomarkers in control samples than in CRC
samples. These maps also showed the negative associations between CRC- and control-associated
microbes. CytoHubba application from the Cytoscape software was used to find influential nodes
in both CRC and control networks (r > 0.4). It provides different topological analysis methods,
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such as Degree, Closeness, Radiality, Betweenness, Stress, a Maximal Clique Centrality, and
others to identify central elements in biological networks 194. We used the Maximal Clique
Centrality method to identify hub species in our analysis. It identified 23 unique hub species in all
CRC and control networks of the US, Chinese and French populations. Many Clostridium spp.,
were identified as hub species, including C. ramosum, C.clostridioforme, C.symbiosum, C.
hathewayi, C. citroniae, C. bolteae, and C. bacterium 1_7_47FAA. Hub species, that were
identified as CRC biomarkers include C.symbiosum, C. citroniae, E. hallii, and F. prausnitzii.
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Figure 11: Highly connected clusters of gut microbial species from CRC and control co-occurrence networks based on
positive correlations > 0.4 (at P value 0.05).
Red nodes- microbial species from CRC networks; blue nodes- microbial species from control nodes; gray edgescorrelation between microbes.
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Figure 12: Visualize interactions among CRC biomarkers using co-occurrence networks based on pairwise correlations
< -0.4 and > 0.4 in CRC samples from the US dataset (P < 0.05).
Red nodes- CRC-associated microbes; Dark blue nodes- control associated microbes; cyan nodes- other microbes in
CRC samples; red edge- positive correlation; blue edge- negative correlation. Sky blue rectangle- oral microbial
cluster.

Figure 13: Visualize interactions among CRC biomarkers using co-occurrence networks based on pairwise correlations
< -0.4 and > 0.4 in CRC samples from the Chinese dataset (P < 0.05)
Red nodes- CRC-associated microbes; Dark blue nodes- control associated microbes; cyan nodes- other microbes in
CRC samples; a red edge indicates positive correlation; a blue edge indicates negative correlation. Sky blue rectangleoral microbial cluster.
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Figure 14: Heatmap showing pairwise correlations among CRC biomarkers from CRC samples of the USA dataset.
dataset. Significance * P ≤ 0.05; **P ≤ 0.01.

Figure 15: Heatmap showing pairwise correlations among CRC biomarkers from the control samples of the USA
dataset. Significance * P ≤ 0.05; **P ≤ 0.01.
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Discussion
Co-occurrence network analysis showed the non-random co-occurrence patterns of
microbes in most of the CRC and control microbial networks (correlation > 0.4, P-value < 0.05).
Node degree distribution curves indicated the co-occurrence patterns of networks with R2 values
> 0.8 (Figure 10), which indicates a scale-free distribution property shown in most biological
networks 195. We observed persistent co-occurrences of microbial species across the communities.
Those species are indicators of the community-specific traits 196 such as pairwise positive cooccurrences between species of Clostridium, Veillonella, Streptococcus, Parvimonas, and
Porphyromonas that were higher in CRC communities, whereas Eubacterium spp., F. prausnitzii,
Lachnospiraceae spp., and Rosuburia spp., were higher in the control communities. Network
clusters or distinct interacting groups in the gut microbial community are driven by cross-species
dependence and shared niche specializations 160. In this study, we have observed a highly distinct
interacting cluster in all three CRC networks of the US, Chinese and French populations that are
formed from oral pathogenic microorganisms from Bacillales, Clostriales, and Bacteroidales.
These oral pathogens are involved in oral diseases such as periodontitis, root canal infections,
tooth loss, and oral cancer and are shown to be associated with CRC 197–200. The oral pathogenic
interactions were lesser in control networks compared to CRC networks. There were different
clusters with positive interactions in CRC networks which were formed from species with the
taxonomically dissimilar origin. In contrast, the positive interaction clusters were formed from
taxonomically similar species in the controls. Short-chain fatty acid producers from
Lachnospiraceae (Roseburia and Ruminococcus) along with Eubacteriaceae members formed
clusters in both CRC and control networks. However, some of these species showed negative
interactions with Clostridium spp. and oral pathogens in CRC networks, indicating competitive
exclusion between coinhabiting species in a community 201,202. In CRC networks, oral pathogenic
species and Clostridium spp., such as C. symbiosum, C. citroniae, etc., are high competitors than
gut commensal microbes. C. symbiosum was identified as an influential hub node in all CRC and
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control networks, which indicated that the overgrowth of this species might have a competitive
exclusion effect on the gut commensals. Other CRC biomarkers, F. prausnitzii identified as
influential hub microbe in France CRC, China CRC and control networks. Alteration in the
abundance of these hub microbes may affect the structure of gut microbial communities. Overall,
co-occurrence networks revealed the different modular structures with varied compositions
between CRC and control networks.
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Functional alterations in the gut microbiome of colorectal cancer
Results
Functional profiles (genes and pathways) of CRC metagenomic sequence data from the USA,
China, and France were identified using HUMAnN2 (the HMP Unified Metabolic Analysis
Network) software 113. It includes both stratified and unstratified functional profiles at the species
level of each microbial community. Principal component analysis based on relative abundances
of pathways revealed the significant differences between CRC and control communities across
the three geographic regions. The variations captured by principal components (PC1, PC2, and
PC3) are shown in Figure 16 A-D. PC1 and PC3 showed significant differences among control
communities of the three geographic regions as well as among corresponding CRC communities
(P-value < 0.05), while PC2 showed significant differences only among control communities of
the geographic regions. The differences between control and CRC communities in the French
population were observed in PC1and PC2 (P-value < 0.05). PC4 (not shown in the figure)
showed significant pathway differences between CRC and control communities of China and
France (P-value < 0.05). Differential analysis of pathways using LEfSe software identified
significant differences between CRC and control samples in the US, Chinese and French
populations (Figure 17A-C). Pathways- isoprene biosynthesis I, thiazole biosynthesis II
(Bacillus), pyridoxal-5-phosphate salvage II (plants), L-glutamate degradation V (via
hydroxyglutarate), glycolysis I, TCA cycle IV (2-oxoglutarate decarboxylase), gluconeogenesis
III, L-glutamate degradation V (via hydroxyglutarate), urea cycle, the super pathway of Lphenylalanine biosynthesis, the super pathway of glucose and xylose degradation, and super
pathway of fucose and rhamnose degradation were enriched in the CRC samples. On the contrary,
stachyose degradation, mannan degradation, D-galactose degradation V (Leloir pathway), the
super pathway of L-lysine-L-threonine and L-methionine biosynthesis II, chorismate biosynthesis
I, pentose phosphate pathway (non-oxidative branch), starch degradation V, glycogen
75

biosynthesis I (from ADP D Glucose), the super pathway of L-serine and glycine biosynthesis I,
and so on were enriched in the control samples. The common pathways enriched in control
communities from all three geographic regions include stachyose degradation, galactose
degradation I (Leloir pathway), and D galactose degradation V (Leloir pathway), whereas there
were no common pathways observed in the CRC communities among all three geographic
regions (Figure 17D).

Figure 16: The pathway profiles of CRC and control cohorts from the US, Chinese and French populations.
(A) PCA of biological pathways of gut microbiomes. (B-D) PC1, PC2 and PC3 of pathways compared among CRC and
control groups. Significance was measured using Wilcoxon rank test. ** P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001, ****P ≤
0.0001.
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Figure 17: Differential analysis of pathways using LEfSe software showing significant differential pathway between
CRC and control samples from different populations.
(A) the US, (B) the French, and (C) the Chinese. The Venn diagram showing the number of significant pathways
among the US, Chinese and French populations, (D) in CRC samples (E) in control samples.

Next, we analyzed the HUMAnN2 stratified output (the abundance based on contributing
gut microbes) of a few pathways that were significantly different between CRC and control
samples. These include D-galactose degradation, urea cycle, starch degradation, stachyose
degradation, and isobutanol pathways. The contributing species for these pathways are shown in
Fig. 18 A-D.
Galactose degradation I (PWY-6317) was contributed by different gut microbes in both CRC and
control samples. However, Faecalibacterium prausnitzii and Ruminococcus bromii were
identified as significant contributors only in control samples (Fig. 18A). They were microbes
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contributed to starch degradation (PWY-6737) in control and CRC samples were different. The
contributions of Faecalibacterium prausnitzii, Ruminococcus bromii, Eubacterium ventriosum,
Roseburia intestinalis, and E. rectale to start degradation were found in controls, whereas R.
gnavus, D. formicigenerans, Subdoligranulum sp 4_3_54A2FAA, and Collinsella aerofaciens,
enriches starch degradation in the CRC samples (P < 0.05) (Fig. 18C). Similarly, different gut
microbes contribute to stachyose degradation (PWY-6527) in CRC and control samples, however
the contributions of R. intestinalis, Coprococcus sp ART55_1, and M. rupellensis were dominant
in controls, and while Lachnospiraceae bacterium 3_1_57FAA_CT1 and S. sanguinis contributed
more in CRC group (Fig. 18B). Urea cycle (PWY-4984) was enriched CRC compared to control,
and the major contributing microbes were Coprococcus catus, Flavonifractor plautii, and
Lachnospiraceae bacterium 7_1_58FAA (Fig. 18D).
We analyzed the stratified pathway profiles of CRC and control gut communities for the
major pathways of butyrate production in CRC and healthy gut microbiota. Those pathways
include 4-aminobutanoate, pyruvate, and glutarate, and lysine pathways. The name of the
pathway indicates the starting substrate that is utilized in the pathway. The final intermediate for
all butyrate synthesis pathways is crotonyl-CoA, which is converted to butyryl-CoA, then to
butyrate, are catalyzed butyryl-CoA dehydrogenase complex (NAD+, ferredoxin) and butyrate
kinase (Ca) 172–174. This analysis did not provide expected results as the species level annotations
for most of the butyrate synthesis pathways were not available. Most parts of it were categorized
as ‘unclassified’ in stratified pathway profiles. However, our analysis showed the presence of ‘Llysine fermentation to acetate’ pathway in F. nucleatum, F. periodonticum, and Fusobacterium
sp. oral taxon 370 and butanoate pathway in Klebsiella pneumoniae, Bacillus subtilis, and
Saccharomyces spp.,
We further analyzed for the presence of microbial gene families involved in butyrate
production pathways in CRC and control gut microbial communities based on unstratified gene
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abundance profiles from all three geographic regions. The genes involved in butyrate production
and related gene families identified from CRC and control gut communities of the US population
are listed in Table 6. In the pyruvate pathway, gene families related to thiolase (Thl) and
crotonase/enoyl-CoA hydratase (Cro) were identified from most of the CRC and control
metagenomes from all three geographic regions; however, the abundance of gene families was
not different between CRC and control samples, except for one gene family,
UniRef90_UPI000289B0D2 (for Cro gene). It catalyzes the formation of crotonoyl-CoA from3hydroxybutanoyl-CoA, which is final common intermediate product in all butyrate production
pathways. In the 4- aminobutyrate pathway, out of three enzymes (4-hydroxybutyrate
dehydrogenase (AbfH), butyryl-CoA:4-hydroxybutyrate-CoA transferase (4Hbt), and 4hydroxybutyryl dehydratase (AbfD)), only AbfH was identified in both CRC and control gut
communities. Out of six enzymes enzymes (2-hydroxyglutarate dehydrogenase (L2Hgdh),
glutaconate-CoA transferase (Gct), 2-hydroxyglutaryl-CoA dehydrogenase (HgCoAd),
Glutaconyl-CoA decarboxylase (Gcd), Glutamate decarboxylase (Gdc), and Glutamate
dehydrogenase (Gdh)) in the glutarate pathway, only Gcd, Gdh, and Gdc were showed related
gene families in both CRC and control microbial communities, and L2Hgdh gene family was
identified in CRC communities. Most of the gene families related to Gdc were significantly
different between CRC and control samples (Figure 19). In the lysine pathway, out of five
enzymes, ((lysine 2,3-aminomutase (KamA), lysine 5,6-aminomutase (Kam D, E), 3,5diaminohexanoate dehydrogenase (Kdd), 3-keto-5-aminohexanoate cleavage enzymes (Kce), and
3-aminobutyryl-CoA ammonia lyase (Kal)), only gene families related to three (KamA, Kdd, and
Kal) were identified in CRC and control gut metagenomes, but none of them were shown as
significant different between CRC and control samples. In addition to the above-mentioned
enzymes, there are four common enzymes in all four pathways those include butyryl-CoA
dehydrogenase (Bcd), Phosphate butyryl transferase (Ptb), Butyrate kinase (Buk), and acetate
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CoA transferase (But). Out of these, Ptb and Buk were identified in CRC and control gut
microbial communities.

Figure 18: The relative abundance (log10-scaled) of microbial species in representative pathways within CRC and
control samples in the US population.
(A) galactose degradation I (PWY-6317), (B) stachyose degradation (PWY-6527), (C) starch degradation (PWY-6737),
and (D) Urea cycle (PWY-4984). Wilcoxon rank-sum test- *P < .05, **P < .01, ns- not significant,
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Lysine pathway

Glutarate pathway

4AB pathway

Pyruvate pathway

Gene

Gene family UniRef90

Metagenomes
Control
(52)

CRC

44

40

-

-

(52)

Thl

UniRef90_Q65Y13

Hbd

-

Cro

UniRef90_UPI000289B0D2*,
UniRef90_UPI0002E9C47E, UniRef90_UPI00030C4174,
UniRef90_UPI000360F89D, UniRef90_UPI00040B3C6F,
UniRef90_UPI00041C192C/ UniRef90_UPI0003B4A707,
UniRef90_UPI0003B4E341, UniRef90_UPI0003B76831,
UniRef90_UPI0004293A25, UniRef90_UPI000463D53F,
UniRef90_UPI0004669499, UniRef90_UPI000378441C

48

49

AbfH

UniRef90_F4KN60, UniRef90_F9Z8R8,
UniRef90_R6QMB8, UniRef90_UPI000366CE21,
UniRef90_UPI0004652210, UniRef90_UPI0004708457

50

47

4Hbt

-

-

-

AbfD

-

-

-

L2Hgdh

UniRef90_Q8RG31

0

3

Gct

-

-

-

HgCoA
d

-

-

-

Gcd

UniRef90_A5TT10, UniRef90_C4Z5R5,
UniRef90_R7NBZ5

52

51

Gdc

UniRef90_R9RBA6*, UniRef90_A8SL35,
UniRef90_X8IQQ0, UniRef90_N2ICS8,
UniRef90_A0A017JM04, UniRef90_R6VEK2,
UniRef90_S6I190, UniRef90_D2NPB5,
UniRef90_C7GYN4

52

52

Gdh

Significant gene families were shown in the figure

52

52

KamA

UniRef90_UPI0002898F29, UniRef90_UPI000289D7BE,
UniRef90_UPI00036F10E3, UniRef90_UPI0003755A42,
UniRef90_UPI0003A09B3B, UniRef90_UPI00047E1909,
UniRef90_UPI00046580AA, UniRef90_UPI0004756347,
UniRef90_UPI00047E1909, UniRef90_UPI00046F9D6A,

38

42

Kam D,
E

-

Kdd

UniRef90_R1CHA5, UniRef90_UPI000287A9EC

3

3

Kce

-

-

-

Kal

UniRef90_A0A017RZH1, UniRef90_A1X0G4,
UniRef90_E3PRK1, UniRef90_UPI000465A158,
UniRef90_UPI000469847B, UniRef90_UPI00046A0556,
UniRef90_UPI0004714DC1, UniRef90_UPI0004797913,
UniRef90_UPI00047ADBA5, UniRef90_Q8RHX1,
UniRef90_UPI00047AE9F4, UniRef90_M1ZIQ8,

37

38

81

Common enzymes in
all pathways

Bcd

-

-

-

Ptb

UniRef90_UPI000301BE39, UniRef90_UPI0003B57112,
UniRef90_UPI0003B64BD4, UniRef90_UPI000417EA94,
UniRef90_UPI000479B33B

43

43

Buk

UniRef90_Q0TMV4, UniRef90_R5BJJ7,
UniRef90_R5D218

41

39

But

-

-

-

Table 6: Enzymes involved in butyrate pathways and related gene families identified in CRC and control gut microbial
communities from the US population.
Thiolase (Thl), crotonase/enoyl-CoA hydratase (Cro), Hydroxybutyryl dehydrogenase (Hbd), 4-hydroxybutyrate
dehydrogenase (AbfH), butyryl-CoA:4-hydroxybutyrate-CoA transferase (4Hbt), 4-hydroxybutyryl dehydratase
(AbfD), 2-hydroxyglutarate dehydrogenase (L2Hgdh), glutaconate-CoA transferase (Gct), 2-hydroxyglutaryl-CoA
dehydrogenase (HgCoAd), Glutaconyl-CoA decarboxylase (Gcd), Glutamate decarboxylase (Gdc), Glutamate
dehydrogenase (Gdh), lysine 2,3-aminomutase (KamA), lysine 5,6-aminomutase (Kam D, E), 3,5-diaminohexanoate
dehydrogenase (Kdd), 3-keto-5-aminohexanoate cleavage enzymes (Kce), 3-aminobutyryl-CoA ammonia lyase (Kal),
butyryl-CoA dehydrogenase (Bcd), Phosphate butyryl transferase (Ptb), Butyrate kinase (Buk), acetate CoA transferase
(But), and 4-Aminobutyrate (4AB).

Figure 19: Extended error bar plot of mean proportions of gene families related to glutamate decarboxylase (Gdc)
in CRC (red) and control (blue) samples, Welch’s t-test.

Discussion
Functional analysis revealed differences between gut microbial communities of CRC and
control samples. The CRC samples were significantly associated with a greater number of
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metagenomically reconstructed biochemical pathways (98 pathways) than control samples (59
pathways) across the geographic regions. The pathways described in this analysis were based on
MetaCyc database. Most of the pathways enriched in CRC samples are implicated in
tumorigenesis, these include glutamate degradation, gluconeogenesis, histidine degradation,
glucose, and xylose degradation, fucose, rhamnose degradation, and others. Pathogenic gut
microbes can alter these pathways and related metabolite profiles of the gut microbiome. Previous
studies reported that gut microbiota has the potential to promote carcinogenesis by altering the
pathways associated with metabolites such as histidine, glutamine, and pyruvate 192. The amino
acid degradation pathways enriched in the CRC sample were L-histidine degradation I and Lglutamate degradation V. These are bacterial putrefaction pathways that are involved in the
production of ammonia,
•

L-histidine → urocanate + ammonia

•

L-glutamate + NAD(P)+ + H2O ↔ 2-oxoglutarate + ammonium + NAD(P)H +
H+ (1.4.1.3)

The concentration of ammonia in the gut is influenced by dietary protein intake. Long-term high
protein-diets increase ammonia concentration in the gut through bacterial putrefaction, and it can
be absorbed into colonocyte by non-ionic diffusion, damage colonic cells, and increase the
incidences of human colonic cancers 203,204. In addition to ammonia production, the L-glutamate
degradation V (via hydroxyglutarate) pathway intermediate D-2-hydroxyglutarate (D-2HG) is
considered as oncometabolite. The D-2HG was shown to be linked with increased expression of
the ZEB1 gene, which encodes the key transcription factors for the regulation of epithelialmesenchymal transition. In CRC, D-2HG levels were shown to be elevated, directly inducing
EMT in CRC cells, and also causing with distant metastasis 205. MetaCyc database annotation of
L-glutamate degradation V (via hydroxyglutarate) pathway showed its presence in
Acidaminococcus fermentans, Fusobacterium nucleatum, Peptoniphilus asaccharolyticus,
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Clostridium sporosphaeroides, and Clostridium symbiosum 173. These annotations support our
results in a way that the enrichment of L-glutamate degradation was contributed from the high
abundance of pathogens, F. nucleatum and C. symbiosum in CRC samples.
In this study, we also identified enrichment of the super pathway of L-phenylalanine
biosynthesis in CRC samples compared to control samples. It was produced by Citrobacter
freundi, Escherichia coli, Klebsiella spp., Proteus mirabilis, Streptococcus spp.,
Propionibacterium freudenreichii, Shigella flexneri, and Enterobacter cloaca, which were
enriched in CRC samples. These results are supported by previous studies showed that an
increased level of serum phenylalanine has shown to be associated with systemic inflammatory
reaction along with the increased level of CRP, IL-6, IL-8, and other amino acid alterations 206.
Phenylalanine, an aromatic amino acid, is synthesized from two precursors, phosphoenolpyruvate
(PEP) and D-erythrose 4-phosphate (D4P). The intermediate product, chorismite, is a common
precursor for the other aromatic amino acids, L-tyrosine and L-tryptophan 173. This pathway is
present in bacteria, plants, algae, fungi, and some protozoans, but not animals. So, animals
depend upon extraneous diet or gut microbial secretions of phenylalanine 207 for these amino
acids.
The deoxyribonucleotide de novo biosynthesis pathways were enriched in CRC samples
compared to control samples, which indicates the increased growth of pathogens in CRC samples
or may be due to disruption of dNTP balances associated with proliferating tumor cells 208.
Gluconeogenesis I and III were enriched in CRC samples compared to control samples indicating
the adaptative mechanism of gut bacteria under glucose deprivation to use non-fermentable
carbon sources 209, a similar mechanism is found in cancer cells. The urea cycle was elevated in
CRC samples, which may be due to the increased concentration of ammonia in the tumor
environment from the catabolism of amino acids that enter the urea cycle and are subsequently
eliminated through urine. The complete urea cycle is described in only a few prokaryotes, while
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most of the prokaryotes show arginase metabolism, which acts in eliminating excess ammonia in
the form of urea from the cell 209. In our analysis, we identified gut microbes contributing to the
urea cycle, those include Clostridium celatum, Coprococcus catus, Flavonifactor plautii, and
Lachnospiraceae bacterium 7_1_58FAA (Figure 18D). In addition to these pathways like the
TCA cycle, degradation of glucose, glucose-1-phosphate, and glucose-6-phosphate, isoprene
biosynthesis, and other pathways enriched in CRC represent increased metabolic requirements for
cancer cells as well as the microbial community in the tumor environment.
On the other hand, we found that the control samples were associated with starch,
stachyose, galactose, and mannan degradation pathways. This indicates the functional adaptation
of the gut microbiome based on gut environment and nutrient availability. Analysis using
stratified pathway output from HUMANn2 showed that microbes, Ruminococcus brommi,
Eubacterium rectale, and Rosuburia were significant contributors to starch degradation in
controls (P-value > 0.05). Other bacteria like F. prausnitzii, Ruminococcus spp., Roseburia spp.,
E. coli, Lachnospiraceae spp., and so on were involved in starch, stachyose, and galactose
degradation pathways in both CRC and control samples (Figure 18). These results are similar to
previous studies, where they showed the enrichment of R. brommi, and E. rectale in association
with resistant starch degradation pathways 210,211. Those studies also indicated that end products
from the resistant starch degradation support the growth of other bacteria involved in beneficial
fermentation pathways such as butyrate production. Overall, the enrichment pathways in CRC
and control samples from our analysis were consistent with previous studies 58.
Analysis of butyrate synthesis pathways showed the presence of related gene families in
the CRC and control metagenomes from the US, Chinese and French populations. Only a few
gene families were significantly different between CRC and control metagenomes (Table 6).
However, we identified the enrichment of pyruvate fermentation to butanoate pathway in control
samples of the US population and enrichment of acetyl CoA fermentation to butanoate II in CRC
85

samples of the French population (Figure 17A &C). This indicates the butyrate production
pathways of gut commensals are different from gut pathogens. These results were consistent with
previous studies, where they showed the presence of butyrate pathways in both commensals and
gut pathogens, and most gut commensals (Faecalibacterium, Roseburia, and others) use the
pyruvate pathway for butanoate production 174. They also reported the presence of glutamate and
lysine pathways for butyrate production in gut pathogens. Consistent with that, our analysis
revealed pathogenic bacterial contributors for 4-aminobityrate were Klebsiella pneumonia,
Staphylococcus equorum, and Bacillus subtilis, and contributing bacteria for the lysine pathway
were Fusobacterium nucleatum, Fusobacterium sp oral taxon 370, and Fusobacterium
periodonticum. However, we could not find microbial contributions for all the genes involved in
butyrate synthesis due to the unavailability of annotations for the butyrate pathways at the species
level. Butyrate production from the glutarate produced by gut pathogens (Fusobacteria) leads to
the release of ammonia as an intermediate product, which is linked to CRC 174,203.
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Gene family analysis of strains of CRC-related microbes
Results
Pangenome based gene family analysis of CRC pathogens was performed to understand
the functional diversity of strain-level gene families of CRC-related microbes present in 346 (180
cases and 166 controls) metagenomes belonging to the US, French, and Chinese populations.
Details of CRC pathogens used in this analysis are shown in Table 7.
CRC-related species

In CRC samples (180) In control samples (166 )

Fusobacterium nucleatum

74* (17)**

11 (1)

Bacteroides fragilis

149 (23)

110 (9)

Ruminococcus torques

179 (14)

166 (12)

Parvimonas micra

71 (23)

21 (2)

Escherichia coli

165 (71)

140 (56)

Table 7: Details of the sample on CRC-related microbes used in the strain-level gene family analysis.
*-The number in the row indicates total samples with CRC-related microbe (species) and **- the number in brackets
indicates strain-level gene families of CRC-related microbial species identified in the total samples. E.g.,
Fusobacterium nucleatum was present in 74 CRC samples and 11 control samples, whereas gene families of F.
nucleatum strains were identified in 17 CRC samples and one control sample.

Fusobacterium nucleatum
Gene families of F. nucleatum strains were identified from 17 CRC and one control
metagenome. Differential analysis of gene families from CRC samples showed 40 gene families
that were significantly different between the US, Chinese and French populations (p < 0.05) (Fig.
20A, Table 8). The UniProtKB database annotations of the UniRef90 gene families identified
pathway differences across the F. nucleatum strains. Pathways such as LPS core biosynthesis,
adenosylcobalamin biosynthesis, NAD (+) biosynthesis, isoprenoid biosynthesis, phospholipid
metabolism, and tRNA modification pathways were identified in F. nucleatum strain from CRC
samples. These pathways could contribute to the functional differences of F. nucleatum across the
three geographical regions. The UniProtKB search analysis also identified the F. nucleatum
strains having these differential gene families, those include F. nucleatum subsp. nucleatum, F.
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nucleatum subsp. polymorphum, F. nucleatum subsp. vincentii, F. nucleatum subsp. animalis, F.
nucleatum CTI-1 and others.
Bacteroides fragilis
PanPhlAn analysis of B. fragilis species across three geographic regions identified strainlevel gene families in 32 metagenomic samples (23 cases and nine controls). Differential analysis
of gene families of B. fragilis strains from CRC metagenomes (23 samples) showed that 115 gene
families were significantly different in the strains from the US, French, and Chinese populations
(P < 0.05) (Fig. 20B, Table 8). Gene family search using mapping ID option against UniProtKB
database showed the functional differences in gene families related to mobilization protein, EpsG
family protein, FecR family protein, SusC/RagA family TonB-linked outer membrane protein,
RteC family protein, TonB-dependent receptor, OmpA/MotB domain protein, multidrug efflux
MFS transporter, and other putative proteins. Differential analysis of gene families of B. fragilis
strains from control metagenomes did not show any significant differences across the geographic
regions.
Escherichia coli
PanPhlAn analysis of metagenomes of E. coli showed gene families of E. coli strain in 71
CRC and 56 control metagenomes. Differential analysis of gene families from CRC samples
showed 148 gene families that were significantly different across the US, Chinese and French
populations (p < 0.01) (Fig. 20E, Table 8). Annotations of the UniRef90 gene families based on
the ID mapping against UniProtKB database were mapped to hemolysin HlyE, ABC transport
ATP-binding protein, ABC transport family proteins, Multiple antibiotic resistance protein MarA,
proteins involved iron transport like FecR, FecA, FecC, ferric aerobactin receptor lutA, and tonBdependent receptor, transposase, type II toxin-antitoxin system antitoxin PemI, tetracycline
repressor, putrescine degradation, Colicin immunity protein, Ethanolamine utilization protein
EutD, phospholipid metabolism, MFS transporter, and other proteins. These gene families could
contribute to the functional differences of E. coli in CRC between the three geographical regions.
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PanPhlAn analysis of control samples showed 353 differentiating E. coli strain-level gene
families between the three geographic regions and mapping these gene families against
UniproKB (Swissprot) database identified the pathways including putrescine degradation, Lphenylalanine biosynthesis, L-tryptophan biosynthesis, 3-phenylpropanoate degradation, 4hydroxyphenylacetate degradation, and glutathione biosynthesis. Gene families related to colicin
protein were observed in E. coli strains from both CRC and control samples.
Ruminococcus torque
Gene families of R. torques strains were identified in 14 CRC and 12 control samples.
Differential analysis of R. torques strain-level gene families from CRC samples showed 35 gene
families that were significantly different across the US, Chinese and French populations (p <
0.05) (Fig. 20C, Table 8). The annotations of the differential gene families based on the
UniProtKB database mapping identified the related encoded proteins such as bacterial type II
secretion system protein F domain protein, D-alanyl-D-alanine carboxypeptidase (EC 3.4.16.4),
Site-specific recombinase XerD, and 30S ribosomal protein S20. Differential analysis of strainlevel gene families of R. torques identified from control samples showed 54 differential gene
families related to nitroreductase A, fructoselysine 3-epimerase, Type IV secretory pathway,
VirB4 components, Outer membrane-specific lipoprotein transporter subunit LolE, and others.
Parvimonas micra
Strain-level gene families of P. micra were identified in 23 CRC and two control
metagenomes. Differential analysis of these gene families from CRC samples showed 14 gene
families that were significantly different across the US, Chinese and French populations (p <
0.05) (Fig. 20D, Table 8). The annotations of the UniRef90 gene families based on the ID
mapping against UniProtKB database identified the genes encoding NADH dehydrogenase, 4Fe4S binding domain protein, NADH: ubiquinone oxidoreductase, GntR family transcriptional
regulator, Hydrogenase, Fe-only (EC 1.12.-. -), and other proteins.
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Figure 20: Heatmaps of the strain-level genomic diversity in gut pathogens across three geographic regions- USA,
China, and France.
(A) Fusobacterium nucleatum, (B) Bacteroides fragilis, (C) Ruminococcus torques, (D) Parvimonas micra, and (E)
Escherichia coli. Significantly different gene families (P-value < 0.05) were identified using Fisher exact test on the
presence and absence of gene family profiles.
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(P < 0.05)
(P < 0.05)

F. nucleatum

B. fragilis

CRC
pathogen

Differential gene families (UniRef90) (among CRC geographic regions)
UniRef90_A0A015PAV4, UniRef90_A0A015Q871, UniRef90_A0A015Q9P0,
UniRef90_A0A015R3T6, UniRef90_A0A015SBU6, UniRef90_A0A015SFT0,
UniRef90_A0A015SG87, UniRef90_A0A015SNF2, UniRef90_A0A015TKW0,
UniRef90_A0A015VAW9, UniRef90_A0A015X469, UniRef90_A0A015X7G0,
UniRef90_A0A015YBF9, UniRef90_A0A016BP87, UniRef90_A0A016C0K4,
UniRef90_A0A016DTF2, UniRef90_A0A016GFQ4, UniRef90_A0A017N6G6,
UniRef90_A0A017NDY9, UniRef90_A0A017PFV9, UniRef90_A0A069D3E5,
UniRef90_A0A069S655, UniRef90_A0A069SBY6, UniRef90_A0A081TTK1,
UniRef90_A0A081TTK6, UniRef90_A0A081U3A1, UniRef90_A0A081U3A2,
UniRef90_A0A081UDU4, UniRef90_A0A088F9N8, UniRef90_A0A0B2JM94,
UniRef90_A0A0E2RNA4, UniRef90_A0A0E2RT97, UniRef90_A0A0E2T6U8,
UniRef90_A0A0E2T9B2, UniRef90_A0A0E2TD42, UniRef90_A0A0I9RYG8,
UniRef90_A0A0I9S8F6, UniRef90_A0A0I9S9K5, UniRef90_A0A0P0F4X5,
UniRef90_A0A133PRD5, UniRef90_A0A149N4V5, UniRef90_A0A173YQS4,
UniRef90_A0A174AEU5, UniRef90_A0A174BMU3, UniRef90_A0A174GXE5,
UniRef90_A0A174RWZ0, UniRef90_A0A174W8R1, UniRef90_A0A174WSN6,
UniRef90_A0A2K9H0L5, UniRef90_A0A2M9USG9, UniRef90_A0A395VSD1,
UniRef90_A0A396E6N8, UniRef90_A0A397WJ09, UniRef90_A0A3A9BM21,
UniRef90_A0A3A9H7E6, UniRef90_A0A3E4GGW1, UniRef90_A0A3E4I387,
UniRef90_A0A3E4IFH2, UniRef90_A0A3E4XFF5, UniRef90_A0A3E5DX79,
UniRef90_A0A3E5DXA0, UniRef90_A0A3E5DXC1, UniRef90_A0A3E5EGN1,
UniRef90_A0A3E5I1Q9, UniRef90_A5ZAW3, UniRef90_A6L268, UniRef90_A6L357,
UniRef90_B0NR18, UniRef90_B7BBG1, UniRef90_C3QQ82, UniRef90_C3RFN5,
UniRef90_D0TH45, UniRef90_D0TH60, UniRef90_D1JLU8, UniRef90_D1JNU2,
UniRef90_D1JV64, UniRef90_D7IZG7, UniRef90_E5CG54, UniRef90_E5V0E8,
UniRef90_E5WVY3, UniRef90_F7L4Z2, UniRef90_F7LM25, UniRef90_F7LM26,
UniRef90_F7LM32, UniRef90_F7LME2, UniRef90_F7M0S8, UniRef90_H1DDZ9,
UniRef90_I3YJ07, UniRef90_I8V886, UniRef90_I8Y104, UniRef90_I8YD22, UniRef90_K1FPT4,
UniRef90_K1FS58, UniRef90_K1FVZ3, UniRef90_K1G2K0, UniRef90_K5YUD6,
UniRef90_K9E5C3, UniRef90_Q4VR85, UniRef90_Q5LCQ6, UniRef90_Q64RW9,
UniRef90_Q64XS2, UniRef90_Q64XT4, UniRef90_Q8A5Z4, UniRef90_Q8A9U9,
UniRef90_R5U2V5, UniRef90_R5U3I7, UniRef90_R5U4U4, UniRef90_R6AKV4,
UniRef90_R6DCI9, UniRef90_R6J8N2, UniRef90_R6V702, UniRef90_R6VBY9,
UniRef90_R7KG75, UniRef90_T4C1L2, UniRef90_U6RGQ3
UniRef90_A0A0M1VTZ1, UniRef90_A0A0M5M5Z1, UniRef90_A0A0M5M7X3,
UniRef90_A0A0S1YSQ6, UniRef90_A0A0S2ZUC5, UniRef90_A0A140PT44,
UniRef90_A0A2B7YMZ2, UniRef90_A0A2C6C4D0, UniRef90_A0A2N6TF47, UniRef90_A5TSU5,
UniRef90_A5TUT6, UniRef90_A5TUV5, UniRef90_A5TWN5, UniRef90_D5RBE8,
UniRef90_D5RC63, UniRef90_D5RDT0, UniRef90_D5RFK1, UniRef90_F3B4Z0,
UniRef90_F7KWV5, UniRef90_F7KZ37, UniRef90_F7L454, UniRef90_F9ELY6,
UniRef90_F9EPQ8, UniRef90_H1HFY5, UniRef90_Q7P2Z9, UniRef90_Q8R688,
UniRef90_Q8R6C8, UniRef90_Q8REH1, UniRef90_Q8RF97, UniRef90_Q8RFS3,
UniRef90_Q8RFY9, UniRef90_Q8RGE1, UniRef90_Q8RGL4, UniRef90_U7SU47,
UniRef90_U7SYB0, UniRef90_U7SZG0, UniRef90_U7T0Z7, UniRef90_U7T2M2,
UniRef90_U7T2N1, UniRef90_X8IQQ8
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(P < 0.05)
(P < 0.05)

P. micra

R. torques

E. coli (P < 0.01)

UniRef90_UPI00092A8639, UniRef90_A0A061KE92, UniRef90_A0A061KM32,
UniRef90_A0A061LCR4, UniRef90_A0A061YL37, UniRef90_A0A066R795,
UniRef90_A0A066RDC7, UniRef90_A0A066T653, UniRef90_A0A085PB76,
UniRef90_A0A0A1A8I1, UniRef90_A0A0B1IQI0, UniRef90_A0A0D6IHZ5,
UniRef90_A0A0D8VFC3, UniRef90_A0A0D8VRA4, UniRef90_A0A0D8WCF3,
UniRef90_A0A0D8WGE2, UniRef90_A0A0D8WI51, UniRef90_A0A0F3VBR0,
UniRef90_A0A0G9FGZ9, UniRef90_A0A0G9FST0, UniRef90_A0A0G9FYY7,
UniRef90_A0A0H0RFC7, UniRef90_A0A0J2AY04, UniRef90_A0A0J2B9B0,
UniRef90_A0A0J2D5U5, UniRef90_A0A0J3Y8H0, UniRef90_A0A0K5ITK3,
UniRef90_A0A0K5UW30, UniRef90_A0A0L6N7C9, UniRef90_A0A0L6XUP0,
UniRef90_A0A0P7MGK6, UniRef90_A0A0Q2YZQ2, UniRef90_A0A136X6T6,
UniRef90_A0A142BNM8, UniRef90_A0A148HSY1, UniRef90_A0A148HXP5,
UniRef90_A0A152WYC0, UniRef90_A0A167D3Y0, UniRef90_A0A1D3KQD1,
UniRef90_A0A1L3Z3F4, UniRef90_A0A1Q4PCA3, UniRef90_A0A1Y5BU01,
UniRef90_A0A210GEH4, UniRef90_A0A244BH27, UniRef90_A0A2A3V312,
UniRef90_A0A2A7M304, UniRef90_A0A2A7M8P9, UniRef90_A0A2A7MAF4,
UniRef90_A0A2G4AEB4, UniRef90_A0A2H9FQU8, UniRef90_A0A2S1JA20,
UniRef90_A0A2X1MTA8, UniRef90_A0A369FFU1, UniRef90_A0A376J9U5,
UniRef90_A0A376JA52, UniRef90_A0A376M3C0, UniRef90_A0A376NXS4,
UniRef90_A0A376Q0G2, UniRef90_A0A376RJ96, UniRef90_A0A377BQ52,
UniRef90_A0A377C212, UniRef90_A0A377CXQ2, UniRef90_A0A377DL89,
UniRef90_A0A397WYU9, UniRef90_A0A3A1QBU2, UniRef90_A0A3A3VP15,
UniRef90_A0A3A6SAE3, UniRef90_A5A612, UniRef90_A7ZK12, UniRef90_A7ZPY3,
UniRef90_C4NV10, UniRef90_C8CGI4, UniRef90_E2QEX9, UniRef90_E2QI13,
UniRef90_E2QP31, UniRef90_E9LLU9, UniRef90_G3F9S0, UniRef90_P03009, UniRef90_P03038,
UniRef90_P0A977, UniRef90_P0AAA6, UniRef90_P0AAU8, UniRef90_P0ABS0,
UniRef90_P0ACH6, UniRef90_P0ADK5, UniRef90_P0CE53, UniRef90_P0CF79, UniRef90_P11289,
UniRef90_P13036, UniRef90_P13975, UniRef90_P14542, UniRef90_P15030, UniRef90_P15033,
UniRef90_P17583, UniRef90_P19932, UniRef90_P21361, UniRef90_P23484, UniRef90_P23485,
UniRef90_P23883, UniRef90_P30015, UniRef90_P30235, UniRef90_P31130, UniRef90_P31436,
UniRef90_P32055, UniRef90_P32152, UniRef90_P33668, UniRef90_P37906, UniRef90_P51026,
UniRef90_P52045, UniRef90_P56259, UniRef90_P67088, UniRef90_P75687, UniRef90_P75851,
UniRef90_P75885, UniRef90_P76091, UniRef90_P76117, UniRef90_P76158, UniRef90_P76482,
UniRef90_P77218, UniRef90_P77237, UniRef90_P77335, UniRef90_P77357, UniRef90_P77668,
UniRef90_P77746, UniRef90_Q1A2D8, UniRef90_Q1RPD3, UniRef90_Q32BN2,
UniRef90_Q3YZB5, UniRef90_Q46892, UniRef90_Q6KDC1, UniRef90_Q7ATJ6,
UniRef90_Q7BPP7, UniRef90_Q83SQ3, UniRef90_Q83W67, UniRef90_Q8FAI6,
UniRef90_Q8FCK7, UniRef90_Q8FE30, UniRef90_Q8G8U3, UniRef90_Q8GH16,
UniRef90_Q8X680, UniRef90_Q8X6H3, UniRef90_Q8X8W8, UniRef90_Q8XA73,
UniRef90_Q8XCY9, UniRef90_R9R0P4, UniRef90_U5QUT5, UniRef90_W8SSS5,
UniRef90_W8T3K5
UniRef90_UPI0006C34D69, UniRef90_A0A173T7W2, UniRef90_A0A174FDD3,
UniRef90_A0A174K3N6, UniRef90_A0A174LMY8, UniRef90_A0A174RSZ2,
UniRef90_A0A174X7K3, UniRef90_A0A174XGH7, UniRef90_A0A174XXG8,
UniRef90_A0A174YJF6, UniRef90_A0A174YKF1, UniRef90_A0A174Z2F0,
UniRef90_A0A174ZFV5, UniRef90_A0A174ZMW9, UniRef90_A0A174ZWX4,
UniRef90_A0A2N5NFI3, UniRef90_A0A2N5NPN6, UniRef90_A0A2N5P335, UniRef90_B0NGI2,
UniRef90_B0P259, UniRef90_B5CQL8, UniRef90_C5EWP5, UniRef90_D3AGE9,
UniRef90_D4LZP3, UniRef90_D4LZP7, UniRef90_D4LZX3, UniRef90_D4M094,
UniRef90_D4M0A3, UniRef90_D4M0I8, UniRef90_D4M0K7, UniRef90_D4M2D3,
UniRef90_E2ZJE0, UniRef90_F0YYV6, UniRef90_G2SZW4, UniRef90_R6NZP8
UniRef90_A0A134ADQ5, UniRef90_A0A381I4R7, UniRef90_A8SIA8, UniRef90_A8SIB0,
UniRef90_A8SIF5, UniRef90_A8SIR5, UniRef90_A8SIT5, UniRef90_A8SL39, UniRef90_A8SLT9,
UniRef90_F5TDB9, UniRef90_F5TDC0, UniRef90_F5TDC1, UniRef90_F5TDC2,
UniRef90_F5TER5

Table 8: Strain-level gene families of CRC pathogens showing significant differences across the US, Chinese and
French populations (P < 0.05).
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Discussion
Pangenome gene family analysis of CRC-associated microbe, F. nucleatum showed a
significant difference in gene families related to isoprenoid biosynthesis, phospholipid
metabolism, ABC transporters, NAD biosynthesis process, ATP synthase, Autotransporter outer
membrane beta-barrel domain-containing protein, and others. Most of these proteins are known as
virulence factors of F. nucleatum. The synthesis of the isoprenoids is mainly from the 2C-methylD-erythritol

4-phosphate (MEP) pathway in the gut microbes like Bacteroides, Fusobacterium, E.

coli, Bifidobacterium, and others. It is similar to the mevalonate pathway of higher eukaryotic
cells. The mevalonate pathway provides isoprenoids and other precursors required for the
synthesis of cholesterol, and dysregulation of this pathway is associated with colorectal cancer 212.
In bacteria, isoprenoid biosynthesis helps in cell growth, virulence and overcome the oxidative
environment in the phagocytosis process of macrophage. The accumulation of antioxidant
compounds such as 2-C-methyl-D-erythritol-2,4-cyclopyrophosphate (MEP pathway) during
oxidative stress allows maintaining/surviving under oxidative environment. In addition to these,
the MEP pathway is also known to stimulate host Vγ9/Vδ2 T cells, but the advantage of this
stimulation is not clear regarding the survival of gut bacteria 213,214. We identified that the gene
families related to glycerol-3-phosphate acyltransferase (PlsB) were significantly different in F.
nucleatum strains of CRC samples. The glycerol-3-phosphate acyltransferase is a membranebound enzyme that catalyzes the first step in phospholipid biosynthesis. It is required for the
growth of the bacterium and it has been shown that the plsB gene is involved in the formation of
persister cells

215

. Interestingly, the ORFs for the glycerol-3-phosphate acyltransferase was

reported as not present in some strains of F. nucleatum (e.g., oral pathogen F. nucleatum Strain
ATCC 25586) 216. This indicates the importance of glycerol-3-phosphate acyltransferase in CRC
pathogenesis and further studies are needed to explore the importance of the plsB gene in CRC.
Another important differential gene family of F. nucleatum strains that was identified in this
analysis include autotransporter outer membrane beta-barrel domain proteins- Fap2 and RadD
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that belong to outer membrane proteins (OMPs). These proteins are involved in the adhesion and
invasion of bacterial components into the host epithelial cells and induce cell death 217. Fap2
protein mediates the colonization of F. nucleatum on tumor cells through Gal-GalNAc receptor
binding and immunosuppression by binding with TIGIT inhibitory receptors present on the T cell
immunoglobulin 130,218. RadD protein facilitates biofilm formation by co-aggregating F.
nucleatum with Streptococcus mutants and Candida albicans on the gut 219,220.
B. fragilis colonizes the gut both as a commensal and a pathogen. The enterotoxigenic B.
fragilis (ETBF) has been shown to contribute to colon carcinogenesis, and its pathogenicity is
mainly due to its capsule, outer-membrane proteins, and a metalloprotease protein toxin
(Bacteroides fragilis toxin). In this study, we identified that the B. fragilis strains present in the
US, Chinese, and French populations mainly differed in their accessory gene families. Most of
these proteins contribute to the B. fragilis virulences through iron transport, biofilm formation,
and antibiotic resistance. FecR family proteins are inner membrane proteins, that maintain the
iron homeostasis through recognizing iron dicitrate in the periplasm, in the absence of citrate, it
activates the FecI, resulting in the activation of ferric citrate transport genes 221. Dysregulation of
iron transport is linked to cytotoxicity, malignant transformation, and cancer progression 222.
RteC family protein is one of the regulatory proteins for the genes involved in the excision of
conjugative transposon, CTnDOT-type element. CTnDOT-type elements are required for
transferring antibiotic resistance genes among Bacteroides spp. 221. Most ETBF strains cause
biofilm formation with a pro-carcinogenic activity and initiate CRC development 223. The epsG
gene is involved in the synthesis of the exopolysaccharide component required for the adhesion of
cells in biofilm formation. Gene families of B. fragilis, that are related choloylglycine hydrolase
were observed in some CRC and control samples. choloylglycine hydrolase is a conjugated bile
salt hydrolase known to be produced by gut microbes (strains of Bacteroidetes). It has the
potential to alter the host fatty acid metabolism by mediating bile salt hydrolysis 224. In the large
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intestine, the bile salts are deconjugated to free bile acids by bacterial bile salt hydrolases. Then,
the free bile acids are converted to secondary bile acids (deoxycholic acid and lithocholic acid) by
bacterial 7α-dehydroxylase. These secondary bile acids are known to carcinogenic and promoters
of colon cancers

225

.

Most E. coli strains live in human gut are commensals. However, some E. coli strains are
pathogenic and involved in many human diseases. It produces a diverse array of virulence factors,
and causes downregulation of the DNA mismatch repair proteins (MLH1 and MLH2),
cytoskeletal rearrangement, and reduced cellular apoptosis of cancer cells (enteropathogenic E.
coli) 226, and blocks mitosis through double-strand breaks and induce megalocytosis (E. coli B2
phylogenetic group) 227. In this study, we found different E. coli proteins that varied across the
CRC samples of geographic regions include hemolysins, ABC transport proteins, iron
transporters, drug resistance proteins, and others. Hemolysin-positive (hly+) type I E.coli has
shown to be associated with female colonic tumorigenesis 228. ABC transport ATP-binding
proteins use the binding and hydrolysis of ATP for the transport of substances across the
membrane. They function either as importers or exporters in prokaryotes- import nutrients and
export toxins, drugs, and lipids across membranes. Overexpression of ABC export proteins leads
to multidrug resistance in cancer cells 229. E. coli strains from CRC samples showed more
UniProtKB mapped virulence proteins than from the control samples. Colicin-related gene
families were identified in E. coli strains from both CRC and control samples; however, the
ethanolamine utilization protein, EutD was identified only in E. coli strains from CRC, and absent
in E. coli strains from the control samples. Recent studies showed the increased E.
coli ethanolamine utilization (eut) operon transcripts in CD patients compared to healthy controls
.

230

We identified very few differential gene families related to virulence from the
pangenome analysis of P. micra. It is known to be an opportunistic pathogen with low virulence,
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which grows in cancer and immunosuppressed people 231. In our study, it showed a high
abundance in CRC samples compared to controls. The differential gene families of P. micra were
GntR family transcriptional regulator (involved in DNA recombination, replication, repair,
transcription), Fe hydrogenase (provides hydrogen as an energy source for the growth of bacteria
and catalyzes the reversible oxidation of dihydrogen), and 4Fe-4S binding domain protein
(cofactors). The gene families of R. torques were significantly different in CRC samples of three
geographic regions, including the type II secretion system. It is comprised of proteins encoded
from 12 genes, and those support the transport of different proteins in and out of the bacterial
cells through the outer membrane 232. Overall, pangenome gene family analysis showed that the
gut microbial species were highly variable across the geographic regions, and this variability is
mainly attributed to the accessory genes. The accessory genes of these pathogens were primarily
involved in bacterial virulence and antibiotic resistance.
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Metabolome changes associated with CRC
Results
In this study, we predicted the metabolite profiles of the gut microbial communities from the US,
French, and Chinese populations based on the Japanese CRC dataset using both metagenomic and
metabolomic profiles. The MelonnPan predictive models identified 135 metabolites from each
dataset. The predicted metabolite profiles of each dataset were filtered to remove < 0.01% relative
abundance in ≥ 10% of the samples 149. That resulted in 70 metabolites in each dataset. These
were merged, normalized, and analyzed for differential metabolites between CRC and control
groups using edgeR and limma software (limma, P-value < 0.05). The CRC group was enriched
with phenylalanine, valine, leucine, alanine, isoleucine, and tyrosine; and other metabolitescadaverine, succinate, and creatine whereas control group was enriched with butanoic acid, Lglutamate, and L-aspartate (Fig. 21A). The differential metabolites were analyzed separately
using MetaboAnalyst (pathway enrichment analysis), which showed the enrichment of amino
acid metabolism in CRC (Fig. 21C), whereas, arginine biosynthesis, nicotinate, and nicotinamide
metabolism, D-Glutamine, and D-glutamate metabolism, and butanoate metabolism were
enriched in controls (p < 0.05, Fig. 21B).
We also estimated the correlations between gut microorganisms and metabolites from
CRC samples and examined the correlations between global CRC microbial biomarkers and
differential metabolites. The heatmap (Fig. 22) showed the clustered separation of CRC microbial
markers in the vertical axis (left side) and metabolites in the horizontal axis (on top of the map).
The upper clusters in the vertical axis include control-associated organisms like E. halli, F.
prausnitzii, E. ventriosum, and E. eligens. The down clusters in the vertical axis contain mostly
CRC-associated microbes.
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Figure 21: Analysis of MelonnPan predicted metabolites from the USA, China, and France datasets.
(A) The relative abundance of significantly different (p-value < 0.05) metabolites between CRC and healthy control
groups. Blue indicates control samples and red indicates CRC samples from all three datasets; Enrichment of pathways
based on predicted metabolites, (B) In healthy controls, (C) In CRC samples.

The CRC-associated microbes were in different clusters such as F. nucleatum, C.
symbiosum and S. moorei were separated from R. torques, B. fragilis, Parvimonas spp, G.
morbillorum, and P. stomatis. Few clusters contain both CRC- and control-associated microbes
such as Alistipes onderdonkii, which is a CRC-associated microorganism clustered with F.
prausnitzii, and E. eligens (control-associated). In the other cluster, CRC-associated
microorganisms, C. citroniae and P. asaccharolytica were grouped with control-associated
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microorganisms, Coprococcus sp. ART55_1 and Burkholderiales bacterium 1_1_47. However, in
these mixed clusters, the microbes have dissimilar correlations with metabolites. For example,
Alistipes onderdonkii was different from control-associated F. prausnitzii, and E. eligens in
correlations with butanoic acid, glutamate, aspartate, and tyrosine. The CRC-associated
microbes, C. citroniae and P. asaccharolytica were differed from control-associated
microorganisms, Coprococcus sp. ART55_1 and Burkholderiales bacterium 1_1_47 in
correlations with aspartate.
Differential analyses showed the enrichment of cadaverine, succinate, and phenylalanine
in CRC samples. These metabolites were positively correlated with most CRC-associated
microbes such as F. nucleatum, S. moorei, P. stomatis, G. morbillorum, B. fragilis, C. symbiosum
and Parvimonas spp., and negatively correlated with control associated microbes, F. prausnitzii,
and E. eligens (p < 0.05). Significant positive correlations were observed between branched-chain
amino acids (valine, leucine, and isoleucine) and R. torques. A short-chain fatty acid, Butyrate,
was positively correlated with gut commensal microbes such as F. prausnitzii and E. ventriosum,
and negatively correlated with pathogenic microbe, C. symbiosum (p < 0.05). C. symbiosum also
showed positive correlation with alanine, which was enriched in CRC samples. Ornithine was
positively correlated with the control-associated microbes and negatively correlated with CRCassocaited microbes (p < 0.05) (Fig. 22). Previous studies showed that ornithine is an important
metabolite in the arginine metabolism, which is produced by Lactobacilli and it helps in gut
mucosal barrier function 233. However, degradation or decarboxylation of L-ornithine linked to
polyamine synthesis, and high levels of polyamines associated with colon cancer 234. Most of the
metabolites like nicotinamide, choline, tryptophan, 2-hydroxy butanoic acid, and others were
positively correlated with control associated microbes, F. prausnitzii and E. eligenes, and
negatively correlated with F. nucleatum, S. moorei, and C. symbiosum. A CRC-associated
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microbe, A. onderdonkii, showed negative correlations with butanoic acid and aspartate (p <
0.05).

Figure 22: Correlation analysis between CRC microbial markers and metabolites.
Red indicates positive correlation and blue indicates negative correlation. * P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.

Discussion
Predictive metabolome analysis revealed the differences in metabolite composition of CRC and
control groups. These changes could represent the metabolic requirements and pathological
changes associated with the tumor cells. Gut microbiota is a key player in modulating the
metabolite composition of the gut. Our analysis revealed altered metabolite and microbial
interactions in CRC, which reflects the role of gut microbiota in CRC. We found the enrichment
of butanoic acid in control samples compared to CRC samples, and it is positively correlated with
Eubacterium spp. and F. prausnitzii. Butanoic acid is an SCFA, which is formed as a byproduct
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in the microbial fermentation of undigested polysaccharides in the colon. It plays a crucial role
the gut homeostasis and the prevention of tumor growth 235,236. Previous studies showed the antiinflammatory action of the butyrate through its binding with GPR109A on colonic macrophages
and dendritic cells. This binding promotes the Treg cells and IL-10 differentiation 237. Another
metabolite, succinate was enriched in CRC samples compared to controls. It is one of the
metabolic intermediates in the TCA cycle and is produced during the fermentation of dietary fiber
by gut microbes such as B. fragilis, F. prausnitzii, Alistipes spp., Prevotellaceae, and others.
Accumulation of succinate has been reported to be associated with dysbiosis, which can lead to
intestinal inflammation 238. It causes intestinal inflammation through binding with SUCNR1
receptors present on intestinal tissue and modulates macrophage activity 239. In our study, taurine
was highly enriched in controls compared to the CRC group and positively correlated to both
CRC- and control-associated gut microorganisms. Taurine is a semi-essential amino acid reported
to be involved in the inhibition of ulcerative colitis-CRC progression and regulation of apoptosis
in breast cancer 240,241. However, high levels of taurine in the large intestine leads to the formation
of hydrogen sulfide, which is a genotoxic compound. Deconjugation of bile salts and oxidation of
dietary methionine and cysteine are main sources of taurine in the large intestine, where it is
metabolized by gut bacteria to SO32- and further reduced to hydrogen sulfide 242,243. Previous
studies also showed that meat-rich diets significantly increase the taurine conjugation to bile
acids, consequently increasing taurocholic acid (TCA) levels in the small intestine. During
enterohepatic circulation, some of the bile salts that reach the colon are transformed
(deconjugation of TCA followed by 7α-dehydroxylation of CA) to a carcinogenic secondary bile
acid, deoxycholic acid (DCA) by gut microbes 36,244.
Next, we found amino acids like valine, leucine, isoleucine, and phenylalanine, which
were enriched in the CRC group compared to controls, comparable to previous studies in CRC
245,246

. But glutamate was enriched in control samples compared to CRC samples, which contrasts
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a previous study 246,247. Glutamate showed varying interactions with both CRC- and controlassociated microbes. The metabolite profiles and pathway associations in CRC indicated the
substantial demand for amino acids to support the high growth rates of CRC cells. In addition to
glucose, the cancer cells use amino acids like glutamine, valine, leucine, and isoleucine as
alternative fuel sources of organic molecules to drive the TCA cycle to meet the high-energy
demand for growth 248. We also found an abundance of phenylalanine in CRC compared to
controls. Increased levels of phenylalanine have been shown to be associated with systemic
inflammation 206. Branched-chain amino acids (BAA- valine, leucine, and isoleucine) and
phenylalanine are the abundant components of gut tissue. The intestinal sloughed cells and
damaged mucin layer are the sources of BAA and phenylalanine in the intestinal secretions/fecal
extracts. Increased abundance of pathogenic microbes/mucinophilic bacteria such as F. nucleatum
and Akkermansia in CRC might cause mucolytic damage to gut tissue 249. Many other gut
pathogens such as B. fragilis, and some strains of B. longum, Ruminococcus torques ,
and Ruminococcus gnavus are involved in mucin degradation in the gut 250.
We identified the enrichment of cadaverine (a diamine molecule) in the CRC group than controls,
and it was positively correlated with CRC-associated microbes, which is consistent with a
previous study 245. Polyamines are polycationic compounds derived from amino acids (protein
putrefaction), which are essential for normal cell growth, and they are produced by the host, gut
bacteria and obtained through diet. However, increased levels of polyamine are often associated
with cancers via altering cell proliferation, apoptosis, and metastasis

. Increased levels of

251–253

polyamine and polyamine synthesizing enzymes were identified in colon cancer compared to
normal colonic mucosa 253. And it has been shown that polyamine catabolism is inhibited by the
KRAS-dependent signaling pathway, and its synthesis is altered by mutated tumor suppressor
(APC gene) in colorectal cancer 254–256. The metabolite, cadaverine is produced by gut bacteria
through decarboxylation of lysine, which may result in increased luminal polyamines and
102

enhanced uptake of these polyamines by neoplastic cells in the colon 257,258. And the high level of
cadaverine in CRC indicates the enhanced protein putrefaction in the large intestine.
Another metabolite, 2-hydroxybutanoic acid, has shown elevated levels in the CRC group
compared to controls, and these results are similar to those from serum metabolomic studies in
CRC 259,260. 2-hydroxybutanoic acid is formed as a byproduct during the formation of alphaketobutyrate, and this reaction is catalyzed by lactate dehydrogenase or alpha-hydroxybutyrate
dehydrogenase. Recent studies reported 2-hydroxybutanoic acid as an early indicator of insulin
resistance and impaired glucose regulation due to its increased levels in lipid oxidation and
oxidative stress 261. Further, the pathway enrichment analysis demonstrated that the differential
metabolites identified in this study are involved in the pathways required for tumor growth. Those
pathways include valine, leucine and isoleucine biosynthesis and degradation, phenylalanine
metabolism and others in CRC samples and butanoate metabolism, glutamate metabolism,
arginine biosynthesis, and others in control samples.
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Gut microbial community metabolic modeling
Results
Individual and community metabolic models
Using three different diet media (vegetarian, US diet, and unhealthy diet), we built individual and
merged metabolic models for CRC-associated (Fusobacterium nucleatum, Clostridium
symbiosum, Bacteroides fragilis, and Gemella morbillorum) and control-associated
(Faecalibacterium prausnitzii, Roseburia hominis, Eubacterium ventriosum, and Eubacterium
eligens) microbial species and performed FBA on those models. Details of all metabolic models
are shown in the following Tables 9 -13.

Genome
Reference ID
GCF_0097303
15.1
GCF_0012865
25.1
GCF_0030197
85.1
GCF_0086322
35.1
GCF_9023879
55.1
GCF_0034751
05.1
GCF_0033124
65.1
GCF_0001461
85.1
CRC
community
Control
community

Metabolic
model on
Unhealthy
diet
Gemella
morbillorum
Bacteroides
fragilis
Fusobacteriu
m nucleatum
subsp.
nucleatum
ATCC 23726
[Clostridium]
symbiosum
Roseburia
hominis
Eubacterium
ventriosum
Faecalibacter
ium
prausnitzii
Eubacterium
eligens
CRCassociated
microbes
Controlassociated
microbes

Gen
es

New
reacti
ons
adde
d

Objectiv
e Value

No.
compo
und in
FBA

770

457

100

0.13898

88

1043

1071

780

75

0.356359

95

CRC

800

887

558

95

0.356359

116

CRC

1030

1061

102
9

88

0.13898

130

Control

957

1012

693

106

0.356359

95

Control

857

922

540

94

0.13898

107

Control

908

959

659

92

0.13898

92

Control

890

936

615

81

0.13898

108

CRC

3573

3529

0.199971

169

Control

3612

3561

0. 16398

134

Associ
ation

No. of
Reactio
n

No. of
compo
unds

CRC

700

CRC

Table 9: Details of individual and community metabolic models of CRC- and control-associated microbes on the
unhealthy diet media.
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Genome
Reference ID
GCF_0097303
15.1
GCF_0012865
25.1

Metabolic model
on Vegetarian
diet

Associ
ation

No. of
Reacti
on

No. of
compou
nds

Ge
ne

New
reactio
ns
added

Objecti
ve
Value

No.
compou
nd in
FBA

CRC

705

776

457

104

0.13898

88

CRC

1045

1075

780

77

0.22250

95

CRC

800

887

558

95

0.22250

116

CRC

1031

1061

102
9

89

0.13898

130

957

1012

693

106

0.22250

95

862

927

540

99

0.13898

107

GCF_0086322
35.1
GCF_9023879
55.1
GCF_0034751
05.1

Gemella
morbillorum
Bacteroides
fragilis
Fusobacterium
nucleatum
subsp.
nucleatum
ATCC 23726
[Clostridium]
symbiosum
Roseburia
hominis
Eubacterium
ventriosum

Contr
ol
Contr
ol

GCF_0033124
65.1

Faecalibacteriu
m prausnitzii

Contr
ol

909

959

659

92

0.13898

92

GCF_0001461
85.1

Eubacterium
eligens

Contr
ol

891

936

615

84

0.13898

108

CRC community

CRC

3575

3534

Control
community

Contr
ol

3619

3566

GCF_0030197
85.1

281
2
250
7

0.19997
1
0.16398
8

169
134

Table 10: Details of individual and community metabolic models of CRC- and control-associated microbes on the
vegetarian diet media.

Genome
Reference ID
GCF_009730
315.1
GCF_001286
525.1
GCF_003019
785.1
GCF_008632
235.1
GCF_902387
955.1
GCF_003475
105.1
GCF_003312
465.1
GCF_000146
185.1

Metabolic
model on the
US diet
Gemella
morbillorum
Bacteroides
fragilis
Fusobacteriu
m nucleatum
subsp.
nucleatum
ATCC 23726
[Clostridium
] symbiosum
Roseburia
hominis
Eubacterium
ventriosum
Faecalibacte
rium
prausnitzii
Eubacterium
eligens

Gene

New
reacti
ons
adde
d

Objective
Value

No.
compou
nd in
FBA

757

457

89

0.13898

86

1044

1074

780

70

0.356359

95

CRC

798

883

558

82

0.356359
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CRC

1024

1060

1029

80

0.13898

130

Control

948

1006

693

96

0.356359

95

Control

848

916

540

83

0.13898

107

Control

899

953

659

82

0.13898

92

Control

882

931

615

73

0.13898

108

Associ
ation

No. of
Reactio
n

No. of
comp
ounds

CRC

690

CRC

105

CRC
community
Control
community

CRC

3556

3515

0.199971

166

Control

3577

3538

0.163988

134

Table 11: Details of individual and community metabolic models of CRC- and control-associated microbes on the US
diet media.

After FBA of the
metabolic model
(CRC-associated)

Medium

Positive flux

Vegetarian
US diet
Unhealthy
Vegetarian
US diet
Unhealthy

Negative flux

*No. of
reactions with
flux
889
919
893
288
299
297

No. of reactions
with flux (No. of
reaction with
KEGG ID)
564 (248)
534 (397)
573 (237)
210 (106)
174 (150)
189 (97)

Reactions in
Known KEGG
Pathways
47
55
48
29
46
30

Table 12: Details of metabolic flux reactions based on the FBA of CRC- associated microbial community metabolic
models on three different diet media. Note: *The same reaction in different organisms is counted separately.

After FBA of the
metabolic model
(Control-associated)

Medium

Positive flux

Vegetarian
US diet
Unhealthy
Vegetarian
US diet
Unhealthy

Negative flux

*No. of
reactions with
flux
910
876
892
279
269
271

No. of reactions
with flux (No. of
reaction with
KEGG ID)
552 (214)
543 (208)
548 (204)
195 (81)
191 (78)
191 (72)

Reactions in
Known KEGG
Pathways
43
41
43
31
31
31

Table 13: Details of metabolic flux reactions in control-associated microbial community metabolic models based on the
FBA on three different diet media. Note: *The same reaction in different organisms is counted separately.

Comparison of metabolic flux in the community metabolic models
After building the community metabolic models, we performed the FBA of those models
under three different diet environments. We then compared the flux values of metabolic reactions
between CRC and control communities. We observed that reactions with positive flux were
higher than reactions with negative flux in both CRC and control communities. Reactions with
flux values in glycan biosynthesis and metabolism, lipid metabolism, and xenobiotic metabolism
were higher in the CRC community than in the control community (Figure 23). Then, we
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analyzed flux values of MEP, mevalonate, and butanoate pathways in CRC and control
communities. Details of these pathways were mentioned in the ‘Discussion’ part of “Gene family
analysis of strains of CRC-related microbes” and ‘Results’ part of the “Functional alterations in
the gut microbiome of colorectal cancer” sections in the thesis.

Figure 23: Comparison of number of reactions with flux in metabolic pathways in CRC and control community models
under three different diet conditions- unhealthy diet, vegetarian diet, and US recommended diet.

Reactions of isoprenoid biosynthesis pathways- MEP pathway and mevalonate pathway
were shown in Figure 24. Some of the reactions in the MEP pathway (R05633, R05634, R05636,
R05637, R05688, and R05884) had certain quantity of flux values in CRC and control
community models (Table 14). These flux values indicate communities' capacity to synthesize
isoprenoids. However, the flux values of the MEP pathway were higher in the CRC community
compared to the control community (Figure 25), whereas reactions of the mevalonate pathway
(R01121, R02245, and R03245) have flux values only in the CRC community models (Table 14,
Figure 26B). Further, we observed higher flux values for pyruvic acid decarboxylation to acetyl
CoA reaction in the control community model than in the CRC community models (Figure 26A,
Table 14). We also observed the differences in flux values of the reaction, R05884 across the
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three media in CRC and control communities. It is one of the reactions in the MEP pathway that
leads to the formation of isopentenyl diphosphate. The flux value of R05884 reaction was higher
in CRC community stimulated on vegetarian diet, followed by Unhealthy diet and the US diet. In
addition, the flux value of butanoate pathway reaction, R0212, was higher in the control
community stimulated on the US diet, followed by vegetarian and unhealthy diet.

Figure 24: Diagram of isoprenoid biosynthesis pathways- MEP and mevalonate pathways.
The enzymes and reactions (KEG IDs) involved in these pathways for both the pathways were shown in blue color.
KEGG IDs marked in dark blue color were observed in CRC and control microbial community models. R*: This
reaction was not annotated in community models and the reaction is identifies as R08689 based on comparison of
reaction definition to KEGG reactions.
KEGG
ID
R05633
R05634
R05636
R05637
R05688
R05884

Reaction Definition
Methylerythritol phosphate (MEP) pathway
CTP + 2-C-methyl-D-erythritol4-phosphate -> PPi + 4--cytidine5diphospho-2-C-methyl-D-erythritol
ATP + 4--cytidine5-diphospho-2-C-methyl-D-erythritol -> ADP +
H+ + 2-phospho-4--cytidine5-diphospho-2-C-methyl-D-erythritol
Pyruvate + H+ + Glyceraldehyde3-phosphate -> CO2 + 1-deoxyD-xylulose5-phosphate
2-phospho-4--cytidine5-diphospho-2-C-methyl-D-erythritol <->
CMP + 2-C-methyl-D-erythritol2-4-cyclodiphosphate
NADP + 2-C-methyl-D-erythritol4-phosphate <-> NADPH + H+
+ 1-deoxy-D-xylulose5-phosphate
NADPH + H+ + 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate ->
H2O + ADP + Isopentenyl diphosphate

Observed in
gut community
CRC & control
CRC & control
CRC & control
CRC & control
CRC & control
CRC & control
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R08210
R01123
R08689
R01121
R02245
R03245
R00212

NADH + H+ + 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate ->
H2O + NAD + DMAPP
Isopentenyl diphosphate <-> DMAPP
NADH + H+ + 2-C-methyl-D-erythritol2-4-cyclodiphosphate ->
H2O + NAD + 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate
Mevalonate pathway
ATP + 5-diphosphomevalonate -> ADP + Phosphate + CO2 +
Isopentenyl diphosphate
ATP + Mevalonic acid -> ADP + H+ + 5-phosphomevalonate
ATP + H+ + 5-phosphomevalonate -> ADP + 5diphosphomevalonate
Pyruvate to butanoate metabolism
Acetyl-CoA + Formate <- CoA + Pyruvate

CRC & control
CRC & control
CRC & control
CRC
CRC
CRC
CRC & control

Table 14: Reactions of MEP, mevalonate and butyrate synthesis pathway observed in CRC and control microbial
community models.

Figure 25: Metabolic flux values of reactions in MEP pathway in CRC and control metabolic models
under three different diet conditions- unhealthy diet, vegetarian diet, and the US recommended diet.
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Figure 26: Metabolite flux values in metabolic pathways of community models in three different diet conditionsunhealthy diet, vegetarian diet, and the US recommended diet. (A) R00212- pyruvate decarboxylation reaction flux in
butanoate pathway between CRC and control metabolic models. (B) Flux in mevalonate pathway reactions in CRC
community.

Discussion
Metabolite secretions of gut microbiota play an important role in human health and disease.
Several studies have shown that metabolites secreted by pathogenic microbes contribute to CRC,
those include H2S, N-nitrosamines and N-nitrosamides (NOC), secondary bile acids (DCA),
Trimethylamine-N-oxide (TMAO) 262–265, etc. The type of metabolites secreted by the gut
microbes depends on the type of diet available in the gut. It indicates that gut microbial
interactions with the host depends primarily on diet and the diet-mediated gut microbial
interactions in dysbiotic gut contributes to CRC development. To understand the effect of
different diets on the metabolite flux in CRC and healthy control gut communities, we used three
different diet media- unhealthy diet, vegetarian diet, and US recommended diet media for
construction of CRC and control community metabolic models. We were able to simulate the
growth of the individual and community microbes on these media after adding micronutrients,
cobalt (2+) and molybdate to all three media. FBA analysis of community models showed
differences in the metabolite flux values between CRC and control communities. Our analysis
showed higher metabolite flux values in the MEP and mevalonate pathway reactions in the CRC
community. These two pathways provide the precursors for isoprenoid biosynthesis, which are
involved in a wide variety of biological functions. It has been shown that the abundance of MEP
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pathway genes in the human distal gut microbiome. And it is a preferred pathway for IPP
biosynthesis in some of anaerobic gut bacteria over mevalonate pathway as it produces a 5:1 ratio
of IPP to DMAPP compared to 3:7 ratio of IPP to DMAPP in mevalonate pathway 266. It has been
shown that the MEP pathway plays a role in host-pathogen interactions and virulence of
pathogens. The virulence of L. monocytogenes has shown to linked with MEP pathway, a ychB
mutant (genes encodes for an enzyme, 4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol 2phosphotransferase in MEP pathway) showed impaired virulence compared to wild-type 267.
Another gene, dxs (encodes for 1-deoxy-D-xylulose-5-phosphate synthase) in the MEP pathway
has been shown to aid in the initial survival of pathogen in phagosomes through accumulation of
antioxidants 268. All these studies support our results, where high flux values of MEP pathway in
the CRC community may contribute to the host-pathogen interactions in CRC. We observed that
F. nucleatum, B. fragilis, and C. symbiosum were the main contributors of metabolite flux in
MEP pathway, whereas G. morbillorum did not contribute to the metabolite flux in MEP pathway
in CRC community. In the control community, all four community members, F. prausnitzii, E.
eligens, E. ventriosum, and R. hominis were involved in the metabolite flux of MEP pathway,
however the flux quantity was less in control community compared to the CRC community.
Interestingly, the CRC community also showed the metabolite flux in mevalonate
pathway in addition to MEP pathway in all three diets. The mevalonate pathway was considered
as the classical ancestral metabolic route for isoprenoid synthesis in archaea, bacteria and
eucaryotes based on phylogenomic analysis 269. The penultimate compound (1-Hydroxy-2methyl-2-butenyl 4-diphosphate) of the MEP pathway was shown to be a potent activator of
human Vγ9/Vδ2 T cells; this mechanism is only shown by the bacteria possessing the MEP
pathway 270,271. In this study, we observed a higher flux of 1-Hydroxy-2-methyl-2-butenyl 4diphosphate compound (reaction R08689) in the CRC compared to control communities. And the
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flux of this compound was contributed by C. symbiosum and F. nucleatum in the CRC
community, and by E. ventriosum, E. eligens and F. prausnitzii in the control community.
Among SCFAs, an important metabolite, butyrate has been reported to be involved in
maintaining the health of gut microbial barrier, suppression of inflammation and induction of
apoptosis 235. And other studies also showed significantly low levels of SCFAs in the CRC group
than the healthy controls 272. We also found higher flux values of the reaction R00212, in the
pyruvate to butanoate pathway in the control community than the CRC community. Overall,
metabolic modeling of gut communities and FBA of those models, showed the relationships
between microbial metabolites and CRC. Metabolites of CRC microbiome contribute to the
growth and progression of CRC by increasing the metabolite flux in cancer associated metabolic
pathways.
In this study, the metabolic phenotypes of communities were inferred in the context of
four-organism communities built based on the microbes identified from metagenomic data. These
models could be improved further by considering the entire community associations and
integrating relative abundance of microbial community members associated with the phenotypes.
The large-scale community-level reconstructions would provide accurate quantitative insights of
communities associated with the host phenotype. Similarly, integration of other ‘omics’
(transcriptomics and metabolomics) data would provide system-level understanding of the role of
microbes in human health and disease.
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CHAPTER 5

Conclusions
Colorectal cancer persists as a significant health challenge in the world with the highest
number of incidences and mortality in women and men. Even though the onset of tumor formation
involves inherited genetic predisposition, most CRCs are sporadic because of environmental
factors, with the gut microbiome as the key player in its development. Emerging in vivo and in
silico studies presented the association of gut microbial dysbiosis with CRC; however, reliable
markers for CRC diagnosis across the multiple cohorts remain ambiguous and the importance of
microbial interactions and metabolite secretions in CRC need to be investigated further to
understand their role in CRC pathogenesis. Here, we developed a computational model to identify
unbiased global microbial biomarkers for CRC based on the meta-analysis of gut metagenomic
sequencing datasets from diverse geographical regions. The strength our biomarker identification
approach lies in the implementation of three robust methods that include LEfSE, Random Forest
and co-occurrence network based DyNet tool and selection of common biomarkers present in more
than two datasets to minimize false positives. This approach provided us with a set of 21 global
biomarkers for CRC that are replicable across geographic regions. The average accuracy of these
biomarkers ranged from 0.62 to 0.78 across all datasets including validation sets. The accuracy of
prediction model can be increased by incorporating more datasets into the analysis with adequate
sample size. Biomarkers identified in this study are consistent with the previous studies and we
also identified two new biomarkers, Alistipes onderdonkii and Clostridium citroniae. These
biomarkers can be used to develop non-invasive diagnostic procedures for CRC. Our study also
showed that Random Forest is the one of the best methods for biomarker discovery in microbiome
studies.
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Analysis of microbial taxonomy and diversity of metagenomic datasets used in this study
showed the enrichment of pathogenic species in CRC gut, while the healthy control gut had the
enrichment of commensal microbes. We also identified the differences between the co-occurrence
networks of CRC and control gut microbiomes. The modularity of the community depends upon
the composition and pairwise correlations among the species. Both in the CRC and control
community networks, we observed non-random patterns of co-occurrences, where the
phylogenetically or functionally related species co-occurred. However, we identified the presence
of co-occurrence correlations among pathogenic species and co-exclusion correlations among
pathogenic and non-pathogenic species in CRC networks. A distinct cluster formed from the oral
pathogens was identified in all CRC networks indicating the significance of oral pathogens in CRC
pathogenicity. Overall, this analysis identified the co-occurring microbial clusters specific to CRC
and control communities, which could be investigated to understand the effect of polymicrobial
interactions on host metabolism in CRC.
Functional analysis of CRC and control gut communities based on metagenomic sequences
showed enrichment of pathways involved in the tumorigenesis in the CRC gut, and enrichment of
galactose and stachyose degradation pathways in the control gut from all three datasets. This
indicates the potential of the dysbiotic CRC gut microbiota to alter the metabolic profiles of the gut
and promote carcinogenesis. Analysis of butyrate synthesis pathways revealed that butyrate
synthesis of gut commensals is different from gut pathogens, most commensals use ‘pyruvate
fermentation to butyrate’ pathway, whereas pathogenic gut microbes also use 4-aminobutyrate and
lysine for butyrate synthesis. FBA of gut community models also showed higher metabolite flux in
the reaction from ‘pyruvate fermentation to butanoate’ pathway in control-associated than in CRCassociated microbial communities. Again, this fermentation also depends upon the dietary source,
which was indicated by the higher fluxes of butanoate pathway in custom made US diet media (as
per dietary guidelines for American), followed by vegetarian diet and lower flux values in
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Unhealthy diet. Based on the CRC and control gut metabolic models, we also inferred the flux
values of MEP and mevalonate pathway. This functional analysis and metabolic flux information
of CRC gut microbes might lead to the development of therapeutic, probiotic, and dietary
interventions for CRC on further detailed investigations.
In addition to gut microbial pathway analysis, we also performed pangenome gene family
analysis of CRC-associated pathogen species present in samples from all three geographic regions.
Based on this, we identified that the pathogenic species present in CRC samples from the US,
Chinese, and French populations mainly differed in their accessory gene families. The accessory
genes in these pathogens are primarily involved in bacterial virulence and antibiotic resistance.
Knowledge on the gene families of CRC pathogens of a geographic region could help understand
the disease etiology and implementation of suitable treatments for CRC patients. Gut microbiota is
a key player in modulating the metabolite composition of the gut. Through predictive metabolome
analysis based on the US, France, and China datasets, we revealed the differences in metabolite
composition of CRC and control groups. These changed metabolites represent the metabolic
requirements of the tumor cells and cause pathological changes in CRC. We also identified the
altered metabolite and microbial interactions in CRC gut, which represents the role of gut
microbiota in CRC development. The identified microbe-associated metabolites from this study
can be used in the exploration of diagnostic and therapeutic strategies for CRC.
Overall, this study identified the reliable microbial biomarkers for CRC diagnosis based
on the US, China, and France metagenomic datasets and metabolite biomarkers based on the
predictive metabolome of the same datasets. The analysis based on the taxonomic and functional
abundance of gut microbiome data using co-occurrence networks, functional, and pangenome gene
family analyses showed the differences between CRC and control gut microbiomes. Results
obtained from these analyses can be used to explore the targets for microbiome-based therapies for
CRC or to restore the commensals population. We also performed the in silico simulation of
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metabolic models of four-membered gut communities and identified metabolite flux differences in
CRC and control gut communities on different diet media. However, this work can be further
developed to build personalized gut microbial community models and predict the individualized
therapeutic interventions for CRC patients. And the integration of other meta-omics data on the
personalized model would allow us to obtain qualitative and quantitative information on the
metabolic potential of microbial communities present in the disease.
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Appendices
Appendix A: Characteristics of the datasets used in this study
Datasets
(Geographic
regions)
USA

Samples used in
this study
52 CRC

Sex (F
& M)
15 F

Age
(Average±s.d.)
67.93±10.44

BMI
(Average±s.d.)
25.62±4.88

37 M

59.37±13.93

24.44±3.68

15 F
37 M

63.46±5.24

25.03±5.24

24 F

60.32±11.24
67.79±12.26

25.47±3.73
25±5.21

29 M

66.0±9.28

33 F

60.51±9.64

26±4.823
24±3.51

28 M

60.64±12.97

12 F

61.25±10.46

25±2.44
25±4.69

30 M
26 F

63.63±8.24
66.70±11.23

26±3.71
24.55±3.70

48 M

65.5±10.02

24.55±2.65

54 Control

21 F

65.85±3.21

23.64±4.022

46 CRC

33 M
18 F

59.39±5.39
67.22±12.15

23.41±2.03
25.53±3.18

28 M

66.96±9.81

27.12±3.53

25 F

68.6±6.30

26.24±3.65

52 Control
France

53 CRC
61 Control
42 Adenoma*

China

Austria

74 CRC

63 Control** (61)

Japan

36 M

65.83±6.22

28.56±3.49

47 Adenoma

24 F

67.70±8.18

27.52±5.04

258 CRC

23 M
97 F

65.21±7.09
63.6±8.88

28.41±4.11
22.11±3.44

161 M

62.14±9.99

23.59±3.03

115 F

61.54±11.63

21.48±2.82

131 M

60.45±13.1

23.69±2.84

19 F

63.0±10.08

21.96±4.83

48 M
11 F

63.2±8.60
63.36±7.65

23.52±4.52
25.09±4.03

15 M

62.73±9.30

25.6±4.09

9F

70.44±7.16

24.33±7.16

13 M

65.84±5.88

25.61±3.15

11 F

61.72±10.24

25.66±3.70

15 M

62.13±11.36

28.40±4.66

16 F

54.68±9.87

25.86±5.51

11 M

56.63±8.85

26.72±3.26

246 Control
67 MP
Italy

26 Adenoma
22 Control

USA-Canada

26 Adenoma
27 Control

Note: MP- multiple polypoid adenomas, F- female, and M- male, * indicates large and small adenomas and ** two
control samples with missing age and BMI data (not imputed). For a few samples (1 or 2 samples in a dataset) with
only missing BMI values were manually imputed based on matched age and sample type.
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Appendix B: Metabolite flux values of the vegetarian diet media
Compound
s
cpd00363
cpd00001
cpd01420
cpd00365
cpd00305
cpd00166
cpd00220
cpd00218
cpd00133
cpd00644
cpd00419
cpd00263
cpd00215
cpd00104
cpd00201
cpd00345
cpd00087
cpd00059
cpd03226
cpd01628
cpd01401
cpd00063
cpd00099
cpd00205
cpd00254
cpd00971
cpd00009
cpd00058
cpd10515
cpd10516
cpd00030
cpd00034
cpd00314
cpd00306
cpd00208
cpd01355
cpd00076
cpd00082
cpd00709
cpd22518
cpd00035
cpd00051
cpd00041
cpd00084
cpd00023
cpd00033
cpd00300
cpd00119

Name
ETOH
H20
Beta-Carotene
Retinol
Thiamin
Calomide
Riboflavin
Niacin
Nicotinamide
PAN (Pantothenate, Vitamin
B5)
PM (Pyrioxamine)
Pyridoxol
Pyridoxal
BIOT (Biotin)
10-Formyltetrahydrofolate
5-Methyltetrahydrofolate
Tetrahydrofolate
L-Ascorbate
VitaminD3
VitaminE
VitaminK1
Ca2+
ClK+
Mg
Na+
Phosphate
Cu2+
Fe+2
Fe+3
Mn2+
Zn2+
D-Mannitol
Xylitol
LACT (Lactose)
Beta-Maltose
Sucrose
D-Fructose
Beta D-Galactose
CELLULOSE
L-Alanine
L-Arginine
L-Aspartate
L-Cysteine
L-Glutamate
Glycine
Urate
L-Histidine

Formula
C2H6O
H2O
C40H56
C20H30O
C12H17N4OS
Calomid
C17H19N4O6
C6H4NO2
C6H6N2O
C9H16NO5
C8H13N2O2
C8H11NO3
C8H9NO3
C10H15N2O3S
C20H21N7O7
C20H23N7O6
C19H21N7O6
C6H7O6
C27H44O
C29H50O2
C31H46O2
Ca
Cl
K
Mg
Na
HO4P
Cu
Fe
Fe
Mn
Zn
C6H14O6
C5H12O5
C12H22O11
C12H22O11
C12H22O11
C6H12O6
C6H12O6
C24H40O19R2
C3H7NO2
C6H15N4O2
C4H6NO4
C3H7NO2S
C5H8NO4
C2H5NO2
C5H4N4O3
C6H9N3O2

MinFlu
x
-100
-100
-100
-100
-100
-100
-100
-100
-100

MaxFlux
26.80796
188463.6
0.007916
0.209459
2.96E+00
9.31E-07
0.001873
0.208699
0.097462

Concentratio
n
26.80796
188463.6
0.007916
0.209459
2.96E+00
9.31E-07
0.001873
0.208699
0.097462

-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100

0.018215
0.00331
0.00331
0.00335
0.000203
0.000185
0.00019
0.000196
7.91E-01
7.05E-06
0.041269
0.00041
18.48184
203.5486
75.81327
15.67538
106.47
10.71283
0.037375
0.108559
0.108559
0.125687
0.116396
0.474278
0.075388
8.533946
0.26293
87.59949
204.9398
0.979152
0.079528
25.69338
17.86199
35.14974
6.746097
83.4289
30.26206
2.124379
7.818073

0.018215
0.00331
0.00331
0.00335
0.000203
0.000185
0.00019
0.000196
7.91E-01
7.05E-06
0.041269
0.00041
18.48184
203.5486
75.81327
15.67538
106.47
10.71283
0.037375
0.108559
0.108559
0.125687
0.116396
0.474278
0.075388
8.533946
0.26293
87.59949
204.9398
0.979152
0.079528
25.69338
17.86199
35.14974
6.746097
83.4289
30.26206
2.124379
7.818073
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cpd00322
cpd00107
cpd00039
cpd00060
cpd00066
cpd00129
cpd00054
cpd00161
cpd00065
cpd00069
cpd00156
cpd01107
cpd01741
cpd03847
cpd15298
cpd17034
cpd00214
cpd15609
cpd01080
cpd15269
cpd01122
cpd30350
cpd03848
cpd16341
cpd14900
cpd00188
cpd05196
cpd05231
cpd03852
cpd00211
cpd03846
cpd00160
cpd00588
cpd00027
cpd05274
cpd05235
cpd00393
cpd16142
cpd00534

cpd30041
cpd00149
cpd11574

L-Isoleucine
L-Leucine
L-Lysine
L-Methionine
L-Phenylalanine
L-Proline
L-Serine
L-Threonine
L-Tryptophan
L-Tyrosine
L-Valine
Decanoate
Ddca (Dodecanoate)
Myristicacid
Tetradecenoate
Pentadecanoate(n-C15:0)
Palmitate
Heptadecanoate(C17:0)
ocdca (Octadecanoic acid)
Octadecenoate
Linoleate
Alpha-Linolenic acid,
C18:3, n-3
Arachidicacid,4
Icosenoicacid
(11Z,14Z)-IcosadienoylCoA
Arachidonate
Docosanoate
Erucicacid,4
Docosahexaenoicacid
Butyrate
Octanoate
Cholesterol
Sorbitol
Glucose
Palmitoleicacid
Tetracosanoate
Folate,4
Amylose(n)
I-,4 (Hydrogen iodide)
Starch n=300 repeat units
(80 units amylose,220units
amylopectin,corresponds to
maize starch)
Cobalt(Co2+)
Molybdate

C6H13NO2
C6H13NO2
C6H15N2O2
C5H11NO2S
C9H11NO2
C5H9NO2
C3H7NO3
C4H9NO3
C11H12N2O2
C9H11NO3
C5H11NO2
C10H19O2
C12H23O2
C14H27O2
C14H25O2
C15H29O2
C16H31O2
C17H33O2
C18H35O2
C18H33O2
C18H31O2

-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100

18.99565
31.40672
17.25396
6.125173
15.54751
36.97122
25.3417
16.51476
3.023109
10.152
25.01799
1.806294
2.105642
5.801977
0.71543
0.621609
39.53952
0.466147
12.48153
82.41643
88.19503

18.99565
31.40672
17.25396
6.125173
15.54751
36.97122
25.3417
16.51476
3.023109
10.152
25.01799
1.806294
2.105642
5.801977
0.71543
0.621609
39.53952
0.466147
12.48153
82.41643
88.19503

Undefined
C20H39O2
C20H37O2
C41H66N7O17P3
S
C20H31O2
C22H43O2
C22H41O2
C22H31O2
C4H7O2
C8H15O2
C27H46O
C6H14O6
C6H12O6
C16H29O2
C24H47O2
C19H17N7O6
Undefined
I-

-100
-100
-100

7.659819
1.111557
0.596999

7.659819
1.111557
0.596999

-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100

0.014505
0.001779
0.304807
0.124956
0.077867
4.691655
1.040827
0.104124
18.12767
102.1381
4.088531
0.090254
0.000198
41.33622
0.001072

0.014505
0.001779
0.304807
0.124956
0.077867
4.691655
1.040827
0.104124
18.12767
102.1381
4.088531
0.090254
0.000198
41.33622
0.001072

undefined
Co2+
Molybdate

-100
-100
-100

0.382707
0.001
0.001

0.382707
0.001
0.001
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Appendix C: Metabolite flux values of the unhealthy diet media
Compound
s
cpd00363
cpd00001
cpd01420
cpd00365
cpd00305
cpd00166
cpd00220
cpd00218
cpd00133
cpd00644
cpd00419
cpd00263
cpd00215
cpd00104
cpd00201
cpd00345
cpd00087
cpd00059
cpd03226
cpd01628
cpd01401
cpd00063
cpd00099
cpd00205
cpd00254
cpd00971
cpd00009
cpd00058
cpd10515
cpd10516
cpd00030
cpd00034
cpd00314
cpd00208
cpd01355
cpd00076
cpd00082
cpd00709
cpd22518
cpd00035
cpd00051
cpd00041
cpd00084
cpd00023
cpd00033
cpd00300
cpd00119

Name
ETOH
H20
Beta-Carotene
Retinol
Thiamin
Calomide
Riboflavin
Niacin
Nicotinamide
PAN (Pantothenate, vitamin
B5)
PM (Pyridoxamine)
Pyridoxol
Pyridoxal
BIOT
10-Formyltetrahydrofolate
5-Methyltetrahydrofolate
Tetrahydrofolate
L-Ascorbate
Vitamin D3
Vitamin E
Vitamin K1
Ca2+
ClK+
Mg
Na+
Phosphate
Cu2+
Fe+2
Fe+3
Mn2+
Zn2+
D-Mannitol
LACT (Lactose)
beta-Maltose
Sucrose
D-Fructose
beta D-Galactose
Cellulose
L-Alanine
L-Arginine
L-Aspartate
L-Cysteine
L-Glutamate
Glycine
Urate
L-Histidine

Formula
C2H6O
H2O
C40H56
C20H30O
C12H17N4OS
Calomid
C17H19N4O6
C6H4NO2
C6H6N2O

MinFlu
x
-100
-100
-100
-100
-100
-100
-100
-100
-100

MaxFlux
294.3449
152721.3
0.002895
4.887388
6.206789
8.25E-06
0.006316
0.455875
0.243514

Concentratio
n
294.3449
152721.3
0.002895
4.887388
6.206789
8.25E-06
0.006316
0.455875
0.243514

C9H16NO5
C8H13N2O2
C8H11NO3
C8H9NO3
C10H15N2O3S
C20H21N7O7
C20H23N7O6
C19H21N7O6
C6H7O6
C27H44O
C29H50O2
C31H46O2
Ca
Cl
K
Mg
Na
HO4P
Cu
Fe
Fe
Mn
Zn
C6H14O6
C12H22O11
C12H22O11
C12H22O11
C6H12O6
C6H12O6
C24H40O19R2
C3H7NO2
C6H15N4O2
C4H6NO4
C3H7NO2S
C5H8NO4
C2H5NO2
C5H4N4O3
C6H9N3O2

-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100

0.029332
0.003974
0.003974
0.004022
0.00027
0.000128
0.000131
0.000136
0.74587
1.71E-05
0.053171
0.000276
53.04456
617.9611
89.05372
17.17515
309.7508
28.47782
0.032984
0.170006
0.170006
0.056027
0.335041
0.133489
43.07096
15.74658
223.6278
92.43135
0.33027
0.033451
86.36929
46.64147
101.0677
16.97236
220.124
84.45735
3.845196
30.96119

0.029332
0.003974
0.003974
0.004022
0.00027
0.000128
0.000131
0.000136
0.74587
1.71E-05
0.053171
0.000276
53.04456
617.9611
89.05372
17.17515
309.7508
28.47782
0.032984
0.170006
0.170006
0.056027
0.335041
0.133489
43.07096
15.74658
223.6278
92.43135
0.33027
0.033451
86.36929
46.64147
101.0677
16.97236
220.124
84.45735
3.845196
30.96119
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cpd00322
cpd00107
cpd00039
cpd00060
cpd00066
cpd00129
cpd00054
cpd00161
cpd00065
cpd00069
cpd00156
cpd01107
cpd01741
cpd03847
cpd15298
cpd17034
cpd00214
cpd15609
cpd01080
cpd15269
cpd01122
cpd30350
cpd15016
cpd03848
cpd16341
cpd14900
cpd00188
cpd05196
cpd05231
cpd16301
cpd03852
cpd00211
cpd03846
cpd00160
cpd00588
cpd00027
cpd05274
cpd05235
cpd00393
cpd16142
cpd00534

cpd30041
cpd00149
cpd11574

L-Isoleucine
L-Leucine
L-Lysine
L-Methionine
L-Phenylalanine
L-Proline
L-Serine
L-Threonine
L-Tryptophan
L-Tyrosine
L-Valine
Decanoate
ddca (Dodecanoate)
Myristic acid
Tetradecenoate
Pentadecanoate (n-C15:0)
Palmitate
Heptadecanoate (C17:0)
ocdca (Octadecanoic acid)
Octadecenoate
Linoleate
alpha-Linolenic acid,
C18:3, n-3
Stearidonic acid, 4
Arachidic acid, 4
Icosenoic acid
(11Z,14Z)-IcosadienoylCoA
Arachidonate
Docosanoate
Erucic acid, 4
Docosapentaenoic acid
Docosahexaenoic acid
Butyrate
Octanoate
Cholesterol
Sorbitol
Glucose
Palmitoleic acid
Tetracosanoate
Folate,4
Amylose(n)
I-,4
Starch n=300 repeat units
(80 repeat units amylose,
220 repeat units of
amylopectin, corresponds to
maize starch)
Cobalt(2+)
Molybdate

C6H13NO2
C6H13NO2
C6H15N2O2
C5H11NO2S
C9H11NO2
C5H9NO2
C3H7NO3
C4H9NO3
C11H12N2O2
C9H11NO3
C5H11NO2
C10H19O2
C12H23O2
C14H27O2
C14H25O2
C15H29O2
C16H31O2
C17H33O2
C18H35O2
C18H33O2
C18H31O2

-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100

61.08776
101.9603
79.12945
26.31822
44.76969
106.9964
77.42339
56.78264
9.950912
35.5929
80.96521
16.85244
20.46177
57.29968
7.459892
5.581835
183.109
4.16889
71.37693
219.9278
82.60523

61.08776
101.9603
79.12945
26.31822
44.76969
106.9964
77.42339
56.78264
9.950912
35.5929
80.96521
16.85244
20.46177
57.29968
7.459892
5.581835
183.109
4.16889
71.37693
219.9278
82.60523

Undefined
C18H27O2
C20H39O2
C20H37O2
C41H66N7O17P3
S
C20H31O2
C22H43O2
C22H41O2
C22H33O2
C22H31O2
C4H7O2
C8H15O2
C27H46O
C6H14O6
C6H12O6
C16H29O2
C24H47O2
C19H17N7O6
Undefined
I-

-100
-100
-100
-100

7.908538
0.085692
2.056876
3.910867

7.908538
0.085692
2.056876
3.910867

-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100

0.308904
1.033969
0.876842
2.215487
0.746898
1.418101
44.40321
10.28946
2.763523
1.561164
119.071
21.78982
0.35402
0.000137
40.117
0.002645

0.308904
1.033969
0.876842
2.215487
0.746898
1.418101
44.40321
10.28946
2.763523
1.561164
119.071
21.78982
0.35402
0.000137
40.117
0.002645

undefined
Co2+
Molybdate

-100
-100
-100

0.371419
0.001
0.001

0.371419
0.001
0.001
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Appendix D: Custom made US diet components for adults, ages 19
through 59
Food group or subgroup
Dark green vegetables (0.21 cup eq/day)
Dandelion greens, raw (chopped)
Broccoli, raw (chopped)
Collards, raw (chopped)
Coast Asia, shanghai Bok choy, UPC: 669212176004
(napa cabbage)
Kale, raw
Spinach, raw
Romaine lettuce, raw (loosely packed)
Red and orange vegetables (0.79 cups eq /day)
Squash, winter type, raw (acorn, cubed)
Carrots, raw (chopped)
Pumpkin, raw (1-inch cubes)
Pepper, sweet, red, raw
Sweet potato, raw, unprepared (includes foods for
USDA’s food distribution program) (cubes)
Tomatoes, red, ripe, raw, year-round average (chopped
or sliced)
Squash, winter, Hubbard, raw (cubes)
Beans, peas, lentils (0.21 cups eq/day)
Black-eyed peas beans, UPC: 015418010558
100% organic lentils, UPC: 661475114434
100% organic kidney beans, UPC: 815421013146
Allens, green and white lima beans, UPC:
034700374109
100% organic chickpeas, UPC: 661475114427
100% organic black beans, UPC: 661475004575
All natural edamame, UPC: 03003491630
Starchy vegetables (0.42 cups eq/day)
Yam slices, UPC: 087738171240
Corn, sweet, yellow, raw
Potatoes, white, flesh, and skin, raw (diced)
Other vegetables (0.51 cups eq/day)
Asparagus, raw
Avocado, raw
Beets, raw
Brussels sprouts, raw
Cabbage, Chinese (Pak Choi), raw (shredded)
Cauliflower, green, raw
Mushrooms, brown, Italian, or crimini, exposed to
ultraviolet light, raw (sliced)
Onions, mature, raw
Celery, raw

gm/day

kcal/day

1.65
2.73
1.08
2.1

0.7473
0.9282
0.3456
0.294

0.63
0.9
1.05

0.2229
0.2088
0.1995

15.4
28.16
12.76
16.39
14.63

5.236
11.6534
3.3792
5.0809
12.5818

19.8

3.564

12.76

5.1194

6.12
7.8
7.8
7.68

20.3796
6.708
6.63
6.6048

7.8
7.8
5.1

10.608
8.97
6.579

21
20.3
21

25.2
17.465
14.49

7.504
8.176
7.616
4.928
3.92
3.584
4.032

1.5176
13.0816
3.27488
2.11904
0.51408
1.12728
0.90104

8.96
6.72

3.584
0.9408
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Fruits (2 cups eq/day)
Apple, raw
Banana, raw
Grapes, American type (slip skin), raw
Blueberries, raw
Raspberries, black, raw
Blackberries, raw
Kiwi fruit, raw
Orange, raw (sections)
Lime juice, raw
Strawberries, raw
Watermelon, raw
Cantaloupe (muskmelon), raw
Pineapple, raw
Grains (whole & refined: 3+3 ounce) (total 6 ounces
eq/day)
100% natural long-grain brown rice, UPC:
015400839686
Eagle, buckwheat white, UPC: 074854310523
100% natural quick oats, UPC: 011225421501
100% whole grain flavored popcorn, UPC:
078742105239
100% whole grain quinoa, UPC: 041512128868
Dairy (3 cups eq/day)
Milk, buttermilk, fluid, whole
Milk, whole, 3.25% milkfat, with added vitamin d
1% low-fat yogurt, UPC: 070552404175
Kefir, low fat, plain, lifeway
Protein foods
Meats, poultry, eggs (3.7 ounces eq/day)
Ground beef, raw
Ham or pork with barbecue sauce (mixture)
Bologna, turkey
Balsamic glazed chicken, UPC: 014500015143
Fat-free turkey stock, UPC: 713733317955
Seafood (1.14 ounces eq/day)
Catfish fry mix, UPC: 073484144652
Crab, coated, baked, or broiled, fat not added in cooking
(cooked, flaked, and pieces)
Tuna, fresh, coated, fried (boneless, cooked)
Lobster, coated, baked, or broiled, fat not added in
cooking (cooked, diced)
Nuts, seeds, soy products (0.714 ounces eq/day)
365 everyday value, black chia seed, UPC:
099482450663
Badia, organic ground flaxseed, UPC: 033844005108
100% natural pumpkin, UPC: 051933039704

18.75
22.5
13.8
66.6
20.1
21.6
26.55
27
36.3
22.8
22.8
23.4
25.9875

9.75
20.025
9.246
38.2365
10.452
9.3675
16.1955
12.69
9.075
7.389
6.951
7.956
12.9945

34.0194

128.593332

34.0194
34.0194
34.0194

109.542468
127.57275
192.9580368

25.51455

94.914126

183.75
183
170.25
182.25

113.925
111.63
158.3325
78.3675

20.9786
20.9786
10.4893
20.9786
20.9786

51.81899851
42.99719751
21.92085212
16.992666
0.842431538

8.0796
8.0796

26.905068
11.87564258

8.0796
8.0796

18.90594798
11.39076536

2.8916

14.458

2.8916
2.8916

15.412228
1.214472
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100% fine ground roasted sesame seeds tahini, UPC:
092378230059
365 everyday value, organic kernels sunflower, roasted
and unsalted, UPC: 099482434434
Mayonnaise, made with tofu
Tempeh
Oils
Olive/peanut/sesame
Total calories (kcal/day)
Limit on calories for other uses (12% per day)

2.8916

16.886944

2.8916

17.552012

2.8916
2.8916

9.310952
5.551872

7

231.39
2001.84
240

Note: Alternate healthy choices can be made for each item
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